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CHAPTER 1 
Introduction to the Obstructive Sleep 
Apnea Syndrome 
Chapter 1 
1.1 Introduction 
Almost twenty years ago obstmctive sleep apnea was considered to be a medical 
curiosity that was of little importance, and snoring was merely the subject of 
humor than one of serious investigation. Although the clinical manifestations of 
sleep apnea syndrome have been described as early as in the fat boy Joe in 
Charles Dickens Pickwick Papers, it was Gastaut in 1965 who provided the first 
detailed polygraphic description of the manifestations of this sleep related 
breathing disorder (1,2). 
Since that date countless studies have been perfornled and published, 
concerning all possible aspects of sleep apnea syndrome. Epidemiological and 
clinical research revealed that the obshuctive sleep apnea syndrome may be 
considered a major public health problem and that the sequelae of the syndrome 
may have devastating consequences for the lives of those affected (3), but the 
long telm sequelae of obstmctive sleep apnea need fmiher elucidation in well 
designed studies (4). 
This chapter provides a review of prevalence, pathogenesis, natural history, 
symptomatology, diagnosis and treatment of Obstmctive Sleep Apnea 
Syndrome (OSAS). First a brief description of the spectnnll of sleep related 
breathing disorders is given. 
1.2 Sleep Related Breathing Disorders 
Through the years different names and synonyms have been used in describing 
rather similar aspects of sleep related breathing disorders (SRBD) (5). The term 
"Pickwickian syndrome", a presumed form of obstructive sleep apnea with 
obesity, CO, retention and diminished ventilatOlY drive has been applied to 
different sleep related breathing disorders, as has the term obesity 
hypoventilation syndrome. These terms should not be used any more. A velY 
rare fornl of SRBD is "Ondine's curse" with primaty failure of the medullary 
automatic respiratOlY centre resulting in hypoventilation and central apnea. 
Patients with Ondines curse are dependent on nocturnal artificial ventilation. 
Although primary fornlS are believed to exist, this disorder is generally 
associated with acquired medullalY dysfunction after trauma or infection. The 
Pickwickian syndrome and Ondine's curse are now classified under the central 
alveolar hypoventilation syndroms (6). 
An apnea has since 1976 been defined as cessation of airflow at the nose and 
mouth lasting at least ten seconds (7). We distinguish three types of apneas. 
Central apneas consist of cessation of airflow and cessation of ventilatOlY effort. 
Obstmctive apneas consist of cesssation of airflow through nose and mouth 
while inspiratory effort is still present. Mixed apneas consist of both central and 
obstructory events, usually starting as central and proceeding into obstruction. 
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Snoring is characterised by inspiratory breathing sounds originating in the 
collapsible part of the upper airway (8). Mild desaturations may be present, but 
this is not a characteristic of this disorder. By the age of 60, approximately 60% 
of men and 40% of women will snore habitually (almost every night) (9). 
Central sleep apnea syndrome, which in its pure fonn is a rare disorder, is 
characterised by cessation or decrease of ventilatory effOll during sleep causing 
central apneas, usually resulting in oxygen desaturation. Obstructive apneas 
and snoring can be present. Excessive daytime sleepiness is a common 
complaint. Sleep is generally disturbed by frequent awakenings, leading to an 
inability to maintain sleep and patients often arouse with a sense of choking. 
Cardiovascular disease, cerebrovascular disease and other neurological damage 
affecting the central control of respiration are contributing and sometimes 
causative factors. The repetitive central apneas are related to the physiologic 
interaction between the pulmonalY system and the central nervous system 
within the feedback loop of the respiratory control system, as is seen in Cheynes 
Stokes breathing. 
Central alveolar hypo ventilation syndrome, sometimes referred to as primalY 
alveolar hypoventilation, is characterised by ventilatOlY impainnent, resulting in 
arterial oxygen desaturation. This disorder occurs in patients with normal 
mechanical properties of the lung. Obstructive and central apneas can 
occasionally be present, but are not predominant. Inability to maintain sleep 
with insomnia may result. A reduced sensitivity to increased C02 has been 
revealed. In the primary fonn a lesion of the medullary chemoreceptors is 
postulated, while brainstem lesions after infarction, trauma or infection are 
found in secondary fOlTIlS. 
Chronic obstructive pulmonGl)' disease (COPD), is characterised by a chronic 
impairnlent of airflow through the respiratory tract to the lung. Difficulty 
initiating sleep, frequent awakenings with feelings of respiratOlY distress and 
shortness of breath or nocturnal cough are frequently encountered. Oxygen 
desaturation is more profound during REM sleep. The presence of both OSAS 
and COPD is referred to as overlap sYl/drome. 
Sleep related asthma refers to asthma attacks during sleep. Patients awaken 
with feelings of dyspnea and wheezing. Mild nocturnal hypoxemia is usually 
present. 
Obstructive sleep apl/ea sYl/drome and the more recently described upper 
ainvay resistance sYl/drome are discussed in detail below. 
It can be very difficult to differentiate between these sleep related breathing 
disorders and OSAS can coincide with all of the disorders mentioned above. 
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1.3 The Obstructive Sleep Apnea Syndrome 
Obstructive sleep apnea syndrome is characterised by repetitive obstruction of 
the upper airway during sleep, causing obstructive apneas leading to oxygen 
desaturations and fragmentation of nocturnal sleep. Snoring, excessive daytime 
sleepiness, cognitive deficits and sexual dysfunction are associated frequently 
(7). 
1.4 Prevalence of Obstructive Sleep Apnea Syndrome 
The prevalence of sleep related breathing disorders and OSAS was investigated 
more systematically in the late seventies and early eighties, but it already was 
the most common diagnosis among patients referred to sleep laboratories in the 
United States before that time (7,10). Interpretation of the data published since, 
is complicated by differences in study design. The most important difference 
between studies was one of methodology. Most investigators selected patients 
with sleep related complaints from a population for polygraphic recording, 
while others performed polysomnography in unselected cohorts. The latter are 
likely to provide higher prevalence data, since polygraphic evidence of sleep 
related breathing disorders may be present in persons without complaints. 
Comparison of data is further complicated by differences in the definition of 
OSAS. Not only the number of sleep related respiratOlY events, but also the 
nature of these events (apnea-index, apnealhypopnea-index, sleep-related-
breathing-disorder-index, desaturation-index) were defined inconsistently, while 
the presence of daytime sleepiness was not always included in the definition. 
Part of the differences in definition of OSAS may be explained by the different 
recording techniques used to evaluate nocturnal breathing. Table l.l 
summarises the most important publications, concerning the prevalence of 
OSAS in the middle aged population. If the data in the different studies were 
sufficiently detailed to allow recalculation of prevalence, defined as Apnea-
Hypopnea-Index (AHI) or Desaturation-Index (D!) of at least five per hour of 
sleep and the presence of daytime sleepiness, this is displayed in the last 
column. 
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Table 1.1. 
Author and Methodology Definition of OSAS prcvalence prevalencc 
Year 1 2 
Lavie 1983 Polysomnography in 72 men, selected AHI ~ 10 0.9% 
by guestionnnaire from n = 1502 
Peter 1985 Polysomnography in 20 of 72 male 50 apneas;:::.. 10 40% in A 
workers seconds or 18%inB 
(A) selectcd by questionnaire from n= 30 apneas ;?: 20 
354 (B) seconds 
Petcr 1986 Portable recording (ECO, Sa02) in 72 AI~IO 12.5 %in 
male A 
patients (A) and 68 unselected lO%inB 
technicians {B} 
Gislason 1988 Polysomnography in 156 men with ~ 30 1.3% 1.4% 
snoring and apneas/hypopneas per 
slee2iness from n = 4064 night 
Cirignotta Polysomnography in 40 men AHI ~ 10 2.7% 4% 
1989 selelected by 
gueslionnaire from n = 3470 
Hida 1993 Flow, sound ,and ECG in 159 ;:::.. 30 apneas per night 16.9% 
unse!ected 
workers from one comEany 
8earpark 1993 MESAM-4 in 294 male volunteers > 1/3 of the night with 8,5% men 
and 106 snoring and desats ;;?: 4,7% 
snoring women (Bussellon cohort n = 4% women 
1568) 
Young 1993 Polysonmography in 602 volunteers AHI;;?: 5 and 4% men 4% men 
after sleepiness 2% women 2% women 
guestionnaire in n = 3513 
Gislason 1993 PoJysomnography in 35 women with > 30 2.5% 
snoring apneaslhypopneas women 
sleepiness, selected by questionnaire n per night 
~4753 
Bearpark 1995 MESAM-4 in 294 men selected by DI ;:::.. 5 and sleepiness ;:::..3% ;;?:3% 
guestionnaire n = 759 
A summary of authoritative pUblications adressing the prevalence of OSAS. The first 
column gives the leading author and year of publication. The second column gives a short 
description of study design and patient selection. The third colunm gives the authors' 
definition of OSAS. The fourth (prevalence I) column the prevalence as estimated by the 
authors (based on their own definition), the last colunm (prevalence 2) the prevalence of 
OSAS as re-estimated following the definition used in this thesis (if presented data were 
detailed enough to allow re-calculation). 
The field survey by Lavie et al in 1983, was conducted on a presumably healthy 
working population required to be alert (II). As the authors already suggested, 
this may eliminate the most severe sleep apnea patients, whose excessive 
daytime sleepiness prevents them from working, resulting in an underestimation 
of real prevalence. Peter et al in 1985, rep0l1ed an extremely high prevalence of 
13 
Chapter 1 
sleep related breathing distnrbance in selected blue-collar workers with mild 
coronary risk factors and reported disturbances in sleep-wake-cycle (12). In 
1986 the same investigators demonstrated again a high prevalence in subjects 
with cardiovascular complaints, but they also showed a much lower prevalence 
in presumably healthy subjects (13). Gislason et al were the first to 
systematically select subjects at risk for sleep related breathing, by using a 
complaint specific questionnaire infornling about snoring and daytime 
sleepiness (14). They did not yet incorporate the presence of daytime 
sleepiness in the definition of sleep apnea syndrome, but their data were based 
on selection of subjects with daytime sleepiness and reflected the prevalence of 
OSAS, as defined in this thesis. Cirignotta et al in 1989 also used a 
questionnaire and a telephonic survey to select patients for recording, and found 
an internlediate prevalence rate (15). Hida et al defined OSAS purely on 
nocturnal respiration parameters and reported a high prevalence (16). Young et 
al were the first to present data on the prevalence of OSAS defined as 
ApnealHypopnea-Index (AID) ~ 5 and the presence of daytime sleepiness (17). 
They showed that approximately 4% of middle-aged men and 2% of middle-
aged women meet the minimal criteria for sleep apnea syndrome. These results 
were confirmed by the works of Gislason in 1993 and Bearpark in 1995, 
demonstrating again that sleep apnea defined as AID ~ 5 and the presence of 
sleepiness is close to 2.5% in women and at least 3% in men (18,19). Despite 
the methodological differences between the studies presented, we may safely 
conclude that the prevalence of OSAS in middle-aged men and women is at 
least 3% and 2% respectively. In 1996 Knuistingh Neven found in a selected 
male population of 35 years and older with daytime complaints suggestive for 
OSAS, a prevalence of 1.7% for SRBD, and 0.45% for OSAS (desaturations 
and daytime complaints) (20). He con-ectly stated that the selection of patients 
by questionnaire and thennistor-recording, before performing polysomnography 
might have underestimated real prevalence. 
Recent epidemiologic data suggest that more than 25% of "healthy" persons 
older than 65 years have more than 5 apneas per hour of sleep (21,22). This 
does not mean that these have sleep apnea syndrome, because daytime 
sleepiness may not be present at all (23). Ancoli-Israel et al found criteria for 
sleep apnea (AI ~ 5) in 18% of their randomly selected volunteers, but they 
demonstrated that, although sleep apnea is widespread in the elderly, it tends not 
to be manifested in sleep-wake complaints (24). Since the relation between 
OSAS and cardiovascular disease in the elderly has not been elucidated, the 
clinical relevance of these data is unclear. 
An extremely high prevalence of OSAS in relatively obese commercial huck 
drivers was shown by Stoohs et al (25). Seventy-nine percent of their subjects 
had more than five desaturations per hour, while 38% complained of daytime 
somnolence. These data are alarming, because the relation between sleep apnea 
and traffic accidents is well established (26,27). 
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1.5 Pathogenesis 
A long history of progressive and excessive snoring almost allways preceedes 
the diagnosis of OSAS in the individual patient. Snoring is the sound generated 
by the vibration of the soft parts of the oropharyngeal walls, caused by 
transmission of a part of the energy of the inspiratOlY airflow and reflects an 
increase in upper airway resistance. It is therefore generally accepted that the 
continuum from habitual snoring to OSAS is caused by the same mechanisms 
influencing upper airway patency (28). 
Certain specific anatomical abnormalities are related with the occurrence of 
obstruction of the upper airway and may result in OSAS. Micrognathia (Pierre 
Robin syndrome), macroglossia (acromegaly, Downs syndrome) and 
hypertrophy of tonsillar and adenoid tissue (frequently encountered in chidren) 
are only a few of the documented causes (8). The "idiopathic" or "primary" 
obstructive sleep apnea syndrome is the result of sleep related changes in 
respiratory control and compliance of the tissue of the upper airway, further 
enhanced by anatomical properties predisposing to narrowing or collaps of the 
upper airway during inspiration (29). 
In normal sleep we distinguish four stages of NREM sleep, characterised by 
progressively slower EEG activity and REM sleep characterised by low voltage 
EEG activity and periods of rapid eye movements (REM). NREM stages I and 
II are considered as "superficial" sleep. The breathing in NREM I and II is 
irregular, but with a regular waxing and waning of breathing amplitude. This 
phenomena is called periodic breathing. NREM I and II are therfore considered 
as unsteady sleep in perspective of respiratory contol (30). During wakefulness 
breathing is responsive to metabolic stimuli (C02, 02 and pH), but two other 
influences on breathing can be identified. The degree of wakefulness has a 
stimulatOlY effect on breathing, acting through the metabolic control system 
(31). This influence is described as "state dependent". Activities as phonation 
demand specific breathing control, which is largely influenced by the cerebral 
cortex. This influence is described as "behavioural" (31). During NREM sleep, 
the ventilatory respons to increased pC02 is relatively slow compared to 
wakefulness. The set-point for ventilatory respons to increased pC02 seems to 
be 3 - 7 mmHg higher than during wakefulness. This means that the respiratory 
control during sleep is less sensitive to increased CO2. During NREM I and II 
sleep respiration is controlled by metabolic and state dependent mechanisms, 
both with a different pC02 set-point. Due to the physiologic properties of 
NREM I in particular, but of NREM II as well, fluctuations between metabolic 
and state dependent control exist. This means that respiratOlY control fluctuates 
between two C02 set-points, resulting in periodic breathing that is considered an 
important condition for the development of as AS (31-39). 
The state dependent decrease in cortical activity decreases the nonautomatic 
dilatation of the upper airway during sleep (40). The tonic-arousal dilatation of 
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the upper airway is also decreased due to deactivation of the reticular system. 
The absence of nonautomatic and automatic dilatations leads to narrowing of 
the upper airway, which can become occluded if other factors are present. The 
upper airway collapses due to the negative intraluminal force resulting from the 
negative intrathoracic pressure during inspiration, resulting in obstructive apnea. 
Subsequently hypoxia, hypercapnia and increased inspiratory muscular activity 
induce arousal and the upper airway is opened again (34,35,40,41). With 
arousal the CO2 set-point of respiratory control is shifted upwards as a result of 
increase in cortical activity. Ventilation is increased, until a change in state 
dependent control with falling asleep decreases the set-point again, and also 
decreases ventilation and dilatation of the upper airway again. The cycle 
repeats. These mechanisms contributes to periodic breathing, causing a vicious 
circle, further enhancing the instabilities in the respiratoty control system 
(35,42). 
The size of the pharyngeal lumen depends therefore on the balance between the 
dilating forces of the upper airway musculature and the narrowing force of the 
SUbatmospheric pressure in the upper airway during inspiration. This is the 
Balance of pressures principle as described by Remmers et al. (29) who 
impliment all the above mentioned principles in a comprehensive model (43). 
The musculus (m) tensor veli palatini, m. genioglossus, m. geniohyoideus and 
the m. stemohyoideus are the most important muscles for maintaining an open 
upper airway aperture during inspiration (44). As stated above the muscle tone 
is decreased during sleep, increasing the upper airway compliance to changes in 
intrathoracic pressure (45). There is evidence that the tone of these muscles is 
lower in OSAS patients than in controls during sleep. Some investigators found 
that the upper airway of OSAS-patients is indeed more compliant with increase 
in negative inspiratory pressures and collapses easier than those of controls (46-
50). 
The muscles responsible for maintaining an open pharyngeal airway seem to be 
influenced by changes in lung volume as well. Hoffstein showed that in obese 
patients with OSAS a considerable variation in pharyngeal cross sectional area 
occurred with changes in lung volume (51). These results were reproduced later 
in obese females with OSAS, but it was also demonstrated that the reduction in 
pharyngeal cross-sectional area between FRC and RV was significantly greater 
in OSAS patients compared to controls (52,53). Factors related to the lung 
volume related compliance of the upper airway have not been precisely 
determined. A reflex activation of the pharyngeal dilator muscles via 
pulmonairy stretch receptors is postulated. Since lung volume decreases in the 
supine position, even more so in the presence of redundant abdominal fat these 
mechanisms partly explain why OSAS occurs at night and why it is usually 
more pronounced in obese patients (54). 
Apart from these neuromuscular and ventilatory control related mechanisms, 
some anatomical aspects of the upper airway are different between patients with 
16 
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idiopathic OSAS and nonnal subjects. Cephalometric analysis in OSAS 
patients showed that the hyoid bone is positioned more inferiorly, the mandibule 
is shorter or posteriorly rotated (resulting in micrognathia or retroposition of the 
mandibula with mandibular deficiency), the space behind the tongue is smaller 
(posterior airway space or PAS), and the dimensions of the soft palate are larger 
(55-62). Computerised tomographic studies also demonstrated that the 
pharyngeal size in OSAS patients was smaller (63-65). One study showed that 
the reduction of pharyngeal diameter was caused by soft tissue and not by 
localised deposition of fat (63). A Magnetic Resonance Imaging based study 
demonstrated that the pharyngeal space of snorers and OSAS patients had a 
circular or elliptic orientation with the long axis in the sagittal plane (66). The 
pharyngeal area of nonnal controls was also elliptic but with the long axis 
orientated in the coronal plane. The pharyngeal volume in OSAS patients may 
be further reduced by erythema or edema as a result of vibration trauma caused 
by repetitive snoring (67). 
The soft palate is the most common site of narrowing at the level of the 
nasopharynx in approximately 80% of patients. Posterior displacement of the 
base of the tongue and the uvula causes narrowing at the level of the oropharynx 
in approximately 40% of patients. Narrowing of the hypopharynx is relatively 
rare in OSAS patients and is achieved by posterior displacement of the 
epiglottis or by a floppy epiglottis (43,68-74). One in three patients have 
obstruction at two or more levels (68). 
OSAS becomes more pronounced with increasing age. Several mechanisms 
seem to be responsible. As life progresses there is an increasing number of 
nocturnal awakenings and the amount ofNREM I sleep increases (5). As stated 
earlier this makes the ventilatory control during sleep more unstable and 
promotes periodic breathing and repetitive narrowing of the upper airway (31). 
White showed that upper airway resistance increases with age in men, he was 
however not able to find a relationship in women (75). With increasing age 
people tend to gain weight, and the mechanisms discussed below may therefore 
also contribute to the cOlTelation between age and OSAS. Bliwise illustrated 
that even in middle-aged and elderly humans in good health an increase in sleep 
related breathing occurred with age (76). The relation between obesity and 
OSAS is indisputable, but the mechanism has not been precised (75,77-79). 
Although it has been postulated that local fat deposits in the phatyngeal wall 
contributed to upper airway narrowing (80,81), other studies presented 
contradictory results (63). In the supine position abdominal deposited fat forces 
the diaphragm upwards and reduces lung volume, resulting in a reduction in 
cross-sectional pharyngeal volume and increasing upper aiway resistance (51). 
The strong relation between obesity and OSAS severity is further confirmed by 
the effect of weight reduction on respiratory parameters (82). Schwat1z 
demonstrated also that upper airway collapsibility decreased after weight loss in 
OSAS patients (78). A relation between honnonal status and OSAS is 
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suggested by its predominance in the male patient and by its presence in relation 
to testosterone and steroid treatment (83,84). Guilleminault demonstrated also 
that respiratory disturbance was lower in postmenopausal women with OSAS, 
compared to premenopausal women with OSAS (85). Differences in 
distribution of fatty tissue between the sexes might however be another 
plausible explanation. 
1.6 Symptoms and Natural History 
Snoring is the most frequent symptom in obstmctive breathing during sleep. 
Snoring is a velY common phenomenon affecting about 20% of the 30- to 35-
year-old population, while by age 60, 60% of men and 40% of women will 
snore habitually (86). With very few exceptions, all OSAS patients have loud 
pharyngeal snoring associated with snorting and apneic periods (7,87). The 
periods of silence are a frequent cause for alarm by the bed partner who may 
repeatedly try to arouse the patient to make him breath again. OSAS patients 
are however often unresponsive, even to painful stimuli, and may be 
disorientated when finally aroused (7). Daytime hypersomnolence is the usual 
reason for adult patients to seek medical attention (7), but it is our experience 
that impailment of daytime functioning due to daytime sleepiness may remain 
unrecognised for many years. Other complaints frequently encountered in 
OSAS are: difficulties maintaining sleep caused by apneas, abnormal 
movements during sleep and noctumal enuresis; mOl1ling headache, cognitive 
deficits and sexual dysfunction (87). Symptoms of OSAS can result in serious 
problems in personal and professional surroundings. Quality of life can be 
severely affected as well. 
Daytime sleepiness is caused by decreased recuperative effect of noctul1lal 
sleep. Every obstructive apnea or hypopnea is terminated by an arousal 
resulting from augmented muscle activity during increased inspiratOlY load, 
causing fragmentation of noctul1lal sleep (88). Sleep fragmentation is indeed 
demonstrated to be an important determinant of daytime sleepiness (85,89,90). 
Some investigators found a relation between the amount of nocturnal oxygen 
desaturation and excessive daytime sleepiness (91,92). In a general population 
based study, obesity, respiratory symptoms (cough or wheeze), gender and age 
were found to be related to daytime sleepiness, suggesting that other factors 
may be complementary to sleep fragmentation and noctul1lal hypoxemia in the 
development of daytime sleepiness in OSAS (93). 
The clinical course of OSAS is rather typical. In a sample of 50 patients studied 
by Kales, 40 patients snored prior to any other symptom, 36 patients had EDS at 
the onset of their illness (87). Other symptoms came later, but in 50% obesity 
and hypeltension preceeded the complaints for at least one year (87). 
Martikainen in 1994 followed a relatively random sample of 626 responders to a 
18 
Introduction 
questionnaire send to 1600 people and found that snoring indeed increased with 
age, as did daytime sleepiness (94). These data indicate again that a continuum 
exists from snoring to OSAS, and that the number and severity of symptoms 
increase with age and severity of the syndrome (86,87,94). Guilleminault was 
the first to state that an increase in upper airway resistance may lead from 
habitual snoring to upper airway resistance syndrome (UARS) and to OSAS 
respectively (95). UARS is characterised by habitual snoring and all the other 
complaints of OSAS, but without the presence of obstmctive apneas to define 
OSAS (95). 
There is epidemiologic evidence that OSAS and hypertension are associated, 
but the criteria for a causal relation have not been satisfied. Some investigators 
found that snoring was an independent risk factor for hypertension (86,96,97). 
Others found that snoring was strongly correlated to other clinical findings in 
apnea patients. Koskenvuo showed a strong association of snoring with 
smoking, obesity, physical inactivity, hostility and morning tiredness (98). 
Snoring was not an independent predictor of hypertension in the presence of 
age, obesity, and alcohol consumption in a study by Stradling (99). A 
multivariate regression analysis by Hoffstein including 1415 persons showed 
that snoring was not a significant detenllinant of blood pressure (100). Snoring 
may thus not be a direct risk factor for hypertension, but may influence blood 
pressure via its association with obesity, obstmctive sleep apnea and nocturnal 
desaturation (10 I). Approximately 30% of patients with primary hypertension 
are found to have OSAS, while half or more patients with OSAS are found to be 
hypertensive (11,102-104). Again age, weight, smoking, alcohol abuse and 
other factors are reported as coinciding factors (104,105). 
A relation between snoring and angina pectoris was found in men aged 40 - 69 
years (97). The same investigators found that frequent to habitual snorers had a 
relative risk of 1.7 for ischemic heart disease and 2.08 for ischemic heart 
disease and stroke combined (106). Coronary atiery disease had been 
diagnosed in 33 of 198 OSAS patients of whom 16 had a previous myocardial 
infarction and 14 a stroke (107). In 1990 Hung demonstrated that an apnea 
index (AI) > 5.3 was in independent predictor for myocardial infarction, after 
adjustment for age, body mass index, hypertension, smoking, and cholesterol 
levels (108). The relation between snoring or OSAS and stroke has been 
repOlied in a small number of studies. After comparing 50 patients admitted for 
stroke and 100 patients admitted for other disorders Partin en found that the risk 
ratio for cerebral infarction between snorers and non-snorers was 10.3 (95% 
confidence limits 3.5 - 30.1), even after correction for age and body mass index 
(107). Palomaki studied 177 consecutive patients with ischemic stroke and 
found an odds ratio for snoring and cerebral infarction of2.13 and an odds ratio 
for a history of OSAS of 8.00 (109). After excluding apnea, obesity and EDS, 
the relation between snoring and stroke disappeared. All epidemiologic data 
suggest a relationship between snoring and especially OSAS and cardiovascular 
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morbidity, but the presence of confounding factors that are so typical of OSAS 
render the interpretation rather difficult (98, 110, III). 
He et al. found that patients with AI>20 had a probability of cumulative eight 
year survival of 0.63 ± 0.17 versus 0.96 ± 0.02 in case of AI < 20 (112). They 
analysed 385 male patients. Bliwise estimated a mortality ratio of a RDI> 10 to 
be 2.7, but cardiovascular death was clearly associated with age in this cohort 
(113). Partinen studied 71 tracheostomised patients and 127 conservatively 
treated patients (weight loss) and found an age-standardised vascular mortality 
rate of 5.9 per 100 patients per 5 years in the conservatively treated patients 
versus a mOltality rate of 0.0 in the operated patients (56). Gonzales-Rothi in a 
retrospective study in 1988 found no statistically significant difference in 
mortality between OSAS-patients and controls (114). Of the 91 patients 9 died 
compared to 4 of 35 controls over a relatively short follow-up period of 4-8 
years. 
Based on the described evidence one may postulate that OSAS could be 
considered a major public health problem (3). A review by Wright et al 
however demonstrates that most evidence associating OSAS with cardiac 
arrhytmias, ischemic heart disease, cardiac failure, systemic or pulmonary 
hypertension and stroke is inconclusive, because most studies were poorly 
designed, contained confounding factors or were based on small numbers of 
subjects (lIS). Although this is hue for most studies, their conclusion that the 
relevance of sleep apnea to public health has been exaggerated can not be 
suppOlted by the same inconclusive evidence. The conclusion must be that we 
indeed need long tenn popUlation based prospective studies to examine the 
association between OSAS and morbidity and mortality (4). 
1.7 Diagnosis 
Due to the complex symptomatology and fast changing insights in the different 
aspects of OSAS, diagnosis and treatment require expert attention of different 
clinical specialities (116). A multi-disciplinary approach including a 
neurologist, otolaryngologist, pulmonologist, and if indicated a maxillofacial 
surgeon, cardiologist or psychologist with experience in the field of OSAS is 
important. In the Netherlands a work-group is preparing a consensus based on 
internationally accepted criteria, stating that diagnosis and treatment of OSAS 
should be reserved for sleep centres or sleep apnea centres. Each centre must 
have an experienced multidisciplinary team and possibilities to perfonn and 
interpret polygraphic or polysomnographic recordings. 
Snoring and daytime sleepiness are the core symptoms of OSAS, but the 
diagnostic value of these symptoms and other clinical features is very low (117). 
The medical history remains however very important because it provides 
infonnation on the impact of daytime complaints in the individual patient and 
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may give clues for considering OSAS related morbidity or other sleep related 
disturbances. Different questionnaires for the evaluation of daytime sleepiness 
and other OSAS related symptoms and comorbidity have been developed (118-
120). The additive value of these questionnaires to a brief but adequate history 
taking is however very small (121). 
A physical examination may not contribute much to an adequate diagnosis of 
OSAS either (117), but it may reveal symptoms of cardio-vascular comorbidity 
or anatomical abnonnalities possibly contributing or causative to OSAS. An 
adequate physical examination must contain: body weight and length, neck 
circumference, inspection of nose, mouth and pharynx, blood pressure, pulse, 
pulmonary and cardial auscultation; peripheral arterial pulsations and inspection 
for gross anatomical abnonnalities of face and thorax (122,123). 
Visualisation of the upper airway is important, because it may reveal causative 
abnormalities (large tongue, tonsillar hypertrophy etc.), and provide evidence of 
upper airway collapse that may need corrective surgical intervention. The 
methods that appear most clinically useful to better define pharyngeal 
narrowing are fiberoptic endoscopy (with or without Mueller manoeuvre) and 
lateral cephalometty (124). Fiberoptic endoscopy with Mueller manoeuvre 
must be perfornled by an experienced oto-rhino-lmyngo logist. The Mueller 
manoeuvre is used to define the level and the degree of upper airway 
obstruction at the nasopharynx and oropharynx, by comparing the inward 
motion of the pharyngeal wall during vigorous inhalation against occluded 
nostrils, with the position of the pharyngeal wall in rest (125). Endoscopic 
examination of the upper-airway during propofol or midazolam induced sleep, 
commonly referred to as sleep-endoscopy, is probably more reliable in assessing 
upper airway collapsibility than examination during wakefulness (126). Lateral 
roengenography of the cranium followed by standardised measurements of the 
upper airway anatomy is called cephalometty or X-cephalometry (55). This 
procedure has defined several anatomical differences between normals and 
OSAS patients, but its predictive value in individual patients undergoing 
surgery is limited (55,56,59,60,124). Computerised Tomography, Magnetic 
Resonance Imaging, and other techniques to define upper airway anatomy and 
collapsibility have been described (65,72,73,127-129). These techniques have 
been used mainly for research purposes and their clinical value needs further 
elucidation. 
OSAS can not be diagnosed without recording of breathing pattern during sleep 
(130,131). The gold standard for a definitive diagnosis of OSAS is 
polysomnography (PSG) (131). A PSG must provide reliable data to enable 
sleep staging and the scoring of arousals, and to differentiate between 
obstructive and central apneas. PSG for evaluating sleep-related breathing 
disorders requires the following channels: EEG, EOG, chin EMG, airflow, 
arterial oxygen saturation, respiratory effort and ECG or heart rate (131,132). 
The European consensus is somewhat more pragmatic and advises to record 
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enough parameters to analyse sleep architecture, sleeping position, respiratOlY 
adequacy and respiratory effort. (116). PSG is an expensive and time 
consuming procedure, and although PSG can be perfOlmed at home, most 
patients will have to be admitted to hospital for at least one night. Based on 
these restrictions other recording strategies and modalities have been developed. 
Daytime PSG, split-night recording and siesta recordings have been reported, 
but these procedures remain unreliable (130). The use of portable recording 
devices has rapidly increased. This equipment has not been standardised in 
terms of the type and number of parameters needed for adequate screening for, 
or diagnosing of OSAS (133,134). The use of portable recordings can lead to 
inadequate diagnosis and as a consequence improper treatment. Following the 
American Sleep Disorders Association, the minimal requirement for a portable 
device are: recording of ventilation, ECG or heart rate and oxygen saturation 
(133,134). Although studies comparing portable devices to standard PSG are 
few, portable devices can be useful in diagnosing OSAS in patients with a high 
pretest probability of OSAS based on clinical features, but in case of a negative 
test outcome, PSG is indicated (133,134). Portable devices must record 
unprocessed data and interpretation of the test result must be in the hand of an 
experienced physician (130,133). In case co-inciding or other sleep related 
disturbancies are suspected to be present, PSG is still the method of choice for 
further evaluation of sleep, body movements and breathing pattem (130). 
The Multiple Sleep Latency Test (MSLT) is not routinely indicated in the 
clinical evaluation of OSAS, although it may provide an objective measure of 
daytime sleepiness (131,135). If more than one sleep disorder is suspected, 
particulary in case of narcolepsy, MSL T may be indicated (135,136). 
Still no definite and intemationally accepted definition of OSAS has been 
reported. The Dutch consensus proposes a combination of polysomnographic 
and clinical criteria. OSAS is present if a polysomnographic recording shows 
more than 10 apneas per hour sleep (AI ~ 10) or more than IS apneas and 
hypopneas per hour sleep (AHI ~ 15) in the presence of daytime sleepiness. In 
this thesis we use a different criterion, allowing evaluation of treatment outcome 
by polygraphy with oxygen saturation trace obtained by a pulse oxymeter. We 
define OSAS as the presence of more than 5 oxygen desaturations exceeding 
3% from base-line per hour sleep and the presence of daytime sleepiness. 
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1.8 Treatment 
1.B.1 General Considerations 
The research based evidence for the burden of OSAS on public health and the 
association with motiality and morbidity may be inconclusive, treatment of 
sleep disordered breathing in the individual patient may however be velY 
rewarding, althought sometimes difficult (3,4,115,137). 
A single treatment modality can not adress the whole spectrum of anatomic, 
physiologic and independent risk-factors contributing to the development of 
OSAS in every individual patient. If anatomical or functional abnotmalities of 
the upper airways are found (septal deviation, nasal congestion, large adenoid 
and tonsils etc), specific treatment is required (138). Surgical and conservative 
treatment should however allways be combined with general measures 
concerning the lifestyle of OSAS patients (\38-140). Patients must be advised 
about the effects of smoking, alcohol and sleep medication on sleep architecture 
and body weight. Abstinence from alcohol before bedtime is an important part 
of therapy (138). Sleep position training may be an appropriate treatment in 
patients who have position-related obstruction. Cartwright demonstrated a 
significant reduction of apneic events in the lateral decubitus position compared 
to the supine position in ten patients (14 I). Sleep position training can be 
accomplished by placing a tennis ball in the back of the patients sleeping 
garment, preventing him from rolling over to his back (140). Peiser reported a 
dramatic reduction in sleep apnea index and daytime complaints in 15 patients 
with OSAS, selected from a larger population scheduled for gastric bypass 
surgery (82). Schwartz found a significant decrease in upper airway 
collapsibility and sleep disordered breathing after weight loss (78). Browman 
followed one patient over three years and found that sleep apnea severity 
parallelled any increase in body weight (77). Although not all patients found 
weight reduction helpful in the treatment of OSAS and weight loss may be 
partial and temporary, dietary control of weight is considered extremely 
important (138,142). Weight reduction surgery should however not be used 
routinely in the treatment of OSAS. The effect of these general measures on 
OSAS related symptoms is limited and further medical intervention is often 
needed. 
Before the simultaneous introduction of UPPP and CP AP for the treatment of 
OSAS, other strategies were tried. Tracheostomy was the first surgical 
treatment for OSAS. It is very effective because it bypasses all the obstructive 
sites of the upper airway. The procedure is psychologically not well accepted 
by patients, but it may still be used as an interim treatment (143). 
Progestational agents have been reported to be useful in a small subgroup of 
patients who are hypercapnic during daytime, but the role of these agents in the 
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treatment of OS AS has not been defined (140,144,145). 
OSAS has severe consequences for driving ability, and the association between 
traffic accidents and OSAS has been well established (26,27,146). Every 
patient should be informed of the regulations and legal implications, as soon as 
the very first consultation (138). 
1.B.2 Uvulopalatophalyngoplasty 
Palatopharyngoplasty with partial resection of the uvula, now known as 
uvulopalatopharyngoplasty, was introduced by Ikematsu in 1952. He 
succesfully treated loud snoring in a 23-year-old Japanese woman. The 
technique was fully reported in 1964 (147). In 1981 Fujita et al. were the first 
to report a modified UPPP, for the treatment of OSAS (148). Many variations 
in surgical technique originated from the earliest reports (149), but they all 
intend to reduce redundant velopharyngeal tissue to reduce the degree of 
pharyngeal obstruction that occurs during the apneic period. The procedure 
consists of resection of the uvula, distal free margin of the soft palate, palatine 
tonsils (if present), and any excessive pharyngeal tissue. In the early nineties 
the UPPP was the most common surgical procedure used for the treatment of 
OSAS (72). 
Since the introduction ofUPPP for the treatment of OSAS an enormous amount 
of studies of the effectiveness of this surgical procedure has been reported in the 
literature (72,124,150, 151). Interpretation of the published material is 
complicated by a number of general limitations of study design (124,151). 
Recent critical reviews of the available UPPP literature by Sher and Pepin in 
1996 revealed methodological and statistical problems (small sample size, 
patient selection, no well defined end-points etc), different criteria for 
effectiveness, short follow-up, and different surgical techniques, to name a few 
(124,151). No prospective randomised study has been performed or published 
since (151). The meta-analysis by Sher et al showed that UPPP is, at best, 
effective in treating less than 50% of patients with OSAS (124). In their 
original report, Fujita et al. already emphasised that although there was a 
dramatic improvement, UPPP did not eliminate sleep apnea entirely, because 
only 8/12 patients had an AHI below 20 and 4/12 had an AHI below 10 after 
surgery (148). A marked inconsistency between the favourable subjective 
improvement, as rated by different questionnaires or scoring methods for 
daytime sleepiness and snoring and the limited objective improvement of sleep 
pattern, breathing pattern or nocturnal saturation by polysomnography or 
polygraphy has been reported frequently (14,148,152-157). Subjective 
improvement in these studies has been reported in 70% to 100% of patients, 
compared to an objective improvement of approximately 50%. The long-term 
respons after UPPP has been studied sparsely, but there is evidence for a relapse 
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of symptoms in2 to 4 years after surgelY (158-160). 
Pre-operative selection of patients might improve treatment outcome, but 
different and unvalidated methods for patient selection have been used in the 
literature (124). Although more sophisticated techniques have been used to 
visualise the upper airway before surgely, fiberoptic endoscopy with the 
Mueller manoeuver and lateral cephalometry appear to be most clinically usefull 
(124). Studies of the Mueller manoeuver showed that patients with 
predominant collaps at the velo-phmyngeal level were better responders to 
UPPP than patients with collaps at any other level (125,161,162). Studies of 
cephalometry showed poor results in patients with a low position of the hyoid 
bone, and smaller posterior airway space at the level of the tongue (72,163,164). 
Several studies evaluating the association between sleep apnea severity and 
outcome after UPPP, found that patients with high apnea index showed poor 
results (14,165). A high body mass index has repeatedly been associated with 
poor surgical outcome as well (14,152,159). The ideal patient for UPPP appears 
to be one with relatively mild OSAS with predominant narrowing of the upper 
airway at the level of the soft palate and a normal body weight. 
The surgical technique is probably also important in detelmining post operative 
outcome. Kimmelman et al reported that a more radical excision of phmyngeal 
tissue may lead to a higher succes rate, without significantly increasing the 
number or severity of post-operative complications (166). Comparable results 
were published by Zohar et al (167). Multiple other mechanisms are thought to 
contribute to failure of UPPP. Most investigators consider persistent collaps in 
the operated segment or UPPP related complications responsible for low 
surgical outcome. However, no conclusive data have been presented so far, 
because most studies made no clear reference to the occurrence of 
complications (124,151). Life threatening complications have been reported to 
result after acute post-operative pharyngeal stenosis or hemorrhage (151,168). 
Minor complications may be: regurgitation of fluids or food due to velo-
phmyngeal insufficiency, loss of taste, foreign body sensation, and change in 
voice quality (151,168,169)]. Most complications are reported to be mild and to 
resolve within weeks to months. Post-operative pain, sometimes severe was 
reported by almost all patients. 
In 1990 the Laser Assisted Uvulopalatoplasty (LA UP) was introduced for the 
treatment of snoring and in the years to follow it was also used in the treatment 
of OSAS (170,171). No prospective randomised trials, comparing UPPP and 
LAUP have been repOited, but the results and complications of LAUP don't 
seem to be different from UPPP (171). 
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Recently a new surgical treatment modality has been described, using 
radiofrequent energy. This radiofrequent coagulation technique results in 
volumetric reduction of the soft palate by causing fibrosis of the underlying 
tissue, without damaging the superficial mucosa. The value of this technique 
for the treatment of OSAS has not been fully assessed, and fiu1her research is 
needed (126). 
1.B.3 Continuous Positive Airway Pressure 
In 1981 Sullivan rep0l1ed that continuous positive airway pressure (CPAP) 
applied through a nose mask completely prevented obstructive apneas during 
sleep (172). Although only one prospective randomised placebo controlled 
study has been perfonned, a substantial number of studies has recognised the 
value of CPAP and it is considered the treatment of choice for OSAS 
(115,137,173,174). 
Although CPAP is effective in eliminating snoring, it is not indicated for the 
treatment of simple or habitual snoring, because no clinical study demonstrates 
the health benefits in these patients (175). CPAP may be effective in 
eliminating the polysomnographic signs of central sleep apnea, but its effect on 
clinical symptoms has not been demonstrated adequately either (175). 
The effect of CPAP is mediated mainly by pneumatic splinting of the upper 
airway (176,177), but changes in lung volume, central chemosensitivity, upper 
airway muscle activity and upper airway configuration have been rep0l1ed to 
contribute also (67,176-182). The improvement of daytime sleepiness and 
alel1ness has been demonstrated in a large number of studies (183-187). The 
subjective improvement of EDS is associated with improvement of sleep 
architecture and sleep latency, but there is insufficient evidence that sleep 
structure nonnalises during CPAP therapy (26,185,188-190). 
A limited number of studies has been perfornled to assess improvement of 
cognitive performance, mood and quality of life. Engleman at al reported an 
improvement of sleepiness, cognitive perfornlance in a placebo controlled study 
(187), but others suggest that in-eversible ischemic neuronal damage may be 
responsible for persisting neurobehaviouralmanifestations (191). 
Although an association between OSAS and cardiovascular sequelae is 
generally accepted, the long-tenn effectiveness of CPAP on improvement of 
morbidity, mortality and quality of life has not been assessed adequately yet 
(4,115,192). A few small and uncontrolled studies found nonnalisation of 
hypertension, improvement of left-ventricular function and a decrease in 
haematocrit (193-196). These changes could however, also be associated with 
changes in body weight during treatment (197). 
Nocturnal breathing and related daytime symptoms are found to improve almost 
immediately or within several days or weeks, but this effect stops as soon as 
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CPAP treatment is stopped (181,186,188,198). If treatment is continued 
however, CP AP remains effective in improving sleep disordered breathing and 
daytime symptoms (185,199,200). CPAP may therefore not be considered 
curative. A study in 57 patients revealed indeed that even after long-tenn 
treatment no significant change in AHI was found by polygraphic recording 
during a single night without CPAP (20 I). The prerequisite for effective 
treatment of OSAS is therefore a good compliance to CP AP. Sanders in 1986 
interviewed 24 patients who possessed their CP AP for 10 ± 8 months, and 
reported that 17 patients used their CPAP all night (85% of compliance) (139). 
Because self-reported compliance was believed to be an over-estimation, 
Krieger and Kurtz used a built-in time counter that measured the time the 
machine was running (202). They found a mean rate of use of 5.14 ± 0.31 hours 
per night and an acceptance rate of 90% after a mean follow-up of 232 ± 27 
days. Barone Kribbs et al. used an even more sophisticated time counter that 
measured actual pressure at the mask (203). They included 35 patients with a 
total CPAP use of 3.743 days. Patients were unaware of the built-in timer. 
They found that their patients attempted to use CPAP an average of 66 ± 37% of 
the days monitored, while only 46% used CP AP at least 4 hours on 70% of the 
days monitored. Only 2 patients (5%) used it at least 7 hours on 70% of the 
days monitored. The American Thoracic Society in 1994 states that the overall 
compliance rates may actually approach 50% at best (175). The acceptance rate 
may be close to 70% (204-206). 
From these figures it may be evident that CP AP is a cumbersome treatment and 
compliance to therapy is very much depending on whether the patient considers 
its discomfort and side effects in proportion to its benefits. The most consistent 
factor associated with good compliance is the experienced improvement of 
daytime sleepiness during CPAP treatment (203,204,207,208). The most 
frequently reported adverse complaints are mask related (too tight, hurts the 
ridge of the nose and upper lip, leaves marks on face and hair, too large, leaks 
etc.) (205,206). CPAP related complications are mostly minor. Local skin 
irritation, drying of nasal and phatyngeal membranes (±50%), nasal congestion 
and rhinonhea (±25%), and eye in'itation by air leak (±25%) are the most 
common (139,175,206,207). Major complications have been described in case 
reports only and include pneumocephalus, bacterial meningitis and atrial 
arhythmia (209-211). 
1.8.4 Other Surgical Procedures 
Because multiple sites of anatomic obstruction have been demonstrated in 
OSAS, and UPPP adresses the velo-pharyngeal level only, other surgical 
treatment strategies have been developed. Although these procedures could be 
indicated and perfoI1'lled individually, they should be part of a stepwise surgical 
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protocol with the primary goal to cure the patient (212). Powell et al. described 
a two-phased surgical protocol with individual stages in which a treatment 
strategy is planned after identifying the regions of obstmction and applying the 
specific surgical intervention for treatment at that level, using the most 
conservative procedures first (212). Phase I includes: nasal reconstmction, 
UPPP, and inferior mandibular sagittal osteotomy with genohyoid advancement. 
Phase II includes: bimaxillary advancement, subapical mandibular osteotomy, 
and base of tongue surgery. Their published data strongly suggest that after 
proper selection of patients the results of this protocol are comparable to CPAP 
in 65% of patients after phase I, and in 90% of patients after phase II (212-214). 
They emphasise that re-evaluation between major steps is mandatory to 
minimise over-operating. No prospective randomised comparative study of 
these surgical procedures with CPAP has been perfOimed. In the Netherlands 
there is no experience with a systematic surgical protocol exceeding beyond 
UPPP. 
Before the introduction of UPPP, tracheostomy was the only surgical 
alternative. Although this intervention is very effective in reducing snoring and 
upper airway obstmction, it is now performed only if other treatment modalities 
remain ineffective in patients with severe cardial and pulmonary symptoms 
(126,215). 
1.B.5 Oral Appliances 
Oral appliances increase the upper airway aperture by repositioning the 
mandible, advancing the tongue and changing the palatal and mandibular 
position or dynamics (216,217). Despite the large variation in design, the 
clinical effects are remarkably consistent. Snoring was improved and often 
eliminated in almost all patients, obstructive sleep apnea improved in the 
majority of patients, but as many as 40% of those treated were left with 
significantly elevated AHI (216). Oral appliances are indicated for patients with 
moderate to severe OSAS who are intolerant of or refuse treatment with CP AP 
or surgery (218). In case of a small orophalynx, any appliance that could 
enlarge the airway by advancing the tongue, the mandible or both could be 
usefull (217). If a dispropOltionally large tongue is found, any device retaining 
the tongue in an advanced position could be used (217). Oral appliances may 
aggrevate temporo-mandibular joint disease and may cause dental 
misalignment. Oral appliances should be fitted by qualified personei only and 
follow-up care by a dentist is necessary (216-218). Poly(somno)graphic follow-
up is mandatory, because any device may worsen OSAS. In the Netherlands the 
experience with oral appliances is increasing (126). 
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1.9 Scope of this Thesis 
The Obstructive Sleep Apnea Syndrome (OSAS) is characterized by repetitive 
cessation of flow through the upper airway, caused by obstruction of the upper 
airway during sleep (chapter 1). Snoring and daytime sleepiness are the core 
symptoms of OSAS, but cognitive deficits, mood disorders and other symptoms 
have been described. The long term sequelae of repetitive apneas and noctumal 
oxygen desaturation have not been fully elucidated yet (4), but the symptoms 
may have devastating consequences for the lives of those affected. OSAS is not 
a rare disorder and its prevalence is estimated to be 4% of middle-aged men and 
2% of middle-aged women (chapter 1) (17-19). In the perspective of its relative 
high prevalence and the severity of its symptoms, the OSAS must indeed be 
considered a major public health problem (3) that deserves expert medical 
attention and treatment. However, without a complete understanding of the 
pathogenesis and long-term effects on health outcome of sleep related breathing 
disorders, the development of effective treatment modalities, that are relatively 
non-invasive and well tolerated will remain difficult, and further research is 
therefore of paramount importance. 
In this thesis we focus on the treatment of OSAS with Uvulo-palato-
pharyngoplasty (UPPP) and Continuous Positive Aitway Pressure (CPAP), and 
pathogenic aspects are studied to illustrate the limitations of surgical therapy 
(chapter 2). The main goal of our studies was to assess the treatment outcome 
after UPPP (chapter 3 alld 4) and to evaluate whether the treatment of patients 
with OSAS caused by predominant collapse at the velo-pharyngeal level should 
be started with UPPP or CP AP (chapters 5 alld 6). 
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2.1 Abstract 
The pathogenesis of sleep related breathing disorders is complex. Upper airway 
anatomy and sleep related changes in respiratOlY and upper airway muscle 
control are likely to be involved. 
Sixty patients, 53 men and 7 women, referred for excessive snoring or suspected 
sleep apnea syndrome were analysed by polysomnography, Mueller manoeuvre, 
cephalometric roentgenography and pulmonary function testing, to evaluate the 
contribution of static and dynamic upper airway obstmction in the pathogenesis 
of sleep related breathing disorders and OSAS. Desaturation index and 
maximal desaturation were used in the analysis as indicators of severity of sleep 
related breathing disorders. Body Mass Index, increased collapsibility at the 
base of the tongue by Mueller manoeuvre, increased distance between hyoid 
and mandibular plane, and increased soft palate diameters by cephalometry as 
well as a decreased peak inspiratOlY flow by pulmonaty function testing, were 
found to be related to increased oxygen desaturation parameters. In a 
multivariate analysis the significant obstmction parameters could explain only 
37% of the variability of maximum desaturation and 31 % of the variability of 
desaturation index, 63% and 69% respectively must therefore be explained by 
other mechanisms. We conclude that instability of respiratory and upper ahway 
muscle control, even enhanced by sleep phase related changes is more important 
in the pathogenesis of sleep related breating disorders than pure anatomic 
nanmving of the airway. 
2.2 Introduction 
The spectrum of sleep related breathing disorders ranges from partial airway 
collapse and increased upper airway resistance, accompanied by snoring and 
periods of hypopnea, to complete airway obstruction, resulting in the fullblown 
obsttuctive sleep apnea syndrome. Until recently the prevalence of obsttuctive 
sleep apnea syndrome was estimated at approximately 1-2% of middle- aged 
adults, but Young et al. showed that 4% of middle aged men and 2% of middle 
aged women are likely to meet the minimal diagnostic criteria for the sleep 
apnea syndrome (1-5). 
Characteristic of the syndrome is excessive daytime sleepiness as a result of 
sleep fragmentation, but a variety of symptoms of functional impairment may 
develop (6). The respiratory disturbances cause oxygen desaturations and 
increased sympathetic nerve activity, both contributing to cardiovascular 
morbidity and mortality in apnea patients. Sleep apnea and snoring are 
associated with hypertension, angina pectoris, myocardial infarction and 
ischemic brain infarction (7-12). 
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The pathophysiologic mechanisms leading to sleep related breathing disorders 
and obstructive apneas are still unknown, but at least two components are likely 
to contribute: narrowing of the upper ainvay and instability of respiratory and 
muscle control. Upper airway patency is not only defined by static anatomical 
configuration, but also by dynamic changes of the muscles and soft tissue, 
caused by airflow and complicated reflex mechanisms of the respiratory system. 
Using cephalometric roentgenography the influence of bony structures and soft 
tissue on upper airway space can be assessed, but no information on dynamic 
obstruction can be obtained. Because it is easily performed and ample 
normative values are at hand, cephalometty remains the method of choice in 
assessing overall upper ainvay morphology (13). Although computed 
tomography and magnetic resonance imaging show more details of the upper 
airways and may even be performed during sleep like states, they are less 
routinely used, because they are expensive, time consuming and only limited 
normative values are at hand (13). By fiberoptic evaluation in combination with 
the Mueller maneuvre, the presence of upper ainvay collapse and local 
anatomical abnormalities can be visualised and scored (13). Pulmonary 
function testing, especially the variables of a maximally forced inspiratory 
manoeuvre, reflects the restriction of airflow caused by dynamic nal1'0wing of 
the upper ainvay (14). 
In comparison to the anatomical factors, the neurological aspects of ventilatOlY 
control and upper airway patency are less accessible for direct investigation. In 
general, however, periodic nocturnal breathing and sleep related changes in 
chemosensitivity and upper airway muscle tone and respiratory control are 
suspected to be major contributors to the development of sleep related breathing 
disorders (15-22). 
In this study we follow the hypothesis that both, disturbed respiratory control 
and altered upper ainvay patency playa role in the pathogenesis of the sleep 
apnea syndrome. We evaluated therefore the contribution of both static and 
dynamic obstruction parameters on the frequency and severity of respiratory 
disturbances during sleep. The quantitative assessment of the role of upper 
ainvay obstruction will enable us to estimate indirectly the role of disturbed 
respiratOlY and muscle control in the complex pathogenetic process. 
2.3 Materials and Methods 
Sixty consecutive patients, 53 men and 7 women, were included in this study. 
The mean age of the study group was 50.6 years (sd = 10.7, range 19 - 75 
years). All of them have been refetl'ed to our clinic because of heavy snoring or 
suspected sleep apnea syndrome. All patients underwent polysomnography, 
fiberoptic evaluation, including Mueller manoeuvre, pulmonary function studies 
and cephalometric roentgenography. The Body Mass Index (weightllength2) 
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was calculated for every subject. All patients included in the study were free of 
concommitant disease and no facial anatomical abnormalities were present. 
Polysol/Illography 
All patients underwent polysomnographic recording for one night. The 
polygraphic recording included electroencephalography, electro-oculography 
and electromyography registration and sleep stages were scored following the 
international criteria of Rechtschaffen and Kales (23). Respiration was 
monitored by thernlistors to assess' oro-nasal flow, by impedance 
plethysmography to assess respiratOlY chest and abdominal excursions and by 
pulse-oxymetry to detect oxygen desaturation. Apneas were divided into central 
type (no respiratOlY excursions and no flow), obsttuctive type (persisting 
respiratory effort, but no flow), and mixed type. 
Obstructive sleep apnea syndrome was defined as the presence of obstructive 
apneas during at least ten seconds or more leading to 5 desaturations or more 
per hour of sleep. Periods of at least 3% reduction of oxygen saturation from 
baseline were included in the calculation of the desaturation index (total 
desaturationsltotal sleep time per hour). The desaturation index and the 
maximal desaturation were used in our final analysis, because these are most 
reliably identified. 
Cephalometric Roentgenography 
Lateral cephalometric roentgenograms were obtained using a standardised 
method, as described by Riley et al (24). No differences in the positioning of 
the head were likely to occur, as rotation and flexion of the neck were prevented 
by using a specially designed frame. All roentgenograms were made in the 
sitting position, during slow inspiration with the mouth closed and the teeth 
relaxedly put together. All roentgenograms were made between 09.00 am and 
noon. Cephalometric parameters were scored by a single physician blind to the 
clinical and polysomnographic results. We used parameters that have been 
shown to be significantly different in groups of OSAS patients compared to 
healthy controls (24-32). The parameters included in our analysis were: the 
minimal posterior airway space at the level of the tongue base (PAS), the 
distance between the mandibular plane and the most cranio-ventral aspect of the 
hyoid bone (MPH), the length of the soft palate, being the distance of the 
posterior nasal spine to the tip of the uvula (SPL) and the diameter of the soft 
palate taken at the widest point (SPD). All measurements were expressed in 
millimeters. 
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Pulmonmy Function Testing 
Forced inspiratory and expiratOlY flow-volume curves were obtained using a 
heated pneumotachometer, which was volume-calibrated before each 
measurement. Peak inspiratory flow (PIF) and peak expiratory flow (PEF), 
were used as markers for upper airway obstruction. The maximum values from 
at least three acceptable manoeuvres were used in the analysis. PIF and PEF 
were expressed as their absolute values. Regular oscillations on the respiratOlY 
curve were considered present or not-present and were judged by eye. None of 
the patients included in the study showed signs of obstructive pulmonaty 
disease, as defined by the European RespiratOlY Society (33). 
Mueller Manoeuvre 
A fiberoptic naso-endoscopic device was used to visualise the upper airway, to 
determine aitway morphology at the level of the soft palate and the tongue base 
and to exclude local anatomical abnomlalities. The Mueller manoeuvre was 
performed to assess the collapsibility at the level of the soft palate (MSP) and at 
the level of the tongue base (MTB), using a five points, semi quantitative scale 
(0=0%, 1=25%, 2=50%, 3=75% and 4=100% of nanowing of airway space). 
The manoeuvre was performed in the supine position. All examinations were 
performed by a otorhinolalyngologist, blind to the polysomnographic data. 
Statistical Methods 
All obstruction parameters and Body Mass Index were dichotomized around 
their medians in order to allow univariate and multivariate regression analysis. 
We report the multiple con'elation coefficient 1'2 (a measure for assessment of 
the contribution of the study parameters to the variation in desaturation 
parameters) and the p- values in univariate regression analysis of each 
obstruction parameter on desaturation index and maximal desaturation. A 
multivariate regression analysis of all study parameters was performed on the 
two desaturation parameters. This was followed by a stepwise (forward and 
backward) regression analysis. P- values below 0.05 were considered 
significant. 
2.4 Results 
Table 2.1 shows the anthropometric data. No significant differences were found 
between the male and female subgroups, and they were further analysed as one 
group. Following our criteria; 35 men and 2 women should be considered sleep 
apnea patients. 
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Body Mass Index (BMI) was a significant contributing factor to desaturation 
index (1'2=0.13, p=0.004), while its contribution to maximal desaturation was 
low and not significant (table 2.2). 
Table 2.1. Anthropometric data of the study populatiou 
Parameter Mean S.D. Range 
Desaturation Index (DI)(nlhour) 13.8 17.7 0-79 
Maximal Desaturatiou (MD)(%) 9.3 7.6 0-32 
Body Mass Index (BMI)(kgln12) 28.1 4.8 18.3 - 42.7 
Mandibular Plane-HyoId (MPH)(mm) 22.4 7.5 5.0 - 46.0 
Soft Palate Leugth (SPL)(nml) 38.5 6.5 25.0 - 57.0 
Soft Palate Diameter (SPD)(mm) 11.5 1.8 8.0 - 16.0 
Posterior Airway Space (PAS)(mm) 11.6 3.5 3.0-21.0 
Peak Iuspiratory Flow (PIF)(Vsec) 7.95 2.07 2.82 - 12.91 
Peak Iuspiratory Flow (PIF)(Vsec) 10.20 2.44 3.83 - 14.55 
Mueller Tongue Base (MTB)(0-4) 0.8 1.1 0-4 
Mueller Soft Palate (MSP)(0-4) 2.7 1.3 0-4 
The results of the analysis using the static cephalometric variables are shown in 
table 2.2. Increased distance of mandibular plane to hyoid (MPH) contributed 
significantly to both desaturation index (1'2=0.10, p=O.O I) and maximal 
desaturation (1'2=0.08, p=0.03). Soft palate length (SPL) contributed 
significantly to desaturation index (1'2=0.13, p=0.004), while its contribution to 
maximal desaturation was far from significant. The soft palate diameter (SPD) 
contributed significantly to maximal desaturation (1'2=0.09, p=0.02). Posterior 
airway space (PAS) was not related to either of the desaturation parameters. 
Although several cephalometric parameters were significantly related to the 
desaturation parameters as individual parameters, they explained only 8-13% of 
the variation in desaturation parameters, as indicated by the r-square values. 
Of the pu Imonaty functions tested both peak inspiratory flow (PIF) and peak 
expiratory flow (PEF) were significant contributing factors to both desaturation 
parameters, but their impact on desaturation index was very low (1'2=0.07, 
p=0.04 and 1'2=0.08, p=0.03 respectively), while their impact on maximal 
desaturation was slightly higher (1'2=0.19, p<O.OO 1 and 1'2=0.10, p=O.O I 
respectively). The results are shown in table 2.2. 
None of the variables assessed by Mueller manoeuvre was significantly 
con'elated to the desaturation parameters and the contribution to oxygen 
desaturation was found to be very low. The relation between collapsibility at 
the tongue base and maximal desaturation was only a trend (1'2=0.07, p=0.05). 
The results are shown in table 2.2. 
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Table 2.2. 
Univariate Multivariate Multivariate 
Analysis Analysis Analysis 
(all parameters) (stepwise) 
Median r' p r' P 
2 
r P 
DESATURATION INDEX 
BMI 27.3 0.13 0.004' 0.42 <0.001' 0.37 <0.001 
MPH 22 0.10 0.01' 0.38 
SPL 38 0.13 0.004' 0.01' 0.006' 
SPD 12 0.02 0.37 0.38 
PAS II 0 0.98 0.36 
PIF 7.16 0.07 0.04' 0.67 
PEF 10.56 0.08 0.03' 0.83 
MTB 0 0.02 0.25 0.38 
MSP 3 0.06 0.06 0.83 
MAXIMAL DESATURATION 
BMI 27.3 0.04 0.11 0.41 0.15 0.31 
MPH 22 0.08 0.03' 0.11 0.04' 
SPL 38 0.04 0.12 0.26 
SPD 12 0.09 0.02' 0.28 0.01' 
PAS 11 0 0.79 0.25 
PIF 7.16 0.19 <0.001' 0.38 
PEF 10.56 0.10 0.01' 0.62 
MTB 0 0.07 0.05' 0.02' 0.003' 
MSP 3 0.01 0.46 0.63 
Univariate and multivariate analysis (including all parameters and the stepwise analysis) of 
the obstruction parameters and BMI in relation to Desaturation Index (top half) and Maximal 
Desaturation (bottom half). For abbreviations; see table 2.1. 
In the multivariate regression analysis including all obstmction parameters, 42% 
of the variation in desaturation index and 41 % of the variation in maximal 
desaturation could be explained by all parameters, while only SPL and BMI 
were significantly related to desaturation index (p=O.O I and p=O.OO I 
respectively) and only MTB seemed to be significantly related to maximal 
desaturation (p=O.02). In the stepwise regression analysis SPL and BMI 
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remained significantly related to desaturation index (p~0.006 and p<O.OO I 
respectively), while SPD, MPH and MTB remained significantly related to 
maximal desaturation (p~O.OI, p~0.04 and lFO.003 respectively). Only 37% of 
the variability in desaturation index and only 31 % of the variability in maximal 
desaturation could be explained by these factors (table 2.2). 
2.S Discussion 
We included patients refen'ed for snoring or suspected obstmctive sleep apnea 
syndrome (OSAS). In the analysis we did not differentiate between patients 
fullfilling OSAS-criteria and heavily snoring patients, because we intended to 
study the continuum of this complex pathogenetic process. We did not use the 
Apnea-Hypopnea-Index (AHI), because the analysis of desaturation parameters 
not only provides information about the number but also about the severity of 
respiratOlY events and the measure of oxygen desaturation is believed to playa 
major role in causing cardiovascular disease in OSAS-patients (11,34,35). In 
addition, desaturation parameters are technically more reliably identified, 
compared to apneas or hypopneas, since measurement artifacts due to motor 
activity may occur frequently in some patients. It should, however, be noted 
that desaturations not preceeded by a respiratOlY event were not included in the 
analysis. 
Our population represents the whole spectrum of sleep related breathing 
disorders, from severe snoring alone to OSAS. The comparison of the 
anthropometric data with other studies is therefore difficult, because most 
studies use selected patient groups of OS AS-patients, heavily snoring patients, 
or healthy persons (1-5,25-32). The Body Mass Index we found in our study 
group is intelmediate in comparison to those of OSAS patients and heavily 
snoring patients presented in the afore mentioned studies. The age group is 
similar and 90% in our study group is male, findings that are consistent with 
earlier reports (27,30). Recent epidemiologic data show, however, that sleep 
disordered breathing is only twice as frequent in men than in women. It may be 
that women do have less complaints, or are less often referred for further 
clinical evaluation. 
The use of cephalometric analysis of the upper airway is widely accepted (13). 
Although numerous diameters, distances and angles can be measured, we 
selected those parameters from recent publications, most constantly showing 
differences in OSAS-patients compared to controls (25-32). Vertical 
displacement of the hyoid bone, increased dimensions of the soft palate, and 
decreased posterior airway space are the most consistent findings in relation to 
sleep disordered breathing. We found increased vertical displacement of the 
hyoid bone (MPH) to be the most important contributing factor to both 
desaturation index and maximal desaturation. The hyoid bone is the origin of 
52 
Pathogenesis 
the hyoglossal musculature. Vertical downward displacement of this shucture 
pulls the tongue backward, into the hypopharynx. Strelzow et al. showed that 
an increase in dimensions of the soft palate, length and diameter, are con'elated 
to an increase in Apnea-Hypopnea-Index (25). We found that increased 
dimensions of the soft palate had indeed a clear influence on desaturation 
parameters, but the impact on oxygen desaturation was low. 
The usefulness of the pulmonalY function variables is limited, because PIF and 
PEF are influenced also by muscle strength and respiratory effort. PIF provides 
not only information on static, but also on dynamic obstruction during 
inspiration; this combination may explain why we found PIF to be the strongest 
predicting factor to maximal oxygen desaturation, while both PIF and PEF 
contributed significantly to desaturation index and maximal desaturation. 
During sleep muscle tone and respiratory control are influenced by sleep phase 
related changes, resulting in lower muscle tone and lower vital capacities (16). 
This means that with unchanged upper airway anatomy, the contribution of 
changes in respiratory control to dynamic narrowing will even be bigger during 
sleep. The presence or absence of oscillations on the respiratory curve is not 
related to either of the desaturation parameters. 
When interpreting data obtained by the Mueller manoeuvre we are realising its 
limitations. The Mueller manoeuvre was performed on awake patients, so the 
results cannot be extrapolated directly to the sleeping situation, since active 
contraction of the upper airway musculature during the procedure might occur. 
On the other hand, with this limitation in mind we believe that the Mueller 
manoeuvre in awake patients is a useful method in comparing overall 
collapsibility of the upper airway between patients. We found that part of the 
desaturation parameters were predicted by collapsibility at the base of the 
tongue. 
A striking finding in our study is that anatomy and collapsibility at the level of 
the tongue base is related to maximal de saturation, rather than to desaturation 
index. This is in concordance with our hypothesis (36), that increased 
collapsibility at the level of the tongue base may lead to longer apneas with 
more desaturation, because more respiratory muscle effort is needed to regain 
nOlmal breathing. However, we were not able to show a relation between 
reduced posterior airway space at this level and the desaturation parameters. 
This suggests that dynamic narrowing, as seen with the Mueller manoeuvre and 
pulmonary function testing, is more important in causing obstruction than 
differences in static upper airway anatomy at that level. 
We believe to have included in our final analysis, all variables with reproducible 
relation to sleep related breathing disorders from the literature (25-32). We 
found that 30-40% of the variation of the desaturation parameters could be 
explained by obstruction parameters. This means that approximately 60% of 
the variability of oxygen desaturation parameters in sleep related breathing 
disorders is not directly explained by obstructive factors. Lugaresi et al. in 1972 
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presented data, suggesting that oscillations within the central nervous system are 
likely to be patt of the mechanism causing sleep related breathing disorders 
(15). Phillipson in 1978 was the first to state that during NREM I1II, the 
carbo dioxide "set-point" was elevated by disappearance of the wakefulness 
stimulus, causing periodic fluctuation between relative hyperventilation and 
hypoventilation, during the physiologic changes between wake and NREMIIII, 
so characteristic of superficial sleep (16). Chapman et al. in 1988 showed that 
increased "loop-gain" in ventilatOlY control during sleep results in periodic 
breathing in OSAS patients (17). Longobardo et al. developed a model-based 
study and demonstrated the inten-elationship between periodic breathing and 
upper airway resistance (18,19). Their results were reproduced by Khoo et al. 
in 1991 in their model based study (20). The precise mechanism of interaction, 
however, remains obscure, but the obstlUctive apneas during sleep were shown 
to be dependent on the chemosensitive component of neuromuscular control of 
respiration and upper airway patency. Onal et al. were able to demonstrate that 
during an obstlUctive apnea a reduction in electromygraphic activity of both the 
diaphragm and the genioglossal muscle could be recorded (21). In general, 
however, upper airway muscle activity is increased in OSAS patients, compared 
to nOlIDal subjects (22). Those findings indicate that oscillating motor output is 
another possible underlying cause of obstlUctive apneas. 
Our results again stress the complexity of the pathogenetic mechanisms of sleep 
related breathing disorders and OSAS. Thitty to 40 percent of desaturation 
parameters may be explained by obsl1lction parameters alone, 60-70% may be 
explained by multiple other mechanisms, including; oscillations within the 
central nervous system, deranged motoneuron activity of the upper airway and 
respiratory musculature, and changes in metabolic set-point increasing the loop-
gain of the respiratory control system during sleep. All of these mechanisms are 
subject to nOlIDal ageing related changes in neuromuscular properties and sleep 
architecture, making the understanding of the pathogenesis of sleep related 
breathing disorders even more difficult. We conclude that instability of 
respiratory and muscle control, even enhanced by sleep phase related changes is 
more imp0l1ant in the pathogenesis of sleep related breating disorders than is 
pure anatomic nan-owing of the upper airway. 
54 
Pathogenesis 
References 
J. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-
disordered breathing among middle-aged adults. N Engl J Med 1993;328: 1230-5. 
2. Partinen M, Telakivi T. Epidemiology of obstructive sleep apnea syndrome. Sleep 
1992;15:SI-S4. 
3. Lavie P. Sleep apnea in a presumably healthy working population: A significant 
relationship with excessive daytime sleepiness. Sleep 1983;6(4):312-8. 
4. Gislason T, Almqvist M, Eriksson G, Taube A, Boman G. Prevalence of sleep apnea 
syndrome among swedisch men: an epidemiological study. J Clin Epidemiol 
1988;41 (6):571-6. 
5. Cirignotta F, D'Alessandro R, Partinen M, Zucconi M, Cristina E, Gerardi R, 
Cacciatore FM, Lugaresi E. Prevalence of every night snoring and obstructive sleep 
apnoeas among 30-69-year-old men in Bologna, Italy. Acta Psychatr Scand 
1989;79:366-72. 
6. Montplaisir J, Bedard MA, Richer F, Rouleau I. Neurobehavioural manifestations in 
ohstmctive sleep apnea syndrome before and after treatment with continuous positive 
airway pressure. Sleep 1992; 15:S 17-S 19. 
7. Gislason T, Benediktsd6ttir B, Bjomsson JK, Kjartansson G, Kjeld M, Kristbjamarson 
H. Snoring, hypertension, and the sleep apnea syndrome: an epidemiological survey of 
middle-aged women. Chest 1993;103(4):1147-51. 
8. Koskenvuo M, Partinen M, Sarna S, Kaprio J, Langinvainio H, Heikkila K. Snoring as 
a riskfactor for hypertension and angina pectoris. The Lancet 1985;893-5. 
9. Bliwise DL, Bliwise NG, Partinen M, Pursley AM, Dement WC. Sleep apnea and 
mortality in an aged cohort. AJPH 1988;78(5):544-7. 
10. Kales A, Cadieux RJ, Shaw LC, Vela-Bueno A, Bixler EO, Schneck DW, Locke TW, 
Soldatos CR. Sleep apnea in a hypertensive population. The Lancet 1984; 1 005-8. 
1 J. Hung J, Whitford EG, Parsons RW, Hillman DR. Association of sleep apnea with 
myocardial infarction in men. The Lancet 1990;336:261-4. 
12. Palomaki H. Snoring and the risk of ischemic brain infarction. Stroke 1991 ;22: 1021-5. 
13. Shepard JWjr, Geller WB, Guilleminault C, Hoffman EA, Hoffstein Y, Hudgel DW, 
Suratt PM, White DP. Evaluation of the upper airway in patients with obstructive sleep 
apnea. Sleep 1991;14(4):361-71. 
14. Bogaard JM, Pauw KH, Versprille A. Flow limitation in upper airway obstruction: a 
theoretical analysis. Oto Rhino Laryngol 1987;49:42-7. 
15. Lugaresi E, Coccagna G, Mantovani M, Lebrun R. Some periodic phenomena arising 
during drowsiness and sleep in man. Eur J Respir Dis 1972;32:701-5. 
55 
Chapter 2 
16. Phillipson EA. Control of breathing during sleep. Am Rev Respir Dis 1978; 118:909-
39. 
17. Chapman KR, Bruce EN, Gothe B, Cherniak NS. Possible mechanisms of periodic 
breathing during sleep. J Appl Physiol 1988;64(3): 1000-8. 
18. Longobardo GS, Gothe B, Goldman MD, Cherniak NS. Sleep apnea considered as a 
control system instability. Respir Physiology 1982;50:311-33. 
19. Longobardo GS, Cherniak NS, Gothe B. Factors affecting respiratory system 
instability. Ann Blomed Eng 1989; 17:377-96. 
20. Khoo MCK, Gottschalk A, Pack AI. Sleep induced periodic breathing and apnea: a 
theoretical study. J Appl Physiol 1991;70(5):2014-24. 
21. Onal E, Lopata M, O'Conner T. Pathogenesis of apneas in hypersonmia-sleep apnea 
syndrome. Am Rev Respir Dis 1982;125: 167-74. 
22. Suratt PM, McTier RF, Wilhoit SC. Upper airway muscle activation is augmented in 
patients with obstructive sleep apnea compared with that in normal subjects. Am Rev 
Respir Dis 1988;137:889-94. 
23. Rechtschaffen, A. and Kales, A. A manual of standardized terminology, teclmiques 
and scoring system for sleep stages of human subjects. University of California: Brain 
informationIBrain research institute. 1973. 
24. Riley R, Guilleminault C, Herran J, Powell N. Cephalometric analysis and flow-volume 
loops in obstructive sleep apnea patients. Sleep 1983;6(4):303-11. 
25. Strelzow VV, Blanks RHI, Basile B, Strelzow AE. Cephalometric airway analysis in 
obstructive sleep apnea syndrome. Laryngoscope 1988;98: 1149-58. 
26. Maltais F, Carrier G, Comlier Y, Series F. Cephalometric measurements in snorers, 
non-snorers, and patients with sleep apnoea. Thorax 1991;46:419-23. 
27. Partinen M, Guilleminault C, Quera-Salva MA, Jamieson A. Obstructive sleep apnea 
and cephalometric roentgenograms; the role of anatomic upper airway abnomlalities in 
the definition of abnormal breathing during sleep. Chest 1988;93(6):199-1205. 
28. Guilleminault C, Quera-Salva MA, Partinen M, Jamieson A. Women and the 
obstructive sleep apnea syndrome. Chest 1988;93(1): 105-9. 
29. Andersson L, Brattstr6m V. Cephalometric analysis of permanently snoring patients 
with and without obstructive sleep apnea syndrome. Int J Oral Maxillofac Surg 
1991;20: 159-62. 
30. deBerry-Borowiecki B, Kukwa A, Blanks RHI. Cephalometric analysis for diagnosis 
and treatment of obstructive sleep apnea. Laryngoscope 1988;98:226-34. 
31. Lyberg T, Krogstad 0, Djupesland G. Cephalometric analysis in patients with 
obstructive sleep apnea syndrome, I. Skeletal morphology. Journal of Laryngology 
and Otology 1989;103:287-92. 
56 
Pathogenesis 
32. Lyberg T, Krogstad 0, Djupesland G. Cephalometric analysis in patients with 
obstructive sleep apnea syndrome,II. Soft tissue morphology. Jountal of Laryngology 
and Otology 1989;103:293-7. 
33. Quanjer PhH. Standardized lung function testing: Official Statement of the European 
Respiratory Society. Eur Respir J 1993;6(9): 1415-6. 
34. De Olazebel JR, Miller MJ, Cook WR, Mithoefer JC. Disordered breathing and 
hypoxia during sleep in coronary artery disease. Chest 1982;82:548-52. 
35. Gainer JL. Hypoxia and atherosclerosis: re-evaluation of an old hypothesis. 
Atherosclerosis 1987;68:263-266. 
36. Bogaard JM, van der Meche FGA, Poublon RML, Gina! AZ, Schmitz PIM, Bubbennan 
A, Siappendel AM, Boot H. Indices from flow-volume curves in relation to 
cephalometric, ENT - and sleep-Ol saturation variables in snorers with and without 
obstructive sleep-apnoea. Eur Respir J 1995;8:801-6. 
57 

CHAPTER 3 
Short-term Results of 
Uvulopalatopharyngoplasty for 
Obstructive Sleep Apnea Syndrome 
Published as: 
Uvulopalatopharyngoplasty for the Obstructive Sleep Apnea Syndrome: 
Value ofPolysomnography, Mueller Manoeuvre and Cephalometry in 
Predicting Surgical Outcome 
Boot H, Ponblon RML, van Wegen R, Bogaard JM, Schmitz PIM, Gina! AZ, 
and van der Meche FGA. 
Clin. Otolaryngol. 1997 Dec;22(6):504-51O 
Chapter 3 
3.1 Abstract 
Sixty consecutive patients with obstructive sleep apnea syndrome, 53 men and 7 
women were analysed by introspective questionnaire, polysomnography, 
roentgenographic cephalometry and Mueller manoeuvre before and six months 
after uvulopalatophatyngo-plasty (UPPP), to assess surgical outcome and the 
prognostic value of pre-operative evaluation. Seventy three percent reported 
improvement of snoring and 55% reported improvement of excessive daytime 
sleepiness. Thirty-five percent showed a decrease of at least 50% in 
desaturation index, 20% showed an increase of mean saturation, and 29% 
showed an increase of lowest saturation. Thirteen percent had post-operative 
desaturation index below 5. Although the improvement of desaturation 
parameters was marked in some patients, the overall change was not significant. 
Body Mass Index, nor any of the cephalometric variables were significantly 
cOlTelated to surgical outcome. Increased difference in collapsibility between 
soft palate and base of the tongue showed a close to significant relation with 
improvement of desaturation index. High desaturation index, low mean 
saturation and deep lowest saturation were found to be slightly predictive of 
improvement in nocturnal desaturation. It is concluded that UPPP is effective in 
reducing snoring and daytime sleepiness over a 6 months follow-up period, but 
that the overall improvement in nocturnal desaturation is limited and difficult to 
predict. Further research is needed to evaluate long telm efficacy of UPPP. 
3.2 Introduction 
Approximately 3-4% of middle-aged men and 2% of middle-aged women are 
likely to meet the minimal criteria of obstructive sleep apnea syndrome (OSAS) 
(1,2). Snoring, excessive daytime sleepiness and nocturnal breathing stops are 
the cardinal symptoms of OSAS (3), but associated neuropsychological defecits, 
mood disorders and cardiovascular sequelaea may diminish daytime 
performance and life expectancy (4-9). 
Many surgical and non-surgical techniques have been developed to treat OSAS. 
Tracheostomy is very effective in improving both snoring and nocturnal 
desaturations, but its invalidating effects are a serious limitation for routine 
OSAS treatment (10). Although nasal Continuous Positive Airway Pressure 
(nCPAP) has been shown to be very effective in improving daytime sleepiness 
and nocturnal desaturations (11), its burden on sleeping and social behaviour 
may be responsible for low long term compliance (12). In 1981 Fujita 
introduced the Uvulopalatopharyngoplasty (UPPP) (13), a procedure developed 
earlier by Ikematsu for the treatment of snoring (14). UPPP can effectively 
reduce snoring, daytime sleepiness and nocturnal desaturations, but its surgical 
outcome is highly variable and difficult to predict. In the absence of simple and 
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easily acceptable treatment alternatives, careful identification of selection 
criteria, may enable us to offer UPPP only to those who will benefit most. 
The goal of this study is to assess the prognostic value of routine pre-operative 
evaluation by polysomnography, Mueller manoeuvre, cephalometric roentge-
nography, Body Mass Index and age to treatment outcome after UPPP. We 
therefore assessed the effectivity of UPPP in reducing snoring, daytime 
sleepiness and nocturnal desaturations after a six months follow-up period in a 
large consecutive series of 60 patients. 
Table 3.1. 
Parameter Base-line 
Median 95% 
Age 49 29 - 71 
Body Mass Index 29.6 21.4 - 38.7 
Snoring score 3 I - 4 
Sleepiness score 3 0-5 
Desaturation Index 15 6 - 89 
Base-Line Saturation 95% 90% - 98% 
Mean Saturation 91% 77% - 94% 
Lowest Saturation 84% 54% - 90% 
Six months 
Median 
28.4 
18 
95% 
91% 
82% 
95% 
21.0 - 38.8 
0-4 
0-5 
0-75 
92% - 98% 
83% - 96% 
61% - 96% 
n 
52 
58 
57 
43 
42 
42 
43 
Anthropometric data, baseline characteristics and six months follow-up data. The second 
colonm under Base-line and Six months displays the 95 interpercentile range of each 
variable. The last colomn presents the number of patients in whom pre- and post-operative 
data are complete. 
3.3 Materials and Methods 
We included sixty consecutive patients, 53 men and 7 women. All patients have 
been referred to our clinic because of snoring or daytime sleepiness; 
polysomnography confirmed the diagnosis of obstructive sleep apnea syndrome 
(OSAS). Anthropometric data and base-line characteristics are summarized in 
table 3.1. A specially designed questionnaire with semi-quantitative scales was 
used to evaluate snoring and daytime sleepiness before and after surgery (see 
table 3.2). 
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Table 3.2 . 
• Scale for severity of Snoring 
o = No snoring or occasional snoring 
I ~ Every night snoring, but not influencing sleep of partner 
2 ~ Every night snoring, sleeps separated occasionally L 1 x I week) 
3 ~ Every night snoring, sleeps separated;e 2x I week but <; 7x I week 
4 ~ Every night snoring, sleeps separated every night 
• Scale for Daytime Sleepiness 
o ~ No sleepiness 
1 ~ Occasionally fighting against falling asleep 
2 ~ All day fighting against falling asleep 
3 ~ All day fighting and falling asleep on quiet moments 
4 ~ All day fighting and falling asleep during activity 
5 ~ All day fighting and sleeping more than 5 hours during daytime 
The semi-quantitative scale for Snoring and Sleepiness (see material and methods). 
Improvement of nocturnal desaturation parameters was assessed by 
polysomnography before and after UPPP. Fiberoptic nasendoscopy with 
Mueller manoeuvre and cephalometric rontgenography were only performed 
during pre-surgical evaluation. The Body Mass Index (BMI = kg/m') was 
calculated for every subject. All patients included in the study were free of 
concomitant disease and no facial anatomical abnOimalities were present. 
Polysolllllography 
The polygraphic recording included electroencephalography, electro-
oculography and electromyography. Sleep stages were scored following the 
international criteria of Rechtschaffen and Kales (15). Respiration was 
monitored by thermistors to assess oro-nasal flow, by impedance plethys-
mography to assess respiratory chest and abdominal excursions and by pulse-
oxymetry to detect oxygen desaturation. Apneas were divided into central type 
(no respiratory excursions and no flow), obstructive type (persisting respiratory 
effort, but no flow), and mixed type. Obstructive sleep apnea syndrome was 
defined as the presence of obstructive apneas during at least ten seconds or more 
leading to 5 desaturations or more per hour of sleep. Periods of at least 3 % 
reduction of oxygen saturation from baseline were included in the calculation of 
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the desaturation index (total desaturations/total sleep time per hour). The 
desaturation index, mean saturation and maximal desaturation were used in our 
final analysis. The recording was repeated six months after surgery. 
Cephalometric Roentgenography 
Lateral cephalometric roentgenograms were obtained using a standardised 
method, as described by Riley et al (16). No differences in the positioning of 
the head were likely to occur, because rotation and flexion of the neck were 
prevented by using a specially designed frame. All roentgenograms were made 
in the sitting position, during slow expiration with the mouth closed and the 
teeth relaxedly put together. All roentgenograms were made between 09.00 am 
and noon, to avoid inter-individual differences that may result from absorbtion 
of pharyngeal oedema. Cephalometric parameters were scored by a single 
physician blind to the clinical and polysomnographic results. The parameters 
included in our analysis were: the minimal posterior airway space at the level of 
the tongue base (PAS), the distance between the mandibular plane and the most 
cranio-ventral aspect of the hyoid bone (MPH), the length of the soft palate, 
being the distance of the posterior nasal spine to the tip of the uvula (SPL) and 
the diameter of the soft palate taken at the widest point (SPD). All measure-
ments were expressed in millimeters. 
Mueller Manoeuvre 
A fiberoptic naso-endoscopic device was used to visualise the upper airway 
morphology. The Mueller manoeuvre was performed to assess the collapsibility 
at the level of the soft palate (MSP) and at the level of the tongue base (MTB), 
using a five points, semi quantitative scale (0=0%, 1 =25%,2=50%, 3=75% and 
4=100% of nan'owing of aiIway space). The manoeuvre was performed in the 
supine position. The subjects were asked to make a maximal inspiratory effort 
with the mouth closed and the examiner pinching the nostrils. By carefully 
releasing the nostrils until a minimal airflow arises, the examiner checks if the 
inspiratory effort is close to maximal. All examinations were perfonned by the 
same otorhinolaryngologist, who was blinded for the polysomnographic data. 
UvulopalatophmJ'ngoplasty (UPPP) 
Subjects were positioned as for tonsillectomy. The surgical procedure was 
performed under general anesthesia with a naso-tracheal intubation. The uvula 
was pulled towards the surgeon. The resulting natural horizontal crease in the 
pillar mucosa was used as the line for incision. The oral side of the palatal 
mucosa and sub-mucosa were removed, expanding laterally if a pre-operative 
lateral collapse was found. The naso-pharyngeal side of the palatal mucosa and 
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sub-mucosa were not removed. The uvula itself was shortened, ifnecessaty, but 
not removed. If present, redundant tonsillar fossa mucosa and tonsillar tissue 
were also removed. The palatoglossal and palatophatyngeal muscles were 
spared during the procedure. Finally the posterior pillar was advanced and 
sutured to the anterior pillar with the suture line away from the nasopharynx. 
Statistical Methods 
Base line characteristics and post-operative data are presented as median and 95 
interpercentile range. Improvement in snoring, daytime sleepiness, nocturnal 
desaturation parameters and Body Mass Index was analysed with the Wilcoxon 
matched-pairs signed-ranks test. The relationship between post-operative 
changes and changes in BMI was analysed by regression analysis. Prognostic 
value of pre-operative measurements on snoring and sleepiness was assessed by 
the chi-square test for a 2xr table. All continuous parameters were divided in 4 
categories (quartiles) to do so. Prognostic value of pre-operative measurements 
on nocturnal desaturation was also analyzed by univariate regression analysis, 
followed by stepwise multi-variate analysis. Body Mass Index, age, soft palate 
length, soft palate diameter, posterior airway space, distance from mandibular 
plane to hyoid, collapsibility of soft palate by Mueller manoeuvre, difference 
between collapsibility between soft palate and tongue base, desaturation index, 
mean saturation and lowest saturation were included in the analysis. P-values 
below 0.05 were considered to indicate significance. 
3.4 Results 
Since no significant differences were found between male and female 
subgroups, they were analysed together. 
Seventy three percent of our population reported improvement of snoring of at 
least one position on the snoring scale, while 20% reported no change and 7% 
repOlted an increase. The improvement of snoring in the group was found to be 
highly significant (p = 0.0001). Fifty five percent reported improvement of at 
least one position on the daytime sleepiness scale, while no change was reported 
by 42% percent. This improvement was also found to be highly significant (p = 
0.0001). Only three percent reported an increase in daytime sleepiness. 
Detailed pre- and post-operative polysomnographic data were available in 43 
patients. Anthropometric data and baseline characteristics were not 
significantly different from the remaining 17 patients. No significant 
improvement in any of the nocturnal desaturation parameters was present. The 
changes in Desaturation Index (DI) are summarised in table 3.3. In only 8 cases 
(13%) a post-operative DI below 5 could be recorded. 28 Patients showed a 
post-operative DI below 20, but only seven of those had a pre-operative DI 
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above 20. The changes in the other desaturation parameters are summarised in 
table 3.4. Increase of mean saturation from below 90% to above this level was 
present in only 8 subjects. 
Table 3.3. 
Change in Desaturatioll Index 
Percentage of patients 
;, -50% 
35 
;, -10% 
55 
<±10% 
10 
;, +10% 
35 
Change in Desaturation Index (DI). The percentage of the studygroup showing a decrease of 
at least 50%, a decrease of at least 10%, a change of less than 10% and an increase of at least 
10% is displayed respectively. Negativity means improvement. 
Table 3.4. 
Change in l\'lcan Saturation ;'+3% < ±3% ;, -3% 
Percentage of patients 20 53 27 
Change in Lowest Saturation ~ +5% < ±S% ;, -5% 
Percentage of patients 29 51 20 
Changes in Mean Saturation and Lowest Saturation respectively. Positivity means 
improvement. The cut-off point are rather arbitrary and result from "visual dichotomisationu. 
In 52 cases the Body Mass Index (BMI) could be assessed reliably both before 
and after surgely. A significant decrease in BMI was present (p = 0.001), 65% 
showed weight reduction, 13% did not change, and 22% gained weight. Change 
in BMI was not related to changes in snoring (p = 0.97), daytime sleepiness (p = 
0.62), or (p = 0.98), mean saturation (p = 0.47) and lowest saturation (p = 0.83). 
The data obtained by Mueller manoeuvre and cephalometric analysis are 
summarized in table 3.5 and 3.6. 
65 
Chapter 3 
Table 3.5. 
Soft Palate (SP) Tongue Base (TB) Difference (SP-TB) 
-25% 
0% 0 21 4 
25% II 13 
50% 9 II 13 
75% 21 4 13 
100% 19 3 6 
The number of patients with collaps of the upper-airway by Mueller manoeuvre at the soft 
palate and at the tongue base, and the difference between the two levels (semiquantitative 
scale as defined in text). 
Table 3.6. 
Soft Palatum Length (n ~ 46) 
Soft Palatum Diameter (n ~ 41) 
Distance Mandibular Plane to Hyoid (n ~ 47) 
Posterior Airway Space (n ~ 46) 
42.5 (27.9 - 55.6) 
13.0 (8.7 - 18.6) 
21.4 (5.7 - 36.9) 
12.7 (4.2 - 32.9) 
The parameters of the cephalometric analysis are presented as their median and 95%-
interpercentile range (in millimeter). 
Body Mass Index, nor age, nor any of the cephalometric measurements was 
related to any of the post -operative changes. The relation between increased 
difference in collapsibility between soft palate and tongue basis, and improve-
ment in DI was almost significant (p ~ 0.051) (see fig 3.1). Subjects with 
higher pre-operative DI showed significantly higher improvement of DI (see fig 
3.2). Improvement inlllean saturation was significantly correlated to lower pre-
operative mean saturation and lowest saturation levels (see fig 3.3 and fig 3.4). 
Improvement in lowest saturation was significantly correlated to lower mean 
saturation and lowest saturation levels (see fig 3.5 and fig 3.6). 
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Figure 3.1. 
Relationship between collapsibility index 
(collapsibility soft palate minus 
collapsibility tongue base by Mueller 
manoeuvre) and improvement of 
desaturation index (desaturation index 
post-operative minus desaturation index 
pre-operative; negativity is improvement). 
Due to unequal distribution of data over 
de different degrees of collapsibility index, 
three subgroups had to be formed to allow 
statistical analysis (p ~ 0.05, R' ~ 0.10). 
Figure 3.2. 
Relationship between pre-operative 
desaturation index and improvement of 
desahtration index (desaturation index 
post-treatment minus desaturation index 
pre-treatment; negativity is improvement) 
(p ~ O.QI, R' ~ 0.15). 
Figure 3.3. 
Relationship between mean pre-operative 
saturation and improvement of mean 
saturation (mean saturation post-treatment 
minus mean saturation pre-treatment; 
positivity is improvement) 
(p ~ 0.001, R' ~ 0.24). 
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Figure 3.4. 
Relationship between lowest pre~operative 
saturation and improvement of mean 
saturation (mean sahlration post-treatment 
minus mean saturation pre-treatment; 
positivity is improvement) 
(p ~ 0.001, R' ~ 0.25). 
Figure 3.5. 
Relationship between mean pre-operative 
saturation and improvement of lowest 
saturation (lowest saturation post-
treatment minus lowest saturation pre-
treatment; positivity is improvement) 
(p ~ 0.0001, R' ~ 0.48). 
Figure 3.6, 
Relationship between lowest pre-operative 
saturation and improvement of lowest 
saturation (lowest saturation post-
treatment minus lowest saturation pre-
treatment; positivity is improvement) , (p ~ 0.04, R ~ O. II). 
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In the stepwise multivariate analysis no simultaneuos significant predictive 
factors could be identified. 
Post-operative complications were relatively rare. Twelve percent of our 
patients needed antibiotic treatment for wound infection, 11 % reported 
intolerable pain, regurgitation was found in 3% and rebleeding in 2%. After 6 
months, only 7% reported mild speech problems, but did not need further 
treatment, while only 2% complained of occasional regurgitation of fluids. 
Ninety-one percent did not experience any long term side effects of the surgical 
procedure. 
3.5 Discussion 
We demonstrate again that UPPP is a powerful tool in the treatment of snoring 
and daytime sleepiness, and our findings confirm those in earlier reports. 
Prominent reduction in the loudness of snoring was reported by the spouses of 
all patients presented by Walker et a!. (17). Eighty-eight percent of patients 
reported by Davis et a!. marked themselves as improved (18). Both studies 
present data obtained by subjective judgement of the patient, without any 
quantification, and may therefore overestimate the real effect. Macnab et a!. 
used a semi-quantitative scale to assess improvement of snoring, and found 76% 
of their population to be significantly improved (19). Although their post-
operative questionnaire contained suggestive questions with more options for 
improvement than for worsening, their data resemble ours. Assessment of post-
operative improvement of snoring expressed in decibels may show different 
results, but introduces a parameter without clinical relevance. The majority of 
studies adressing improvement of daytime sleepiness after UPPP, report un-
quantified and subjective markings of the patients (18,20-22). Seventy-one 
percent of 38 patients improved at least 50% on a semi-quantitative sleepiness 
scale presented by Regestein (23). Although it is impossible to compare two 
different semi-quantitative scales directly, their data seem to be in concordance 
with our findings. We used our semi-quantitative scale to assess snoring and 
daytime sleepiness before and after surgery, and since it is unlikely that patients 
recall their ratings from 6 months earlier, we believe to have an objective 
assessment of the improvement of snoring, and daytime sleepiness complaints. 
The disparity between improvement of complaints (subjective improvement) 
and improvement of respiratOlY parameters (objective improvement) is reported 
repetitively, and our data are in concordance with these earlier 
reports.(17,18,20-26) Due to the absence of consensus on the definition of the 
sleep apnea syndrome, different criteria are used to describe post-operative 
changes in respiration. Most authors use a combination of apneas, hypopneas 
and oxygen desaturations, and define apnea-index, apnea-hypopnea-index, 
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respiratory-distress-index or severity index. We used the desaturation-index 
(01), because respiration related desaturations are easy to detect and movement 
related artifacts can easily be excluded. The improvement of sleep apnea, 
defined as improvement of respiratOlY parameters of at least 50%, ranges from 
20% to 90%, with a mean respons rate of approximately 50%.(13,17,20-22,24-
35). If we define respons as improvement of 01 of at least 50%, our respons 
rate is only 35%. He et al. showed in a retrospective study that mortality was 
significantly increased in untreated patients when the apnea-index exceeded 20 
(7). If this conclusion is valid for or as well, than this may mean that 47% 
(28/60) of our patients could be considered sufficiently treated, but only 7 of 
them had a pre-operative or above 20. Since we consider OSAS to be present if 
at least 5 desaturations exceeding 4% from base line per hour are found, only 
13% can be considered cured. The use of or < 5 as a criterion for respons may 
be more sensible, since Hung et al. found that a AI > 5.3 was an independent 
predictor of myocardial infarction (8). 
The variation in response can be explained by differences in criteria for 
improvement, differences in surgical technique (36), and differences in patient 
selection. Many investigators have tried to isolate useful clinical selection 
criteria for UPPP, but published results have been inconclusive so far. 
We did not find BMI to be related to post-operative outcome. This is in 
concordance with other repolis (26,27,33,37), but some authors demonstrated 
that high weightlBMI correlated to a low respons (22,24,29,31). In contrast to 
these reports, Fujita et al. found that all non-responders showed a body weight 
less than 125% of ideal body weight (21). However they did not find that 
response increased systematically with increase in body weight. These data 
suggest that patients with high BMI may be unsuitable candidates for UPPP in 
general, but BMI alone is not sufficient to predict surgical outcome. 
As far as we know no data are available on age and surgical outcome. We 
found that increased age tended to be related to improvement in Dr. Age and 
nocturnal desaturation were not related before surgery, and we believe that this 
finding may be a coincidence. 
Small posterior airway space (PAS) tended to be correlated with improvement 
of sleepiness and increased distance between mandibula and hyoid (MPH) to 
improvement of mean saturation, but none of the cephalometric measurements 
was significantly related to post operative outcome. It is interesting however to 
notice that especially these two parameters (PAS, MPH) are found to be related 
to surgical outcome by other authors. Riley demonstrated that good responders 
had MPH values below 20 millimeter and PAS of at least 10 millimeter, but he 
did not present a reliable statistical analysis (38). DeBeny-Borowiecki showed 
that the position of the hyoid bone and the size of the tongue in relation to the 
oral cavity were highly correlated with the level of succes of UPPP (25). These 
findings suggest that the position of the hyoid bone, the fulcrum of the 
hyoglossal musculature and the size of the tongue may indeed be important. A 
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vertical downward displacement of the hyoid pulls the tongue deeper in the 
airway and reduces the airway space. This effect is even more pronounced in 
the presence of a large tongue mass. 
The possible role of narrowing of the upper airway at the base of the tongue is 
further illustrated by the findings of the Mueller manoeuvre. We found that 
increased difference in collapsibility between the level of the soft palate and the 
level of the tongue base is related to improvement in desaturation index (p = 
0.05, R' = 0.10). Velopharyngeal collaps was shown to be correlated with a 
good respons (25), and collaps at the tongue base with a negative influence on 
surgical outcome (39,40). Although the Mueller manoeuvre is performed 
during wakefulness, it may give us infOlmation regarding the differences in 
potential collapsibility between the region of the soft palate and the region of 
the tongue base during sleep, and may therefore be useful in pre-operative 
selection. 
The other statistically significant predictive factors we found were high pre-
operative desaturation index, low pre-operative mean saturation and low pre-
operative lowest saturation. These findings are in accordance with those of 
Calderelli et aI., who showed that UPPP appears to be most effective in patients 
whose apnea index is above 70 (37). However our data show that although 
patients with severe nocturnal desaturation are likely to show a decrease in 
nocturnal desaturation severity of approximately 50%, only a minority of them 
should be considered cured (DI < 5). In contrast many investigators report that 
patients with light to moderate sleep apnea severity tend to show a better 
respons than severe sleep apnea patients (24,25,27,29,41), and others report no 
difference between responders and non-responders (21,26,30,33). The value of 
respiratOlY parameters as assessed by polysomnography as predictors of surgical 
outcome is therefore uncertain, but patients with severe nocturnal desaturation 
seem to be poor candidates for UPPP, because, although they may show 
significant respons, they improve insufficiently to be considered cured. 
We conclude· that UPPP is very effective in reducing snoring and daytime 
sleepiness in sleep apnea patients, but that the improvement in nocturnal 
desaturation is poor and impossible to predict in any individual patient. With 
other treatment modalities to our disposition we must be very selective in 
proposing surgical treatment for OSAS, but no rational predictive factors are 
isolated yet. UPPP should maybe be reserved for those patients who refuse or 
do not respond to other modalities and who preferably show little or mild 
collaps at the base of the tongue, do not suffer from severe nocturnal desaturati-
on, and are not severely overweight. It is however our experience that quite a 
number of initial good responders will suffer from sleep apnea again in two to 
three years after UPPP. No large studies on the long term outcome of UPPP for 
sleep apnea are available yet, but if this high probability of relapse is true we 
must show even more reservation in perfOlming UPPP for obstructive sleep 
apnea. 
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4.1 Abstract 
Objectives: Assessment of the long-tenn effect of uvulopalatopharyngoplasty 
(UPPP) on snoring, excessive daytime sleepiness (EDS) and nocturnal oxygen 
desaturation index (aD!) in patients with Obstmctive Sleep Apnea Syndrome. 
Study Design: Evaluation of snoring, EDS and aD! in patients treated by UPPP 
earlier. Materials and methods: Patients (n = 58) with a follow-up period of 11 -
74 months (median 34) were included in this study. Snoring and EDS were scored 
on specially designed semi-quantitative scales. In all patients aD! was calculated 
from pulse-oximetty combined with polysomnography at base line and by 
polygraphy (MESAM 4) during follow-up in 38 patients. Long-tenn response was 
compared to 6-months response in the same cohort. Results: There was a long-
term improvement of snoring in 63% of patients, no change in 23%, and a 
deterioration in 14% (p < 0.00001). Overall snoring increased slightly between 6 
months and long-tenn follow-up. There was an improvement of EDS in 38%, no 
change in 27%, and a deterioration in 35% (p = 0.80). EDS showed a relapse to 
pre-operative levels between 6 months and long-tenn follow-up. The median 
improvement of aD! was -I (95%-interpercentile range -73 to 51) and was not 
significant (p = 0.35). In 5 of 13 patients in whom aD! at baseline exceeded 20, 
aD! was reduced below 20. In 4 of the 38 patients aD! was reduced below 5. The 
improvement of aD! decreased significantly between 6 months and long-tern1 
follow-up (p = 0.03). We found no relation between Body Mass Index, Mueller 
maneuver, X-cephalometty and long-tenn outcome. An additional finding was 
that the ODI decreased after UPPP in combination with tonsillectomy, compared 
to a slight increase after UPPP alone; the difference was significant (p = 0.008). 
Conclusion: The response to UPPP for OSAS decreases progressively over the 
years following surgery. UPPP in combination with tonsillectomy was more 
effective than UPPP alone. 
4.2 Introduction 
Since the introduction of uvulopalatopharyngoplasty (UPPP) for the treatment of 
sleep apnea syndrome in 1981 (I) the short-tenn effect of this procedure has been 
established, but the long-telm response has been studied less frequently and 
remains inconclusive (2-4). 
The prevalence of obsttuctive sleep apnea syndrome (OSAS) is estimated to be 3-
4% in middle-aged men and 2% in middle-aged women (5,6). Snoring, excessive 
daytime sleepiness and nocturnal apneas are the cardinal symptoms of OSAS. 
These symptoms and other related sequelae may have devastating effects on the 
lives of those affected. Because of its prevalence and sequelae OSAS should be 
considered a major public health problem (7). 
Many surgical and non-surgical tt'eatment modalities for OSAS have been 
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described. In comparison to other surgical procedures UPPP is less invasive and 
relatively well tolerated, but the response rate as defined by different criteria 
predominantly based on respiratory parameters is approximately 50% or less on 
shott-tenn follow-up (2,3,8). The long-telill effectiveness of UPPP in OSAS has 
been investigated in a small number of studies with the number of included 
patients ranging from 15 to 50. Improvement of snoring and daytime sleepiness 
are assessed on subjective basis without a scaled reference and all studies consider 
different respiratory parameters to define response (9-13). 
Continuous Positive Airway Pressure (CPAP) was also introduced in 1981 (l4). 
Although CPAP has been shown to be effective in improving both daytime 
sleepiness and nocturnal desaturations and is considered as treatment of first 
choice (IS), its therapeutic use seems to be seriously limited by low long-tenn 
compliance (16). Furthennore, the effectiveness of CP AP in improving health 
outcome has not been assessed reliably in experimental studies, providing no 
evidence-based standard for indication and clinical follow-up for this treatment 
modality (17). 
Although no clear evidence-based criteria for the indication and patient selection 
for UPPP exist either, UPPP can not be regarded as ineffective and a small number 
of patients might indeed be pennanent1y cured after this relatively simple surgical 
procedure. Therefore it is of paramount importance to more precisely evaluate the 
long tenn outcome of UPPP and to identify useful criteria to select patients that are 
likely to respond well to this surgical procedure (3,4). 
In the present study we assessed the effectiveness of UPPP in improving snoring, 
daytime sleepiness and nocturnal desaturation after long tenll follow-up. Snoting 
and daytime sleepiness were scored on a semi-quantitative scale and nocturnal 
desaturations were obtained by oximetry in combination with polysomnography or 
a multichannel recording device (MESAM 4). Pre-operative data obtained by the 
Mueller maneuver, cephalometry, and polysomnography were analyzed to identify 
possible selection criteria. In addition the contributive effect of tonsillectomy in 
combination with UPPP compared to UPPP alone was also analyzed. We studied 
58 of 60 patients included in an earlier report on the effects of UPPP six months 
after treatment and evaluated whether early responders proved to be late 
responders as well (8). 
4.3 Materials and Methods 
We included 51 men and 7 women of a cohort of 60 patients with OSAS we 
desclibed in a report on short-tenn follow-up in 1997 (8). All patients had been 
referred to our clinic because of snoring or daytime sleepiness, and underwent 
polysomnographic recording to con finn the diagnosis of OSAS. None of the 
included subjects used CP AP, was suffering from concomitant disease or had 
abnonnal facial anatomy. All UPPPs were perfonned between February 1988 and 
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September 1993. Long-tetID follow-up ranged from II - 74 months with a 
median of34 months after surgety. Anthropometric data are listed in Table 4.1. 
Table 4.1. 
Baseline 6molllhs 34 11~74 moulhs 
Median Median Median 
(95%-inte ocentile ran e) (9SO/.,..inte 'r~entile ran e) (9So/.,..inte ercentileran e) 
age (years) 49(29-72) 
8MI 29.6 (2 1.3 - 38.8) 28.4 (20.9 - 38.9) 28.4 (18.5 - 42.0) 
Snoring score 3 (I -4) 1(0-4)' 2 (0-4)' 
Sleepiness score 3 (0 - 5) 1(0-5)' 3(0-6) 
Polysomnography at baseline and MESAi\'1 after 34 (11 - 74) months 
Desaturation Index 114 (6 - 98) not available 13 (\ - 87) 
Re-sponse;:: -50% DI not available 34% 
Polysomnography at baseline and 6 months and i\'lESA:1\'I nftel' 34 (11 - 74) months 
Desatunltion Index 13 (7 -98) 14 (0-75) 12(1 -87) 
Response 2': -50% or 41% 31%** 
n 
58 
45 
57 
57 
38 
38 
29 
29 
Baseline data and follow-up data expressed as median and 95%-interpercentile range (95%-
range). The last column shows the number of patients with complete data to allow analysis 
for the specific parameter. Desaturation parameters were analyzed in two groups: a group of 
patients with complete data on baseline and long-term follOW-Up only (n~38) and a group of 
patients with complete data on baseline, 6 months and long-tenn follow-up (n~29). 
* ~ Compared with baseline p ~ 0.0001. Note ** ~ The difference in percentage of 
responders between 6 months and long-term is significant, p ~ 0.02. (The 6 months follow-
up data were not subject of this study, but are included to allow comparison with long-tenn 
results.) 
Snoring and excessive daytime sleepiness (EDS) were evaluated using a specially 
designed questiOtUlaire with semi-quantitative scales (snoring coded 0 - 4 and 
daytime sleepiness coded 0 - 5, see Table 3.2 for details) (8,18). Desaturation 
parameters at baseline and at 6 months postsurgety were obtained by standard 
polysomnography, while 10ng-tetID desaturation parameters were obtained by 
MESAM 4 (Madaus, GelUmny). The procedures are descdbed in detail below. In 
38 patients desaturation parameters were obtained at baseline and long-term 
follow-up. In 29 patients desaturation parameters were available on base line, 6 
months and 10ng-tetID follow-up. These two groups were analyzed separately. 
Response was defined as a reduction of at least 50% in oxygen desaturation index 
(ODI). A clinically relevant response was defined as a reduction of ODI from 
above to below 20 after treatment (19). Patients were considered cured ifODI was 
under 5 after treatment (20). Thirteen patients refused pmticipation in long-tenn 
polygraphic follow-up and 7 recordings were of poor quality. In 17 patients no 
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recording was available at 6 months. Body Mass Index (BM! = kglm2) was 
calculated. Upper airway collapsibility and anatomy were assessed by the Mueller 
maneuver and X-cephalometry, following the procedures described in our earlier 
report (8). The Mueller maneuver was perfOlmed in the supine position, and the 
collapsibility at the level soft palate, the tongue base, and the difference in 
collapsibility between soft palate and tongue base were assessed and included in 
the analysis of pre-operative selection criteria. The X-cephalometric parameters 
included in this analysis were: the minimal posterior airway space at the level of 
the tongue base, the distance between the mandibular plane and the most cranio-
ventral aspect of the hyoid bone, the length of the soft palate, being the distance 
of the posterior nasal spine to the tip of the uvula and the diameter of the soft 
palate taken at the widest point. All measurements were expressed in 
millimeters. 
The baseline polygraphic recording included electroencephalography, electro-
oculography and electromyography and sleep stages were scored following the 
international criteria of Rechtschaffen and Kales (21). Respiration was monitored 
by thelmistors to assess oro-nasal flow, by impedance plethysmography to assess 
respiratOlY chest and abdominal excursions, and by pulse-oximehy to detect 
oxygen desaturation. Obstructive sleep apnea syndrome was defined as the 
presence of obst11lctive apneas during at least 10 seconds or more leading to 5 
desaturations or more per hour of sleep. Periods with oxygen desaturation 
exceeding 3% reduction baseline were included in the calculation of the 
desaturation index (total desaturations/total sleep time per hour). The oxygen 
desaturation index (ODI) was used in our analysis. 
The Madaus Electronic Sleep Analysing Machine type 4 (MESAM 4, Madaus, 
Germany) is a four-channel digital recording device (22,23). Oxygen saturation is 
measured using a pulse oximeter in a finger probe. Hem1 rate is monitored 
through a single lead ECG, by calculation of R-R intervals in milliseconds. 
Snoring sounds are monitored through a very small microphone (Conrad 
Electronics, Hirschau, Germany), which is taped above the larynx. Body position 
is monitored through a sensor applied on the lower patt of the sternum. MESAM 
4 provides information on heat1 rate variability, snOling spechum, body position 
and nocturnal desaturation. An oxygen desaturation was defined as a desaturation 
of at least 4% from baseline during at least to seconds. If saturation has increased 
again to 95% of baseline level, the desaturation is considered ended. Every 
recording was scored by one of the investigators (HE). The patient noted the time 
of "lights-out" and "lights-on" on a accompanying sheet during the night of the 
recording. The total time considered for analysis was made more precise by taking 
the time between stabilization of heart rhythm after "lights-out" and the recunence 
of inegular heat1 rhythm before "lights-on". Any period noted as awake by the 
patient or showing itl'egular healt rhythm and movement attifacts exceeding 30 
minutes was left out of the final calculation of desaturation parameters. All 
automatically scored desaturations were individually inspected and at1ifacts were 
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removed from analysis. Only recordings with a minimal recording of five hours of 
good quality were included in the analysis. Recordings were performed at home 
and all patients received detailed infonnation, and application of the different 
sensors was practised several times in hospital prior to the recording night. 
For UPPP subjects were positioned as for tonsillectomy. The surgical procedure 
was performed under general anesthesia with a naso-tracheal intubation. The 
uvula was pulled towards the surgeon. The resulting natural horizontal crease in 
the pillar mucosa was used as the line for incision. The oral mucosa and sub-
mucosa were removed, expanding laterally if a preoperative lateral collapse was 
found. The naso-pharyngeal mucosa and sub-mucosa were removed in the same 
manner, while the uvula itself was shortened, but not removed. If present, 
redundant tonsillar fossa mucosa and tonsillar tissue were also removed. The 
length of the uvula was trimmed if necessaty, but not excised. The palatoglossal 
and palatopharyngeal muscles were spared during the procedure. Finally the 
posterior pillar was advanced and sutured to the anterior pillar with the suture line 
away from the nasopharynx. Nineteen patients underwent UPPP alone and 39 
patients underwent UPPP in combination with tonsillectomy (UPPP + TE). 
Baseline characteristics and follow-up data were not normally distributed, and are 
presented as median and 95%-interpercentile range. Improvement in snoring, 
daytime sleepiness, ODI and BMI was analysed with the Wilcoxon matched-pairs 
signed-ranks test. Differences in baseline data between groups in the am analysis 
were analyzed by the Mann-Whitney U test for unpaired data. 
The relationship between post-operative changes and changes in BMI was 
analysed by regression analysis. The predictive value of any of the pre-operative 
parameters obtained by the Mueller maneuver, X-cephalometry and 
polysomnography was analysed by regression analysis, and its contribution to the 
variation in improvement of snoring, daytime sleepiness and desaturation index 
was estimated by calculation of r-square. The difference in improvement of 
snoring, daytime sleepiness, and am between UPPP and UPPP+TE treated 
patients was analyzed by the Mann-Whitney U test for unpaired data. P-values 
below 0.05 were considered to indicate significance. 
4.4 Results 
The absolute values of baseline and long-term follow-up data are listed in Table 
4.1. Snoring improved at least one point in 63% of patients, no change was found 
in 23%, and 14% reported a deterioration of at least one point. The median 
improvement of snoring was one point (range: -4 to +2 points) and was highly 
significant (p < 0.0001). Daytime sleepiness improved at least one point in 38% of 
our patients, no change was found in 27%, while 35% showed a deterioration of at 
least one point. The median improvement of daytime sleepiness was 0 points 
(range:-5 to +3 points, p = 0.80). 
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Detailed infonnation on aD! at baseline and long-tenn follow-up was available in 
38 patients (see Table 4.1). aD! improved at least 50% in 13 of these patients 
(34%), a deterioration of 50% or more was found in 8 patients (21%) and no 
change in aD! (± 50%) was found in 17 patients (45%). The median change in 
aD! was -1 (95%-interpercentile range -73 to 51) and was not significant (p = 
0.35). In 5 of the 13 patients showing improvement, aD! was reduced from above 
to below 20. Only 4 patients showed a reduction of aD! below 5 (ODI at baseline 
7, 12, 13 and 35, respectively). 
Age, snoring, daytime sleepiness and aD! at baseline and long-telm follow-up 
were not different between patients with and without long-tenn polygraphic 
follow-up (all p-values > 0.10), but BMI in these patients was significantly 
lower at baseline (27.5 versus 31.0, p = 0.02) and at long-term follow-up (28.1 
versus 32.0, p = 0.049). The change in BMI was not different between these 
patients. 
In 29 patients infonnation on aD! was available at baseline, 6 months and long-
tenn follow-up. In this group the response rates at 6 months and long-tenn could 
be compared (see Table 2). The improvement of aD! between 6 months and long-
tenn was significantly decreased during follow-up (p = 0.02). In the initial report 
43 patients with aD! at baseline and 6 months were presented, 14 of these were 
not available for long-tenn polygraphic follow-up. Of the remaining 29 patients, 
12 (41%) showed a reduction of at least 50% in aD! at 6 months and 9 (31%) 
patients showed this reduction at long-tenn. Seven patients showed this response 
after both 6 months and long-tenn. At 6 months, in only 5 patients the aD! was 
decreased below 20. Four of these patients remained responders according to this 
criterion. In 7 patients the aD! was < 5 at six months, 3 of these patients showed 
the same long-tenn response. One long-tenn responder with aD! < 5 was not a 
responder at 6 months. 
Body Mass Index (BMI) in our population did not change during follow-up (see 
Table 1) (p = 0.54). No relation between BMI and improvement of snoring (p = 
0.39), daytime sleepiness (p = 0.72), or aD! (p = 0.12) was found. In only one 
responder a decrease in aD! from 29 to 19 to 12, a clinically relevant decrease in 
BMI was present (37.8 -31.0 - 31.6, at baseline, 6 months, and long-tenn 
respectively). 
The upper airway collapsibility assessed by the Mueller maneuver at the level of 
the soft palate, the base of the tongue or the difference in collapsibility between 
soft palate and the base of the tongne were not related to treatment outcome. A 
relative long soft palate, as assessed by cephalomehy, was related to improvement 
of daytime sleepiness and aD!, but its contribution was small (r-square = 0.09 and 
0.13, respectively, and p = 0.04). A high preoperative aD! was related to a greater 
reduction of aD! (r-square = 0.34 and p < 0.0001), but not to improvement of 
snoring or daytime sleepiness. 
Compared with UPPP alone, the improvement of snoring was better after UPPP 
combined with tonsillectomy (upPP + TE), but the difference was not significant 
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(p = 0.06). The improvement of daytime sleepiness was not different between 
these two groups. UPPP + TE resulted in a significant decrease of 001 (median-
7.5, 95%-interpercentile range -73 to +26, P = 0.02), compared to a non-
significant increase after UPPP alone (median 4.5, 95%-interpercentile range -18 
to +51, P = 0.10). The difference in improvement of 001 between UPPP + TE and 
UPPP alone was significant (p = 0.008, see Figure 4.1). 
Figure 4.1. 
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Improvement of OD! after UPPP alone and after UPPP + TE. The horizontal lines with plus 
(+) signs mark the group medians. The increase in OD! in the UPPP group was not 
significant (p ~ 0.10). The decrease in OD! in the UPPP + TE group was significant (p ~ 
0.02). The difference in change of OD! between the two groups was significant (p ~ 0.008). 
4.5 Discussion 
Our results show that snoring remains improved until years after UPPP for OSAS, 
but that daytime sleepiness relapsed. Although OD! did not improve significantly 
in our population, a minority of patients should be considered responders up to 
approximately 3 years after surgery. 
Clinical symptoms are velY relevant in the subjective rating of treatment outcome, 
but in the literature the response is usually defined by poly(somno)graphic criteria. 
Polysomnography is considered the standard for the diagnosis of OSAS, but other 
recording techniques have been used to evaluate the results of UPPP (24). We 
selected the 001 to evaluate postoperative response, because pulse-oximetry was 
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incorporated in our pre-operative polysomnographic (PSG) procedure and 
postoperative MESAM 4 registration. Oximetry has been shown to be useful in the 
detection of apneic events and the ODI obtained by automatic analysis with the 
MESAM 4 device reaches a specificity and sensitivity of 97% and 92%, 
respectively, for the identification of OSAS compared to the RespiratOlY 
Disturbance Index (apneas and hypopneas per hour sleep = RDI) ~ 10 obtained by 
PSG (23,25). Manual scoring of the MESAM 4 recording was found to be even 
more accurate with a sensitivity of aD! of 97% to 100% (26,27). For these 
reasons we scored the MESAM 4 recordings by hand. These figures indicate that 
a 50% reduction of aD! equals a 50% reduction of apnea-hypopnea-index (AHI) 
or respiratOly-distress-index (RDI), and this allows comparison with the literature. 
The use of different recording techniques, different criteria for response, different 
follow-up periods and differences in patient selection complicate the interpretation 
of the results in studies on long-term follow-up after UPPP. All our patients had 
mild to severe OSAS and our population is therefore comparable to those in other 
papers. All but 5 patients had predominant collapse at the velo-pharyngeal level 
by the Mueller maneuver (8). This was an imp0l1ant selection criterion before 
considering UPPP as an option for treatment of OSAS in our patients The other 
studies on long-tenn results after UPPP seem to have included unselected patients, 
although this was specifically mentioned in one report only (11). The different 
criteria we used for response are based on the UPPP literature and on 
epidemiologic data on OSAS related morbidity and m0l1ality. Reduction of at 
least 50% in aD! (Apnea-Hypopnea Index, RDI etc.) is generally used to define 
response, but other definitions may prove to be more useful (2). A reduction of 
aD! below 20 is based on the paper by He et al. who found increased mortality in 
untreated and UPPP treated patients with apnea index (AI) ~ 20 (19). A reduction 
of aD! < 5 is based on our definition of OSAS as the presence of aD! ~ 5 and on 
the findings of Hung et al. who showed an increased cardiovascular mortality if AI 
~ 5.3 (20). 
Only a few papers on the long-term results ofUPPP have been published. Larsson 
et al. evaluated 50 unselected consecutive patients at 6, 21 and 46 months after 
UPPP for OSAS (10,11). Response was defined as the combination of at least 
50% reduction in aD! (~4%lhour), postoperative aD! < 20 and only minor drops 
in SaO, below 90%. He showed that the initial response rate at 6 months of 60% 
(30/50 patients) decreased to 40% (19150 patients) after 21 months, and increased 
again to 50% (24148 patients) after 46 months. Subjective improvement of EDS 
was reported in approximately 90% of patients and remained unchanged, but 
change in EDS was graded only as "complete recovery", "improvement" or "no 
improvement". A semi-quantitative estimate of actual improvement could 
therefore not be made. When we convert our results to the definition of response 
used by Larsson et aI., 11129 patients (40%) should be considered responders at 6 
months and 10/38 (26%) at long term. Due to different presentation of baseline 
characteristics (mean versus median) we were not able to compare the two 
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populations, so the difference between improvement of aD! in the paper of 
Larsson et al. and our study remains largely unexplained. Since the repOlied 
complications are minor and comparable to our 6 months complications, the 
surgical approach by Larsson does not seem to have been more aggressive. In the 
study by Lu et al. response was defined as at least 50% reduction in respiratOlY 
disturbance index (RDI) (12). In the latter study 101l5 patients were considered 
responders after 3-12 months, while only 5/10 patients could be considered 
responders after 66-109 months. RDI increased significantly between initial and 
late follow-up (p<0.05). These long-te/ill results are in concordance with our data. 
Subjective improvement was reported in 80% of patients, but snoling and EDS 
were again rated as "improvemenf', "no improvemenf' or "getting worse", not 
allowing quantifiable comparison with our results. None of their patients 
subjectively worsened with respect to snoring or EDS, which is in contrast to our 
data. Janson et al. studied 25 patients 6 months and 4-8 years after UPPP (13). 
Response was defined as 50% reduction in Apnea Hypopnea Index (AHI) and 
postoperative AHI below 10. After 6 months 16/25 patients (64%) were classified 
as responders versus 12/25 patients (48%) after 4-8 years. Despite the more 
nan'ow definition of response, the response rate is higher than in our study. The 
authors stated, however, that the high number of non-pm1icipants in the long-tenn 
follow-up had more severe OSAS and that inclusion of these patients might have 
lowered the response rate. Although no direct comparison can be made, their 
baseline data do not differ significantly from ours. Snoling and EDS were 
significantly reduced in the latter study, but again a different rating scale was used. 
No validated questionnaires for the evaluation of sleep apnea related snoring or 
daytime sleepiness were available, at the beginning of the present study. We used 
a different and specially designed semi-quantitative scale to assess severity of 
snoring and EDS both before and after treatment (18). Our results show for the 
first time an evident relapse of EDS to pre-operative levels after long-tetill follow-
up. This finding con'esponds well to the decrease in response as defined by 
different respiratory parameters. We did not find the inconsistency between the 
pronounced improvement of snoring and EDS versus the relatively small 
improvement of respiratory parameters that has been reported in most studies 
(8,28,29). A good explanation for this inconsistency is lacking, but it is possible 
that patients tend to attribute positive effects to a rather invasive treatment 
modality such as UPPP (30). This mechanism of attlibution may also pm11y 
explain why subjective rating scales for snoling and EDS tend to overestimate 
improvement, when specifically asking for improvement, and this may explain 
why other studies reported more SUbjective improvement of snoring and EDS than 
we do (10-12). MESAMA provides an objective measure for snoring, 
discliminating "snoring" from "loud snoring" with a threshhold of 1.1 m V at 1000 
Hz. Although this signal was found to be reliable in a soundproof chamber by 
Penzel et al. in 1990 (22), we found that it was very susceptible to other sounds 
generated by the bed partner and by friction of the blankets. This was the main 
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reason we decided not to use this parameter in our analysis. Furthermore, we 
believe that the discomfort experienced by the patient and his (her) bed partner 
is the most relevant aspect of snoring and this subjective improvement was a 
primary objective of this study. 
We compared the response rates at 6 months and 10ng-tetID follow-up by using the 
different definitions described earlier. Four of 5 patients with a decrease in aD! 
from above 20 to below 20 could be considered responders after 34 months, while 
only 3 of 7 patients maintained a response of aD! < 5. This means that the 
initially already insignificant cure rate in our patients decreases even more over the 
years. However, a small number of patients (7/38 = 18%) must still be considered 
good responders, even after 3 years offollow-up. 
Only 38 of 58 patients participated in the long-term polygraphic recording and 
although these patients had significantly lower pre-operative BM! than the 20 non-
patticipating patients, none of the postoperative changes could be related to pre-
operative BM! or to post-operative changes in BM!. The results of this study are 
therefore not influenced by differences or changes in BM!. Only one study on 
long-term follow-up found a relation between a high pre-operative BM! and a low 
response to uppp (10). Although this relation was not found by others (12,13), it 
can not be ruled out completely and this could mean that hypothetical inclusion of 
those patients without a full polygraphic follow-up in the analysis of aD! might 
have resulted in lower response rates in our study. 
No clinically useful pre-operative selection criteria to identify good responders to 
uppp have been found by analyzing the data obtained by the Mueller maneuver 
and cephalometry. The improvement of aD! was most pronounced in patients 
with a relative high pre-operative aD!, which is in concordance with our earlier 
repOit (8). 
The improvement of aD! in UPPP + TE patients was significantly better 
compared to UPPP only patients. Eleven of the 13 patients showing more than 
50% improvement of aD! underwent UPPP + TE. All 5 patients with a reduction 
in aD! from >20 to < 20, and 2 of the 4 patients with reduction of aD! below 5, 
did so after UPPP + TE. From an anatomical viewpoint, the presence of tonsillar 
tissue reduces the upper airway aperture and makes it more likely to collapse 
during inspiration. Although this mechanism is not supported by the finding of the 
Mueller maneuver, it is reflected by the higher sleep apnea severity as expressed in 
aD! between UPPP + TE and UPPP only patients at baseline (see Figure I). 
Removal of this causative contributing factor may itself result in better 
improvement of aD!, but the resection of tissue in the tonsillar fossa results in a 
more lateral expansion of the incisure and consequently the suture line. A more 
generous resection of the soft palate may therefore be complementaty to the effect 
of tonsillectomy alone and may contribute to better treatment outcome (31). 
Although it was not an objective of this study to evaluate this aspect, it is an 
important finding that may indicate that the presence of tonsillar tissue may be the 
only useful selection criterion for UPPP. However, not all UPPP + TE patients 
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were good responders, which indicates that other factors must contribute to 
treatment outcome. 
We found that the initial results of UPPP for OSAS decrease progressively over 
the years. Snoring remained improved, although long-term results were slightly 
worse compared to 6 months results. Daytime sleepiness relapsed to pre-operative 
levels. Improvement of Oxygen Desaturation Index and response rates defined by 
different criteria deteriorated during long-term follow-up. UPPP remains effective 
in approximately 20% of patients only. Improvement of ODI was better after 
UPPP combined with tonsillectomy than after UPPP alone. Further research is 
needed to identify useful pre-operative critelia for selecting patients for UPPP. If 
such criteria could be established to identify these long-term responders before 
considering any kind of treatment, a considerable number of patients could profit 
from a single and relatively simple surgical procedure, while they would be spared 
years of troublesome treatment by CPAP. 
86 
Long-term Results o/UPPP 
References 
Fujita S, Conway W, Zorick F, Roth T. SurgicaJ correction of anatomic abnormalities in 
obstructive sleep apnea syndrome: uvulopalatopharyngoplasty. Otolaryngol Head Neck 
Surg 1981 ;89:923-34. 
2 Rodenstein DO. Assessment of uvulopalatopharyngoplasty for the treatment of 
obstructive sleep apnea syndrome. Sleep 1992;15:s56-s62. 
3. Sher AE, Schechtman KB, Piccirillo JF. The efficacy of surgical modifications of the 
upper airway in adults with obstructive sleep apnea syndrome (An American Sleep 
Disorders Association Review). Sleep 1996; 19(2): 156-77. 
4. Pepin JL, Veale D, Mayer P, Bettega G, Wuyam B, Levy P. Critical analysis of the 
results of surgery in the treatment of snoring, upper airway resistance syndrome (UARS), 
and obstructive sleep apnea (OSA). Sleep 1996; 19(9 Suppl):S90-1 00. 
5. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-
disordered breathing among middle-aged adults. N Engl J Med 1993;328: 1230-5. 
6. Bearpark H, Elliott L, Grunstein R, Cullen S, Schneider H, Althaus W, Sullivan C. 
Snoring and sleep apnea: A population study in Australian men. Am J Respir Crit Care 
Med 1995;151:1459-65. 
7. Phillipson EA. Sleep apnea: a major health problem (editorial). N Engl J Med 
1993;328: 1271-3. 
8. Boot H, Poublon RML, Van Wegen R, Bogaard JM, Schmitz PI, Ginai AZ, Van der 
Meche FG. Uvulopalatopharyngoplasty for the obstructive sleep apnoea syndrome: value 
of polysomnography, Mueller manoeuvre and cephalometry in predicting surgical 
outcome. Clin Otolaryngol 1997;22(6):504-10. 
9. Conway W, Fujita S, Zorick F, Sicklesteel BA, Roehrs T, Wittig R, Roth T. 
Uvuloplatopharyngoplasty: one year follow-up. Chest 1985;88(3):385-7. 
10. Larsson H, Carlsson Nordlander B, Svanborg E. Long time follow-up after UPPP for 
obstructive sleep apnea syndrome: results of sleep apnea recordings and sUbjective 
evaluation 6 months and 2 years after surgery. Acta Otolaryngol (Stockh) 1991 ;111 :582-
90. 
II. Larsson LH, Carlsson Nordlander B, Svanborg E. Four year follow-up after 
uvulopalatopharyngoplasty in 50 unselected patients with obstructive sleep apnea 
syndrome. Laryngoscope 1994; 104: 1362-8. 
12. Lu SJ, Chang SY, Shiao GM. Comparison between short-terrn and long-term post-
operative evaluation of sleep apnoea after uvulopalatopharyngoplasty. J Laryngol Otol 
1995; 109(4):308-12. 
87 
Chapter 4 
13. Janson C, Gislason T, Bengtsson H, Eriksson G, Lindberg E, Lindholm CE, HuHcrantz E, 
Hetta J, Boman G. Long-tenn follow-up of patients with obstructive sleep apnea treated 
with uvnlopalatopharyngoplasty. Arch Otolaryngol Head Neck Surg 1997;123(3):257-
62. 
14. Sullivan CE, Berthon-Jones M, Issa FG, Eves L. Reversal of obstructive sleep apnoea by 
continuous positive airway pressure applied through the nares. The Lancet 1981;1:862-
5. 
15. Polo 0, Berthon-Jones M, Douglas NJ, Sullivan CEo Management of obstructive sleep 
apnoea/hypopnoea syndrome. Lancet 1994;344:656·60. 
16. Barone Kribbs N, Pack AI, Kline LR, Smith RK, Schwartz AR, Schubert NM, Redline S, 
Henry IN, Getsy JE, Dinges DF. Objective measurements of patterns of nasal CPAP use 
by patients with obstructive sleep apnea. Am Rev Respir Dis 1993; 147:887-95. 
17. Wright J, Johns R, Watt I, Melville A, Sheldon T. Health effects of obstructive sleep 
apnoea and the effectiveness of continuous positive airways pressure; a systematic review 
of the research evidence. BMJ 1997;314:851-60. 
18. van Knippenberg FCE, Passchier J, Heysteck D, Shackleton D, Schmitz P1M, Poublon 
RML, van der Meche FGA. The Rotterdam daytime sleepiness scale: a new daytime 
sleepiness scale. Psychological Reports 1995;76:83-7. 
19. He J, Kryger MH, Zorick FJ, Conway W, Roth T. Mortality and apnea index in 
obstructive sleep apnea: experience in 385 male patients. Chest 1988;94(1):9-14. 
20. Hung J, Whitford EG, Parsons RW, Hillman DR. Association of sleep apnea with 
myocardial infarction in men. The Lancet 1990;336:261-4. 
21. Rechtschaffen, A. and Kales, A. A manual of standardized terminology, techniques and 
scoring system for sleep stages of human subjects. University of California: Brain 
infonnationIBrain research institute. 1973. 
22. Penzel T, Amend G, Meinzer K, Peter JH, von Wichert P. MESAM: A heart rate and 
snoring recorder for detection of obstructive sleep apnea. Sleep 1990; 13(2): 175-82. 
23. Stoohs R, GuilleminauH C. MESAM 4: An ambulatory device for the detection of 
patients at risk for obstructive sleep apnea syndrome (OSAS). Chest 1992; 101 :1221-7. 
24. Stradling JR. Sleep studies for sleep related breathing disorders (consensus report). J 
Sleep Res 1992;( I ):265-73. 
25. Pepin JL, Levy P, Lepaulle B, Brambilla C, Guilleminault C. Does oximetry contribute to 
the detection of apneic events? Mathematical processing of the SaO, signal. Chest 
1991;99:1151-7. 
26. Koziej M, Cieslicki JK, Gorzelak K, Sliwinski P, Zielinski J. Hand-scoring of ME SAM 4 
recordings is more accurate than automatic analysis in screening for obstructive sleep 
apnoea. Eur Respir J 1994;7: 1771-5. 
88 
Long-term Resllits o/UPPP 
27. Esnaola S, Duran J, Infante-Rivard C, Rubio R, Femandez A. Diagnostic accuracy of a 
portable recording device (MESAM IV) in suspected obstmctive sleep apnoea. Eur 
Respir J 1996;9:2597-605. 
28. Zorick F, Roehrs T, Conway W A, Fujita S, Wittig R, Roth T. Effects of 
uvulopalatopharyngop1asty on the daytime sleepiness associated with sleep apnea 
syndrome. Bull Eur Physiopath Resp 1983;19:600-3. 
29. Davis JA, Fine ED, Maniglia AJ. Uvulopalatopharyngoplasty for obstmctive sleep apnea 
in adults: Clinical correlation with polysomnographic results. ENT Joumal 
1993;72(1 ):63-6. 
30. Festinger L. A theory of cognitive dissonance. Stanford: Stanford University Press; 1957. 
31. Kimmelman PC, Levine B, Shore ET, Millman RP. Uvu10palatopharyngoplasty: a 
comparison of two techniques. Laryngoscope 1985;95: 1488-90. 
89 

CHAPTERS 
Uvulopalatopharyngoplasty and 
Continuous Positive Airway Pressure for 
Obstructive Sleep Apnea Syndrome; 
a Prospective Randomised Trial 
Writing Committee 
for the Dutch Sleep Apnea Study Group 
Boot H, Schmitz PIM, Poublon RML, van Hout BA, and van der Meche FGA. 
Submitted janumy 2000 
Members of the Dutch Sleep Apnea Study Group 
F.G.A. van der Meche, J.M. Bogaard, J. Passchier, R.M.L. Poublon, P.I.M. Schmitz, J.C.M. 
van der Sluys, B.A. van Hout, R. Seerden, A.Z. Gina'i, H. Boot, A. Plug, RM. van den Hoven 
(Erasmus University Medical Center Rotterdam), A.C. Declerck, K.E. Schreuder, E. Voets-
Peliet (Centrum voor Slaap-Waak Onderzoek Kempenhaeghe, Heeze), A.M. de Vries 
(Diaconessenhuis, Eindhoven), J.C.R. van Drie (Maria Ziekenhuis, Tilburg), F.C.P.M. 
Adriaansen (Catharina Ziekenhuis, Eindhoven), F.L. van Buchem (Elisabeth Ziekenhuis, 
Tilburg), J.H.M. de Groen, J. Berg, G. ten Velde, R. Koopmans, J.I. Manni (Academisch 
Ziekenhuis Maastricht), H.Th.M. Foigering, J.J.S. Mulder (Academisch Ziekenhuis 
Nijmegen), A.R.I. van Keimpema, P.M.J.M. de Vries, G.J. Hazenberg, R.L.M. Strijers, N. de 
Vries, M.I.B. Taphoom, D.P. Kooper, M. Vaartjes, M.K.F. Beckman (Academisch 
Ziekenhuis van de Vrije Universiteit van Amsterdam), M.M.N Eijsvogel, J. Lycklama a 
Nijeholt, G. Wilts, A.G. de Roos, L.I.I. van der Maas, E.S. Nijdam (Medisch Spectrum 
Twente), R. van Uffelen, J.F.C. van der Drift, C. Oppelaar (Drechtsteden Ziekenhuis 
Dordrecht), M.I. Zwarts, D.I. van Petersen, B.I.M. Biezenbos, J. de Vries, W.I. Snoek 
(Martini Ziekenhuis Groningen). 
Chapter 5 
5.1 Summary 
Study Objectives: Comparing two strategies for the treatment of Obstructive 
Sleep Apnea Syndrome (OSAS); stm1ing with Continuous Positive Airway 
pressure (CPAP) or starting with Uvulo-Palato-Pharyngo-Plasty (UPPP), with 
the possibility to switch to the other treatment modality, to evaluate which 
strategy results in better improvement of daytime sleepiness, quality of life, and 
nocturnal desaturations. Design: A randomised prospective trial using the 
Intention To Treat principle. Setting: Eight centers with a multi-disciplinairy 
approach of OSAS in the Netherlands. Patients: Subjects with complaints of 
daytime sleepiness caused by obstructive sleep apneas and predominant collaps 
of the upper airway at the level of the soft palate were included. Interventions: 
Patients were randomly allocated to UPPP or CPAP. Measurements alld 
Results: Daytime sleepiness was scored using the Rotterdam Daytime 
Sleepiness Scale. Quality of life was assessed with the Nottingham Health 
Profile, the Hopkins Symptom Checklist, the Bradburn Affect Balance Scale 
and the Profile of Mood Scale. Desaturation parameters were obtained by 
MESAM-4. Immediate and consequential costs were distinguished. 125 
Patients were included between November 1992 and May 1995. Follow-up 
ranged from 6 to 24 months. At the end of follow-up 77% of UPPP-first 
patients were switched to CP AP and 23% CPAP-first patients were switched to 
UPPP. We found no statistical significant differences in improvement of 
daytime sleepiness or quality of life. CPAP-first strategy resulted in early and 
better improvement of nocturnal desaturation. The mean direct costs per patient 
in the UPPP-first strategy is estimated at 5.257 US Dollars versus $ 2.802 per 
patient in the CPAP first strategy (p ~ 0.02). The cumulative consequential 
costs per patient in the UPPP-first strategy is estimated at $ 6.019 versus $ 
2.052 in the CPAP-first strategy (p ~ 0.08). COllelusions: This study shows 
that treatment of OSAS in patients with predominant collaps at the 
velopharyngeallevel should start with CPAP. 
5.2 Introduction 
A treatment strategy for Obstructive Sleep Apnea Syndrome (OSAS), 
comparing Continuous Positive Airway Pressure (CPAP) with 
Uvulopalatopharyngoplasty (UPPP) as the initial treatment modality has never 
been evaluated in a single randomised prospective study. UPPP and CPAP 
were both introduced in 1981 for the treatment of OS AS (1,2), but most studies 
conducted since report non-randomised single treatment results. CPAP is 
considered the treatment of first choice, but a selective group of patients with 
predominant collaps of the velopharyngeal airway can be treated by UPPP 
effectively (3). It is still unclear whether treatment of these patients should be 
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started with UPPP or CPAP, with the opportunity to switch to the other therapy 
in case of treatment failure. 
To answer this question we evaluated two treatment strategies in a randomised 
prospective trial. In the UPPP-first strategy treatment was started with UPPP, 
with the possibility to switch to CPAP if insufficient improvement of OSAS 
was reached. In the CPAP-first strategy the initial treatment was CPAP with the 
possibility to switch to UPPP. The main questions to be answered were: how 
effective are both strategies in reducing excessive daytime sleepiness and 
improving quality of life? Secondary questions to be answered were: how 
effective are both strategies in reducing nocturnal oxygen desaturations; in 
which strategy will the number of therapy switches be smaller; which of both 
strategies has the best results in a cost-minimalisation analysis? 
5.3 Materials and Methods 
Patients with complaints of daytime sleepiness caused by obstructive sleep 
apneas and predominant collaps of the upper airway at the level of the soft-
palate were eligible for the study. Diagnosis of OSAS had to be confirmed by 
standard polysomnography. OSAS was defined as the presence of at least 5 
oxygen desaturations exceeding 4% from base line per hour (ODI), caused by 
obstructive apneas of at least 10 seconds. Frequency of reasons for not 
including or for excluding patients are listed in figure 5.1. 
Two treatment strategies were evaluated, UPPP-first versus CPAP-first. 
Treatment failure was defined as: insufficient improvement of daytime 
sleepiness as judged by the patient; insufficient improvement of nocturnal 
desaturations as judged by the investigator and as intolerance to further 
treatment with CPAP. Switching from UPPP to CPAP (UPPP-first strategy) 
was allowed after 6 months only, to be sure that incomplete healing of the 
operation wound was not responsible for persistent daytime complaints. 
Switching from CPAP to UPPP (CPAP-first strategy) was allowed anytime 
during the follow-up. The protocol was approved by the ethics committees of 
all participating institutions. 
The sample size of 2 x 37 = 74 patients was calculated on the basis of the 
following assumptions: the succes rate of UPPP defined as at least 50% 
reduction in aD! was estimated to be 50% (=pl); the succes rate ofCPAP was 
estimated to be 80% reduction in aD! (=p2); a = 0.05 (two-sided) and /3 = 0.20 
(4). In order to obtain smaller confidence intervals of calculated differences 
between the two strategies, allowing more accurate interpretation of results for 
decision making in public health care, we aimed at including 150 patients. 
However a maximal study period of 3 years existing of a 2.5 years intake period 
and a minimal follow-up of 0.5 year was a preset limit, potentially restricting 
the number of included patients. The duration of the study was defined by 
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regulations of the health care technology assessment program of the 
Investigative Medicine Committee of the Dutch Health Insurance Council. 
Figure 5.1. 
I Eligible Patients (0 = 470>1 
I 
Not Randomlsed (0 = 345) 
ReawQ'! \0 exclude: 
Symptomatic apnea> (n - 32) 
Other causes o(da)'lime sleepiness (n = 30) 
UPPP or CPAP before (n = 24) 
Elective treatment not possibk (n = 12) 
Concurrent dissea>es (n = 13) 
R~aI2!lS 90110 in~l~!l:~: 
No daytime sleepiness (n - 119) 
Insufticient number of desalutalions (n = 84) 
insurticienl duration of desa(uralions (n = 4) 
Obstruction at other level in ain',ay (n = \02) 
Age (0(1\ 19 - 75 years) (n = 4) 
No Infonned Consent (n = 96) 
~
UPPP-flrsl strategy (n = 62) CrAP·first strategy (0 = 63) 
Receil'cd Ir<"almen! as allocate.;! (n = 53) 
Did not receive Ire.alemenl as allocate.:! (n = 9) Receiwd treatment as alloc.lled (n = 63) 
6 months follow-up 6 months follow-up 
Da}1ime sleepiness questionnaire returned (n = 50) Da}time s!e~piness questionnaire returned (n = 55) 
MESAM-4{n=43)' MESAM-4 (n = 50)' 
Lost to (oJlow-up (n = 3) Lost to (oJlow-up (n = 8) 
Patients swit'hed to CPAP (6%)"* Patients mitched to UPPP (16%)" 
12 months follow-up 12 months follow-up 
Da~1ime sleepiness questionnaire returned (II" 49) Da}1ime sleepiness questionnaire returned (II" 53) 
MESAM_4(1I=41)· MESAM-4 (n = 43)· 
Losl to follow-up (II = I) Lost to (oHow-up (II "'2) 
Patients switched to CPAP (45%)·· Patients switched to UPPP (17%)·· 
18 months follow-up 18 months follow-up 
Da)time sleepiness questionnaire returned (n = 48) Da}1ime sleepiness questionnaire returned (n = 53) 
MESAM_4 (II = 34)' MESAM-4 (n = 34)' 
LosIto (ollow-up (n = I) Lost to (ollow-up (n = 0) 
Patients switched (0 CPAP (62%)"* Patients SWitched to UPPP (21%)·· 
24 months follOW-Up 24 months follow-up 
Da)1ime sleepiness questionnaire returned (n = 48) Da)1ime sleepiness questionnaire returned (n '" 52) 
MESAM-4(n=21)· MESAM-4 (n =21)· 
Lost to fol1ow-up (n = 0) Lost 10 fol1ow-up (n = I) 
Patients switched to CPAP (77%)" Patients switched to UPPP (23%)·' 
... see lext for details •• = Cumuhtive percentage 
Flow-chart describing the progress of patients through this trial, from eligible patients to 
number of patients available for statistical analysis during the follow-up visits. The reasons 
for exclusion or non-inclusion are listed in the second box from the top. 
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Randomisation was centralised. The investigators telephoned the coordinating 
centre and the patients were then assigned treatment strategies, according to a 
"block-wise" randomisation procedure for each participating institution. Eight 
centers with an experienced multi-disciplinairy approach of OSAS participated. 
The inclusion started on the first of november 1992 and ended on the first of 
may 1995. The fomlal follow-up closed 6 months later on the first of november 
1995. In addition all patients were contacted by telephone to complete data on 
daytime sleepiness and actual therapy in december 1997, 2.5 years after 
inclusion of the last patient. 
Data were obtained on moment of randomisation (base-line), and 6, 12, 18 and 
24 months after start of therapy. The date of operation was start of therapy in 
the UPPP-first strategy. The first day following a successful habituation period 
was start of therapy in the CPAP-first strategy. Daytime sleepiness was scored 
using a four points subscale of the Rotterdam Daytime Sleepiness Scale ( 0 = no 
daytime sleepiness, I = once per week, 2 = several times per week and 4 = evelY 
day) (5). Quality of life was assessed with the Dutch translated and evaluated 
versions of the Nottingham Health Profile (NHP), the somatic subscale of the 
Hopkins Symptom Checklist (SOMA T), the Bradburn Affect Balance Scale 
(ABS) and the Profile of Mood Scale (POMS). Desaturation parameters were 
obtained by ambulatory registration using the MESAM -4 device. A standard 
physical examination was perfOlmed on every visit. Mueller manoeuvre and 
Roentgenographic cephalometry were perfomled before randomisation only. 
The Mueller manoeuvre was used to select patients with predominant collaps at 
the level of the soft palate (6). The treatment related costs of both strategies 
were distinguished in immediate and consequential. The immediate costs are 
composed of: days of hospitalisation, any medical treatment consumed (UPPP, 
CPAP and OSAS related), outpatient contacts (visits and telephone) and days on 
CPAP. The consequential costs were calculated from data obtained by a 
questionnaire designed by the Institute for Medical Technology Assessment 
(iMTA) and are composed of loss per day of non productivity as assessed by 
age related contribution to the blUto national income measure. The difference in 
total costs between the two strategies was assessed. 
We used the Madaus Electronic Sleep Analysing Machine type 4 (MESAM 4) 
(Madaus, Germany), a four channel digital recording device (7,8). Oxygen 
saturation is measured using a pulse oximeter in a finger probe. Heart rate is 
monitored through a single lead ECG, by calculation of R-R intervals in 
milliseconds. Snoring Sounds are monitored through a velY small microphone 
from Conrad Electronics, Hirschau, Germany. This microphone is taped above the 
latynx. Body position is monitored through a sensor applied on the lower part of 
the sternum. MESAM 4 provides detailed infonnation on heart rate variability, 
snoring spectlUm, body position and nocturnal desaturation. The ODI expresses 
the number of oxygen desaturations ~ 4 percent from base line saturation per hour 
of analysed time. An oxygen desaturation was defined as a desaturation of at least 
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4% from base line during at least to seconds. As saturation has progressed to 95% 
of base line level, the desaturation is considered ended. Every recording was 
scored by one of the investigators (HB), who was unaware of the treatment 
strategy. We calculated the ODI, baseline desaturation,mean saturation, lowest 
saturation and the percentage of evaluation time with saturation below 90%. The 
patient noted the time of "lights-out" and "lights-on" on a accompanying sheet 
during the night of the registration. The total time considered for analysis was 
further precised by taking the point of stabilisation of heart rhythm after "lights-
out" as stati and the recutl'ence ofin·egulat· heati rhythm before "lights-on" as end 
of the evaluation period. Any period noted as awake by the patient or showing 
irregular heati rhythm and movement artifacts exceeding 30 minutes was left out 
of the final calculation of desaturation parameters. All desaturations were 
individually inspected and artifacts were removed from analysis. A minimal of 
five hours of registration of good quality was requiered. Since the MESAM 4 is 
an ambulatory device, all registration were petformed at home. All patients 
received detailed information and application of the different sensors was practised 
several times in hospital prior to the registration night. 
For UPPP subjects were positioned as for tonsillectomy. The surgical 
procedure was performed under general anesthesia with a naso-tracheal 
intubation. The uvula was pulled towards the surgeon. The resulting natural 
horizontal crease in the pillar mucosa was used as the line for incision. The oral 
side of the palatal mucosa and sub-mucosa were removed, expanding laterally if 
a pre-operative lateral collapse was found. The naso-pharyngeal side of the 
palatal mucosa and sub-mucosa were not removed. The uvula itself was 
shortened, if necessary, but not removed. If present, redundant tonsillar fossa 
mucosa and tonsillar tissue were also removed. The palatoglossal and 
palatopharyngeal muscles were spared during the procedure. Finally the 
posterior pillar was advanced and sutured to the anterior pillar with the suture 
line away from the nasopharynx. A UPPP-committee set up the protocol and 
monitored all procedures to reduce variability between the institutions. 
The REMSTAR -plus® from Respironics was used in all patients on CP AP. A 
BIPAP®-device (Respironics Inc; Murrysville, Pal could be used if necessary. 
Humidifiers were prescribed without restrictions and all types of masks were 
allowed. Three different procedures were used to determine the optimal 
inspiratory pressure: clinical titration during one night, clinical titration during 
several nights and titration at home with support in an outpatient setting. The 
habituation period consisted of support by telephone and repetitive visits in a 
outpatient setting. The institutions were allowed to follow their own procedures 
according to their experiences and to the wishes of their patients. Titration and 
habituation were succesful if the patient was satisfied with the improvement of 
daytime sleepiness and no further improvement in nocturnal desaturation could 
be obtained by increasing pressure. A CPAP-committee monitored all 
procedures and advised in case of habituation problems. 
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We defined as primary end-point: improvement of at least one point on the 4-
point daytime sleepiness scale. SecondalY end-points are: treatment failure 
(switche of therapy); improvement of at least one point on any subscale of the 
quality of life questionnaires; the absolute improvement of de saturation 
parameters (especially the ODI); 50% reduction in ODI and ODI below 20 
(criterion A "improved") (9); 50% reduction in om and om below 5 (criterion 
B "cured") (10,11). Continuous outcomes were compared within groups with 
the matched-pairs signed-rank test of Wilcoxon, and between groups with the 
Mann-Whitney U test. Percentages between groups were compared with the 
chi-square test without cOll'ection for continuity. All analyses were perfonned 
using the Intention-To-Treat principle. An interim analysis was performed after 
6 months offollow-up of the first 75 patients. 
5.4 Results 
The interim analysis showed no difference in improvement of daytime 
sleepiness on the 4-point sleepiness scale between the two strategies. In fact the 
results were similar as found in the larger sample as described below. The 
intake period was therefore closed after 2.5 years (as predetermined). 
120 Men and 5 women (mean age 49 years, 95 interpercentile range 28 - 60) 
were included, 62 in the UPPP-first strategy and 63 in the CPAP-first strategy. 
There were nine drop-outs. In the UPPP-first strategy 7/62 patients refused 
operation and in one patient operation could not be perfonned within the 
defined period. In the CPAP-first strategy one protocol violation occuned by 
including a patient without daytime sleepines. Eleven other patients were 
excluded because the data at base-line or at six months follow-up did not allow 
statistical analysis. 105 Patients were therefore available for analysis of the 
primmy end-point. After closure of the study we were able to complete data on 
actual therapy and daytime sleepiness in 48 of the 62 UPPP-first patients and in 
52 of the 63 CPAP-first patients. All switches of therapy occurred within 24 
months after inclusion. 
At the end of follow-up 37 of 48 UPPP-first patients (77%) have been switched 
to CPAP. The reasons for switching were insufficient improvement of daytime 
sleepiness in 34 and insufficient improvement of nocturnal desaturation in 3 
cases. 12 of 52 CPAP-first patients (23%) have been switched to UPPP at the 
end of follow-up. All patients reported CPAP-problems (pressure related in 2, 
mask related in 5, nasal congestion in 2 and general complaints in a total of 9), 
and in 3 cases insufficient improvement of daytime sleepiness was reported 
also. Figure 5.2 displays the percentage of patients that remained without 
switching in each strategy during the course offollow-up. 
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Figure 5.2. 
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Curve showing the percentage of patients that did not switch from therapy during follow-up 
in the UPPP-first and CPAP -first strategies. 
Table 5.1. 
Strategie 6 months 12 months 18 months 24 months 
UPPP-first 64 71 81 76 
CPAP-first 65 65 80 69 
p-value 0.88 0.55 0.91 0.58 
The percentage of patients per strategy with a decrease of at least one point on the four points 
daytime sleepiness scale. 
Table 5.1 summarises the percentage of patients with improvement of daytime 
sleepiness. No significant differences between the two strategies were found. 
The quality of life measurements showed significant improvement within both 
strategies on almost every subscale of the questionnaires used. The NHP and 
SOMA T showed no differences between the strategies. The ABS showed a 
significant difference in increase in positive experiences in the CPAP-first 
versus the UPPP-first strategy (p = 0.02) at 24 months. The POMS showed a 
significant, but very small difference in decrease of depression score in the 
UPPP-first versus the CPAP-first strategy (p = 0.05). No other significant 
differences were found. 
The base line and follow-up data of desaturation parameters are summarised in 
table 5.2. In both strategies the aD! decreases after treatment. In the UPPP-
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first strategy the decrease was only significant after 12 months (p < 0.0003, with 
median decreases of 19, 24.5 and 37 desaturations per hour on 12, 18 and 24 
months respectively). The decrease in the CPAP-first strategy was significant 
from 6 months on (p < 0.0008, with median decreases of 19, 26, 27 and 26.5 
respectively). The difference between the strategies was found to be significant 
at six months only. Table 5.3 summarises the improvement of ODr as defined 
by criterion A and B. The initial significant difference between the strategies 
disappeared during follow-up. 
At the end of follow-up the mean direct costs per patient in the UPPP-first 
strategy is estimated at 5.257 US Dollars versus $ 2.802 per patient in the CPAP 
first strategy (p 05; 0.02). The cumulative consequential costs per patient in the 
UPPP-first strategy is estimated at $ 6.019 versus $ 2.052 in the CPAP-first 
strategy (p 05; 0.08). 
Table 5.2. 
Base line 6 months 12 months 18 months 24 months 
UPPP·firs\ 0-48 n -43 11-41 n -34 0-21 
Base line Sa02 96 (88-98) 96 (90-98) 96 (93-98) 96 (90-98) 97 (94-98) 
Mean Sa02 88 (61-93)' 89 (73-94) 90 (62-94) 92 (84-93) 91 (88-94) 
Lowesl Sa02 74 (41-90)' 77 (42-94) 84 (43-93) 87 (70-93) 87 (74-94) 
Percentage < 90% 20 (0-95)' 10 (0-85) 2 (0-61) I (0-89) I (0-23) 
Desaturation·index 39 (7-83) 27 (0-89)''' 10 (0-56)'" 10 (0-54)'" 4 (0-37)''' 
CPAP·first n=50 0=50 n=43 u=34 11=21 
Base line Sa02 96 (91-98) 97 (90-98) 97 (94-98) 97 (93-98) 96 (91-98) 
Mean Sa02 90 (74-94)' 92 (85-94) 92 (87-95) 92 (87-96) 92 (86-93) 
Lowest Sa02 80 (42-91)' 87 (65-93) 88 (58-94) 88 (70-95) 88 (78-93) 
Percentage < 90% 5 (0-84)' 0(0-31) 0(0-15) 0(0-31) 0(0-87) 
Desaturation-index 26 (2-90) 3 (O.43t X2) 3 (0-45)''' 2 (0-32)''' 5 (0-30)''' 
All desaturalion parameters obtained by MESAM-4. The median and 9S%-interpercentile 
range are shown. The differences at base line that were found to be significant between 
strategies are marked by (*). The desaturation-index is used in the comparative analysis 
only. The significant improvement within each strategy is marked by (I), p < 0.0008. The 
significant difference in improvement between strategies is marked by (2), P ~ O.OOOS. 
Table 5.3. 
6 months 12 months 18 months 24 months 
Criterion A 
UPPP-first 12% 44% 65% 76% 
CPAP-first 77% 79% 77% 65% 
P <0.0001 0.001 NS NS 
Criterion B 
UPPP-first 5% 13% 29% 57% 
CPAP-first 55% 55% 67% 45% 
P <0.0001 <0.0001 0.002 NS 
The percentage of patients showing SO% decrease in Oxygen Desaturation Index (OD!) and 
OD! below 20 (Criterion A) and SO% decrease in OD! and OD! below S (Criterion B). 
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5.5 Discussion 
This is the first prospective randomised multi-centre trial comparing CPAP and 
UPPP as altemative treatments in patients with OSAS and predominant 
obstruction at the level of the soft palate. We found that CP AP is to be 
preferred over UPPP as the initial treatment of OSAS because, it is better 
accepted by patients, it leads to a better and faster improvement of nocturnal 
desaturations, and it is cheaper. Improvement of daytime sleepiness was 
equally large in both strategies. Measures of quality of life were marginally 
better in the CPAP-first strategy. 
An important value of this study is, that it was designed to represent the 
situation in everyday clinical practice where both UPPP and CP AP are available 
for treatment of OSAS. The design of our protocol allowed therefore a change 
of therapy in case of insufficient improvement in daytime complaints and 
nocturnal saturation. Within the conditions of the protocol evelY patient was 
able to select the treatment with the optimal individual result. This proces of 
pragmatic self-selection resulted in an increasing similarity in all outcome 
parameters between the two strategies during follow-up. Due to this approach, 
the results of this study will be easily implemented in the routine treatment of 
patients with OSAS. 
Several aspects of this study should be considered. From the beginning we 
were more interested in investigating the difference in improvement of daytime 
sleepiness and quality of life than in the difference in desaturation parameters 
between the two strategies. However no detailed data on improvement of 
daytime sleepiness and quality of life after either UPPP or CP AP were available 
in the literature to estimate the difference in improvement for calculation of 
sample size at that time. Sample size was calculated on an estimated difference 
in desaturation index. This means that the power of the study may not be 
enough to rule out that small differences in improvement in daytime sleepiness 
and quality of life exist between the two strategies. 
As explained earlier, the fixed study duration had its influence on the number of 
inclusions as well. There were nine drop-outs, seven of whom refused 
operation after being assigned to UPPP. We consider it likely that these 
subjects consented to participation in the hope to be assigned to treatment with 
CPAP. During this study CPAP-treatment was not easily refunded in the 
Netherlands. The base-line characteristics of the drop-out were not different 
from the whole group. 
Our data show that over 75% of patients in the UPPP-first strategy were 
switched to CP AP after 24 months, while less than 25% of patients in the 
CPAP-first strategy were switched to UPPP. This means that on the long run 
approximately 75% of all patients will be treated by CPAP, independent of the 
initial therapy. Eight of the 12 switches from CP AP to UPPP occurred in a 
single institution. This centre included 15 patients in the CPAP-first strategy. 
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No differences in improvement of daytime sleepiness or noctumal desaturations 
between these particular patients and the others were present, so no bias was 
caused by this subgroup of patients. A substantial part of switches from CPAP 
to UPPP is however caused by a local policy. This indicates that over all less 
patients will switch from CPAP to UPPP, than our data suggest. 
The improvement in daytime sleepiness was impressive in both treatment 
strategies. The process of self-selection can explain why no differences were 
found between the two strategies. Insufficient improvement of daytime 
sleepiness was the main reason for switching from UPPP to CPAP (34 of 37 
cases), while only 3 of 12 patients switched from CP AP to UPPP for this 
reason. Considering that eventually 75% of both strategies existed of CPAP-
treated patients, it was vety unlikely that any difference would develop during 
follow-up, especially when we realise that all those patients who did not switch 
from therapy were sufficiently treated with respect to desaturation parameters 
(details on results per treatment are not given, but will be published separately). 
In this context it is hard to explain why we did not find a difference in 
improvement of daytime sleepiness at 6 months, where the difference in 
improvement of ODI was much better in the CPAP-first strategy. Four possible 
explanations exist. From the literature we know that the improvement of 
daytime sleepiness after UPPP may be impressive on shott-term follow-up, but 
that complaints tend to recun' after 6 - 18 months (12). It is also possible that 
following any surgical procedure, patients tend to over estimate the 
improvement of their complaints. This proces is hypothesised on the basis of 
the "cognitive dissonance" theory. This theory assumes that persons have a 
drive to mental consistancy. Two conditions (to undergo a surgical procedure 
and, at the other hand, the improvement perceived) need to be brought into 
harmony, otherwise mental discomfort arises (13). Discomfort of using CPAP 
during the night may influence sleep quality and as a consequence the 
improvement of daytime sleepiness will not be maximal. The same discomfort 
of CPAP will reduce patient compliance with additional decrease of efficacy 
(14-18). 
All the scores on base line indicate a low quality of life, that improves drasticly 
and significantly in both strategies. Because the data on quality of life are so 
extensive, they are not presented here in detail. Some parameters showed a 
better improvement in the CPAP-strategy. These differences were however not 
consistent over all scales and domains. There is however a tendency towards 
better improvement in the CPAP-first strategy. 
We used the MESAM -4 to obtain detailed infonnation on nocturnal oxygen 
desaturation. Although the absence of sleep parameters, airflow and respiratOlY 
movements limits the use of the MESAM-4 as a diagnostic tool, it is valuable 
for research purposes. The comparison of desaturation parameters is relatively 
unbiased due to the automatic analysis. We selected the oxygen desaturation 
index (ODI), for our final analysis, because it is easily reproduced and comes as 
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close to the apnea index as possible (8). At base line the differences in mean 
Sa02, lowest Sa02 and percentage of registration time with Sa02 below 90% 
between the two strategies were significant but small (see teble 4.). The 
difference in 001 at base-line was however not significant. At six months the 
difference in improvement of OD! is significantly in advantage of CPAP-first 
strategy. This is the only moment during follow-up where the relatively pure 
UPPP and CP AP results can be compaired, because no switches from UPPP to 
CPAP occurred yet. The improvement in the UPPP-first strategy was small and 
not significant, while the improvement in the CPAP-first strategy was 
impressive. This is in concordance with data from the literature (3,19). Later in 
the follow-up the initial difference disappears as a result of the self-selection 
proces. 
It is not clear from the literature when we should consider patients sufficiently 
treated (20). Several criteria are proposed. Based on epidemiologic data 
concerning cardiovascular complications and death from OSAS, we defined two 
criteria. We defined a reduction of at least 50% in OD! and OD! after treatment 
below 20 as a good respons (Criterion A) (9), and a reduction of at least 50% 
and OD! after treatment below 5 as curative (Criterion B) (10). Our results 
show that the process of self-selection is so effective that after 24 months of 
follow-up no differences between the two strategies exist. It is however 
important to notice that the 6-months improvement in the CPAP-first strategy is 
77% for criterion A and close to 55% for criterion B and that this remains rather 
unchanged during follow-up. In the UPPP-first strategy over two years of 
treatment were needed to reach similar results (table 5). 
The cost-minimalisation anlysis shows that starting treatment with CPAP is 
cheaper than starting treatment with UPPP, although the difference in 
consequential costs is not significant. Two exceptional cases were however left 
out of the analysis. In the UPPP-strategy a traumatic intubation led to 
prolonged medical consumption ($ 9.175). This complication is UPPP related. 
In the CPAP-first strategy a serious cardio-vascular event resulted in several 
surgical interventions in olle patient ($ 34.061). This complication is 
considered OS AS-related, but not direct CPAP related. If we include the costs 
of the UPPP-related complication, total costs per patient in the UPPP-first 
strategy will even be higher and the difference between the strategies will even 
be more impressive. 
This study shows that treatment of OSAS in patients with predominant collaps 
at the velopharyngeallevel should begin with CPAP. UPPP should be reserved 
for selected patients who do not tolerate CPAP. 
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6.1 Abstract 
Recently the results of the first prospective randomised study comparing Uvulo-
Palato-Pharyngoplasty (UPPP) and Continuous Positive Airway Pressure 
(CPAP) in the treatment of Obstructive Sleep Apnea Syndrome (OSAS) have 
been described. No difference in improvement of daytime sleepiness was 
found, but CP AP resulted in significantly better improvement of noctumal 
desaturation, was better accepted by patients, and was superior in a cost-
minimalisation anlysis. A prospective evaluation of the effect of UPPP and 
CPAP on Quality of Life (QoL) parameters has never been described. 
The aims of this study were to evaluate QoL in untreated patients and to 
compare the effect of treatment with either UPPP or CP AP. We analysed 105 
of 125 patients with polysomnographically documented OSAS and daytime 
sleepiness. In case of treatment failure, patients switched to the other 
treatment. We performed an analysis following the Intention-To-Treat 
principle (ITT), comparing UPPP-first with CPAP-first treated patients and an 
As Treated analysis (AT), comparing UPPP, CPAP,CPAP after UPPP, and 
UPPP after CPAP.. QoL was assessed at base-line and 6, 12, 18 and 24 
months, with the Nottingham Health Profile part 1 (NHP partl), the Somatic 
subscale of the Hopkins Symptom Checklist (SOMAT), the Bradburn Affect 
Balance Scale (ABS), and the Profile of Mood States (POMS). 
The base-line scores on all subscales of the NHP part 1, SOMAT, ABS, and 
POMS were found to be in the range of diseased to severely diseased norm 
groups. In the ITT analysis a statistically significant improvement was found 
on almost all subscales, but mean scores were still in the diseased range. The 
overall comparison of the UPPP first and CP AP first treated patients showed 
no statistically significant differences in improvement of QoL. CPAP first 
treated patients however, tended to show a better respons. In the AT analysis 
the differences between UPPP, CP AP, CP AP after UPPP, and UPPP after 
CPAP were not significant. 
QoL is severely affected in patients with OSAS, and treatment with UPPP or 
CP AP results in a considerable improvement, but without restoring QoL to 
normal values. 
6.2 Introduction 
Although the symptoms and sequelaea of Obstructive Seep Apnea Syndrome 
(OSAS) may have devastating consequences for the lives of those affected (l), 
quality of life before and after treatment with either Uvulo-Palato-
Pharyngoplasty (UPPP) or Continuous Positive Airway pressure (CPAP) has 
scarcely been investigated (2-4). Since the introduction of both UPPP and 
CP AP for the treatment of OSAS in 1981 (5,6), the effectiveness of treatment 
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has mainly been assessed by changes in snoring, daytime sleepiness, nocturnal 
desaturation and respiratory parameters (7). Recently we described the first 
prospective randomised clinical study (The Dutch Sleep Apnea Study) 
comparing two treatment strategies for OSAS, comparing UPPP and CPAP in 
125 patients with mild to severe OSAS (Chapter 5). We found no differences in 
improvement of daytime sleepiness between the UPPP and CP AP strategies, but 
CP AP resulted in significantly better improvement of nocturnal desaturation. 
The inconsistency between improvement of subjective daytime complaints and 
objective respiratoty parameters in UPPP-treated patients has been reported 
earlier (8-10). FUl1helmore the improvement of respiratoty parameters was not 
found to be invariably related to improvement of sleep architecture and daytime 
function in CPAP-treated patients (I 1-13). We wanted to investigate whether 
the difference in improvement of respiratory parameters between UPPP and 
CP AP was also present in Quality of Life parameters or that the same 
inconsistency between subjective and objective improvement was present. 
The aims of this study were therefore to evaluate Quality of Life (QoL) before 
and after treatment of OSAS and to assess the differences in changes in QoL 
between UPPP and CP AP treated patients. The QoL measures were compared 
to norm values, both before and after treatment to describe the impact of OSAS 
on QoL and the clinical relevance of changes in QoL. Because no evaluated 
disease specific questionnaires to assess QoL in OSAS existed at the time we 
started this study (2,3,14), we selected the Nottingham Health Profile part I, the 
Somatic sub-scale of the Hopkins Symptom Checklist, the Bradburn Affect 
Balance Scale, and the Profile of Mood States, as generic and domain-specific 
measures for QoL and somatic and psychological well-being. 
6.3 Materials and Methods 
We perfotmed a prospective randomised clinical multi-centre trial to assess the 
efficacy of UPPP and CPAP in the treatment of OSAS in the Netherlands. The 
study design is described in detail in our earlier report (Chapter 5). 
We included patients with daytime sleepiness caused by obstructive sleep apnea 
syndrome defined as the presence of at least 5 oxygen desaturations exceeding 
4% from base line per hour of sleep (ODI), caused by obstructive apneas of at 
least 10 seconds. All patients had predominant collaps of the upper airway at 
the velopharyngeal airway by Mueller manoeuvre. Two treatment strategies 
were evaluated: starting treatment with UPPP versus starting treatment with 
CPAP-first. In case of treatment failure, defined as: insufficient improvement 
of daytime sleepiness as judged by the patient; insufficient improvement of 
nocturnal desaturations as judged by the investigator and as intolerance to 
further treatment with CPAP, patients could switch to the other treatment 
modality (chapter 5). The inclusion started on the first of november 1992 and 
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ended on the first of may 1995. 
Data were obtained on moment of randomisation (base-line), and 6, 12, 18 and 
24 months after start of therapy. The procedures for UPPP and CP AP are 
described earlier (chapter 5). 
QoL was assessed in a generic way with the Dutch translated and evaluated 
versions of the Nottingham Health Profile part I (NHP part I) ,and in a domain 
specific way, focussing on somatic and psychological well-being with the 
Somatic subscale of the Hopkins Symptom Checklist (SOMA T), the Bradbum 
Affect Balance Scale (ABS) and the shortened Profile of Mood Scale (POMS) 
in reliable and validated Dutch versions. 
The NHP palt I is composed of several subscales: Emotional Respons (ER), 
Pain (P), Energy (E), Sleep (S), Social Isolation (SI) and Physical Mobility 
(PM), all refelTing to different health aspects. Every subscale is scored 
seperately following the criteria defined in the manual (15). A high score on 
every subscale indicates that this specific aspect of phsychological and physical 
well-being is more affected by any underlying illness. Erdman presented norm 
values for diseased and healthy subjects obtained from 276 patients from a 
general practitioners population in the Netherlands (15). He distingnished four 
groups: men < 50 years, men ~ 50, women < 50 and women ~ 50. Due to the 
male predominance and the median age of 49 of our population, we compare 
our data to recalculated mean scores for the entire male popUlation from 
Erdman. These recalculated scores are displayed in table 6.2. 
The SOMA T is composed of 8 questions referring to somatic complaints. Every 
item can be scored from 0 to 3 (not at all - very much). The total score is 
obtained by summation of the subscores (16). A high score indicates more 
physical complaints resulting in more dysfunctioning during daytime activities. 
The scores for the translated Dutch SOMAT were normated for 3 populations 
(nom13ls, psychiatric patients, and psycho-somatic patients). The results are 
summarised in the manual by Luteijn in 1984 (16). We compare our results to 
the sore found in normals (see table 6.3). 
The ABS is composed of 5 positive and 5 negative items, reflecting positive and 
negative experiences/feelings respectively. Each item can be denied or 
confirmed. The total score per item is obtained by summation of the 
confilmative answers. No norm scores were available for comparison with our 
data. 
The POMS measures five dimensions: Depression (8 items), Anger (7 items), 
Fatigue (6 items), Vigor (5 items) and Tension (6 items). Every item can be 
scored 0 to 4 (17). A total score per dimension is calculated by summation of 
the item scores. A high score indicates that the specific dimension is more 
affected. Wald et al. presented scores obtained in 1984 from 481 men and 491 
women in a general practitioners practice. We compared our data to the scores 
in the male population. These scores are displayed in table 6.3. 
Due to the study design we performed our analysis using the Intention-To-Treat 
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principle and the As-Treated principle. Using the Intention-To-Treat principle 
two treatment strategies were compared: statting treatment of OSAS with UPPP 
(including all patients switching to CPAP during follow-up) versus starting 
treatment with CPAP (including all switchers to UPPP). These two strategies 
will be referred to as: UPPP-first strategy and CPAP-first strategie. Using the 
As-Treated principle four therapy groups are compared: UPPP, CPAP, CPAP 
after UPPP, and UPPP after CPAP. During follow-up the composition of every 
therapy group is changing, because between every follow-up visit patients 
switched from therapy. 
The change in QoL is defined as the difference between the scores on evety 
subscale during follow-up and the scores on base-line. In the "Intention-To-
Treat-analysis" (ITT) the changes of QoL within the UPPP-first and the CPAP-
first strategies were compared to base-line with the matched-pairs signed-rank 
test of Wilcoxon and the differences in changes between the two strategies were 
compared with the Mann-Whitney U test. In the "As-Treated analysis" (AT) 
the changes of QoL within each therapy group were compared with matched-
pairs signed-rank test of Wilcoxon and the differences between the therapy 
groups by Kruskal-Wallis. The ITT analysis was considered most important, 
because it reflects evety day clinical practice where patients seek the best 
treatment for their complaints in dialogue with their physician. The ITT 
analysis is therefore presented in detail, while the AT analysis is presented 
briefly to assess differences in the netto effect ofUPPP and CPAP. 
Table 6.1. 
Base-line 
illtentioJl-To-Treat analysis 
UPPP-first 
CPAP-first 
As-Treated analysis 
UPPP 
CPAP 
CPAP after UPPP 
UPPP after CPAP 
62 
63 
6 Months 
50 
55 
47 
46 
3 
9 
12 Months 18 Months 24 Months 
43 
45 
26 
38 
17 
7 
35 
40 
15 
34 
20 
6 
25 
25 
8 
22 
17 
3 
The number of patients in each strategy and treatment group that were available for analysis 
on base-line and every follow-up visit. The progressive decrease in patients is due to the 
limited study duration. In the As Treated analysis no base-line data are presented, because of 
the changing composition of each treatment-group as a result of switching from treatment 
modality during follow-up. 
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6.4 Results 
Hundred and twenty men and 5 women were included with median age of 49 
years (95%-interpercentile range 2S- 70). All patients were sleepy according to 
the Rotterdam Daytime Sleepiness Scale (ROSS) (IS). Median desaturation 
index was 32.5 (95%-interpercentile range 5 - 90). The anthropometric data 
were described in detail earlier (chapter 5). There were nine drop-outs and 11 
patients were excluded because their questionnaires did not allow full statistical 
analysis. The remaining 105 questionnaires were suitable for analysis. 
The number of patients decreases progressively during follow-up, due to the 
limited duration of the study. The numbers of patients available for analysis are 
displayed in table 6.1. 
Table 6.2. 
Base-line 6 Months p 12 Months p 18 Months P 24 Months p 
Emoliolla/ Response (diseased score 11.7, healthy score 3.2) 
uppp 21.1(27.5) 16.2{2S.0) om 13.0(24.5) 0.005 15.2(27.6) 0.01 19.6(25.7) <0.02 
CPAP 31.3(25.6) 15.6(26.1) <0.0001 14.8(24.4) 0.003 13.1(\9.0) 0.0005 12.5(22.1) 0.008 
P NS NS NS NS NS 
Pain (diseased score 8.6, healthy score 4.4) 
uppp 17.4(27.4) 16.4(25.0) NS 14.7(25.6) NS 22.5(33.2) NS 20.0{29.1) NS 
CPAP 20.2(27.5) 16.6{30A) NS 12.7(24.1) 0.Q7 15.4(26.8) NS 11.5(26.7) NS 
P NS NS NS NS NS 
Energy (diseased score 12.7. healthy score 5.0) 
uppp 55.4(37.5) 26.7(37.5) 0.0001 24.8(36.5) 0.002 24.8(37.3) 0.0001 29.3(37.7) <0.005 
CPAP 60.6(38.1) 24.2(38.2) <0.0001 20.0{34.4) <O.QO{}I 20.8(34.3) <0.0001 23.6(37.4) 0.0004 
p NS NS NS NS NS 
Sleep (diseased score 10.9, healthy score 9.2) 
uppp 26.6(24.7) 16.9(23.4) 0,0) 20.9(22.2) 0.Q7 18.9(22.2) 0.Q7 16.8(19.7) <0.01 
CPAP 25.3{25.1) 13.8(20.0) 0.0007 9.3(14.5) 0.0002 14.5(21.2) <0.02 9.6(18.4) 0,01 
p NS NS NS NS NS 
Social/solatioll (diseased score 6.2, healthy score 1.5) 
UPPP 14.9(23.4) 8.4(19.0) NS 6.5(17.3) 0,02 9.7(22.9) NS 11.2(10.9) 0.04 
CPAP 14.1{17A) 6.5(17.2) <0.003 4.0(10.1) 0.001 2.5(9.3) 0.005 4.8(11.9) 0.006 
p NS NS NS NS NS 
Phys;cal MobUity (diseased score 9.0, healthy score 3.7) 
uppp 20.5(13.9) 16.8(21.7) 0.Q7 12.5(17.7) 0.01 17.1(25.4) <0.10 17.5(19.8) 0.09 
CPAP 15.1(20.8) 13.7(21.3) NS 9.8(15.3) NS 8A{15.9) 0.03 7.5(16.9) <0.01 
P NS NS NS NS NS 
The absolute scores with their standard deviation between brackets on every subscale of the 
NHP part I in the UPPP-first strategy (UPPP) and the CPAP-first strategy (CPAP). The level 
of significance (Wilcoxon signed-rank) of the improvement of every score is displayed in the 
column following every follow-up visit (vertically). The level of significance of the 
difference in improvement between the two strategies (Mann-Whitney U) is displayed in the 
last row of the corresponding score (horizontally). NS means not significant and no trend (p 
> 0.10). The noml scores for diseased and healthy persons are derived from Erdman 1994 
(15) and are displayed between brackets behind the title of every subscale. 
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6.4.1 !ntelltion-To-Treat Analysis 
The scores on the NHP part 1 are shown in table 6.2. Compared to the norm 
scores by Erdman, oUl' scores at base-line exceeded these values by almost 2 to 
3 times. Almost all scores decreased significantly after treatment in both 
strategies. No statistically significant differences in improvement of any of the 
scores was found between the two strategies, but almost all scores were lower in 
the CPAP-first strategy on evelY follow-up. The Pain-score showed an 
increase, although not significant, in the UPPP-first strategy. Especially the 
improvement on the Energy-and Sleep-scores was salient. 
The scores on the SOMAT are displayed in table 6.3. Base-line scores in both 
strategies were 2 to 3 times higher than the norm score by Luteijn et aI, and 
were situated between the 80lh and 95 1h percentile (16) The score decreased 
significantly in both strategies on almost evelY follow-up, but no statistically 
significant differences were found between the two strategies. UPPP-first 
scores were (insignificantly) lower during the first 12 months of follow-up and 
the CPAP-first scores in the second 12 months. 
The scores on the ABS are displayed in table 6.3. A significant increase in 
positive experiences and a significant decrease in negative experiences was 
found in both strategies, but the improvement disappeared in the UPPP-first 
strategy. Only at 24 months a statistically significant difference in favor of 
CP AP was found between the strategies. 
The results on the POMS are also displayed in table 6.3. Compared to the norm 
values by Wald et al.(17), all negative mood domains showed higher scores. 
Again all scores showed a significant improvement on almost evelY follow-up. 
Only one statistically significant difference and two trends in favor of CPAP 
first treated patients were found (depression at 6, anger at 12, and vigor at 24 
months). 
6.4.2 As-Treated Analysis 
No statistically significant difference on any subscale was found at base-line. 
The number of patients in the CPAP after UPPP therapy group at 6 months and 
the UPPP after CPAP therapy group at 24 months were too small to allow 
statistical analysis (see table 6.1). None of the subscales of the four 
questionnaires used, showed statistically significant differences between any of 
the four therapy groups during the total follow-up time. 
The NHP part 1 showed that an improvement was present in all groups, but 
most pronounced in the CP AP group. The differences between the groups were 
however small, and not significant. Patients in the CPAP after UPPP and UPPP 
after CPAP groups showed a smaller improvement than the other two groups. 
Patients in the UPPP group scored higher on Pain. The improvement of energy 
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was most pronounced in the CPAP and CPAP after UPPP groups. 
The SOMA T showed a persistent and statistically significant decreased score in 
the CPAP group during the total follow-up. In the UPPP and UPPP after CPAP 
groups a statistically significant decrease was found during the first 12 months 
only. No change was found in the CPAP after UPPP group. 
The increase in positive experiences and the decrease in negative experiences on 
the ABS were persistently significant during the total follow-up in the CPAP 
group only. In the other groups no trend was found in any direction. 
The POMS showed a decrease in the domains of depression, anger, fatigue and 
tension in the UPPP and CPAP groups. Vigor increased in these two groups. In 
the CPAP after UPPP and UPPP after CPAP groups no persistent changes were 
found. 
6.5 Discussion 
Quality of Life in patients with OSAS is significantly improved after treatment 
with either UPPP or CPAP. The results of the NHP part I, SOMAT, ABS and 
POMS all showed the same improvement and no differences were found 
between between UPPP and CP AP treated patients. The improvement of QoL 
was not influenced by switching from UPPP to CPAP or vice-versa. 
We included patients with mild to severe OSAS. All patients complained of 
daytime sleepiness and were shown to have obsttuctive sleep apnea by 
polysomnography following the internationally accepted standards (19). 
Predominant collaps at the velo-pharyngeal level was the only selection 
criterion we used. Because the international "consensus", as reviewed by Sher 
in 1996, advised against UPPP in patients with predominant collaps of the upper 
airway at any other level (20), we considered it unethical to include these 
patients. 
The study was designed to reflect every day clinical practice, allowing the 
dialogue between physician and patient to evaluate the effect of treatment and to 
switch from therapy if insufficient improvement of daytime sleepiness or 
nocturnal desaturation were present. At the end of follow-up over 75% of 
patients switched from UPPP to CP AP, compared to less than 25% from CP AP 
to UPPP (chapter 5). In the ITT analysis the UPPP-first strategy and the CPAP-
first strategy were both composed of75% ofCPAP-treated patients at the end of 
follow-up. The almost equal composition of both strategies does not explain 
why we found no difference in improvement of QoL, because the AT analysis 
showed that indeed no differences existed between CP AP and UPPP treated 
patients, even after switching of therapy. 
A limitaton of this study is that the follow-up matrix was not complete, because 
the study duration was limited to 3 years by the study regulations of the 
Investigative Medicine Committee of the Dutch Health Insurance Council. An 
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intake period of 2.5 years yields a preset minimal follow-np duration of 0.5 
years with a maximum of2 years (see Table 6.1). 
Table 6.3. legend on next pa e) 
Base- 6 p 12 I P 18 P 24 P line Months Months Months Months 
Somatic subseale of the Hopkins Symptom Checklist 
UPPP·first 5.4(4.2 3.8(3.9) 0.006 3.8(3.9) I NS 4.2(4.0) NS 4.4(4.5) 0.02 
crAp·first 5.9(3.9) 4.4(3.8) 0.002 4.3(3.2) 0.05 4.1(3.2) 0.02 3.4(3.4) 0.02 p NS NS NS NS NS 
Bradburn Affect Balance Scale 
Positive experiences 
UPPP-first 2.3(1.6) 2.8(1.6) <0.04 3.2(1.6) I 0.01 3.2(1.7) 0.02 2.7(1.8) NS 
CPAp·first 1.9(1.5) 2.8(1.7) 0.009 2.7(1.7) <0.04 3.0(1.6) <0.003 3.0(1.6) 0.003 
ip NS NS NS NS 0.02 
Negative experiences 
UPPP·first 1.4(1.4) 1.0(1.3) NS 0.8(1.0) I 0.06 1.0(1.5) NS 1.1(1.1) NS 
CPAP·first 1.7(1.4) 1.1(1.3) 0.002 0.9(1.1) 0.002 0.9(1.1) 0.008 1.0(0.9) 0.04 
" 
NS NS NS NS NS 
Profile of Mood States 
Depression (1.9 ± 4.4) 
UPPP·first 5.5(6.4) 3.1(4.8) 0.07 2.5(4.5) I <0.03 4.0(6.1) NS 3.8(5.2) 0.01 
CPAP·first 6.3(5.5) 4.0(6.7) 0.005 3.2(5.4) 0.0003 2.9(4.9) 0.001 4.6(7.6) <0.03 
10 NS 0.05 NS NS NS 
Anger (3.7 ± 4.6) 
UPPP·first 9.1(7.4) 6.0(5.6) 0.01 6.8(5.8) I 0.09 6.8(6.4) 0.03 6.9(6.5) 0.06 
CPAP·first 10.3(6.1) 6.1(5.8) <0.0001 5.5(4.8) <0.000 5.1(4.9) 0.0003 6.6(6.8) <0,005 
ip NS NS 0.06 I NS NS 
Fatigue (3.3 ± 4.4) 
UPPP·first 11.5(6.0) 6.1(5.9) <0.0001 6.1(6.0) I 0.0001 5.5(6.0) 0.0001 6.4(6.2) 0.002 
CPAP·first 13.0(6.9) 6.4(7.7) <0.0001 7.1(7.6) <0.000 4.8(5.4) <0.0001 4.6(5.6) 0.0004 p NS NS NS I NS NS 
Vigor(12.1 ± 4.5) 
UPPP-firsl 7.1(4.3) 9.9(4.9) <0.002 10.8(4.8) I 0.0005 10.9(3.8) 0.0001 9.6(4.5) 0.07 
CPAp·first 6.3(4.5) 10.3(5.8) <0.0001 10.4(5.6) 0.0001 9.4(5.3) <0.003 10.3(5.4) 0.002 
0 NS NS NS NS 0.09 
Tension (3.6 ± 4.0) 
VPPP-first 6.6(5.5) 3.8(4.6) I 0.0002 3.4(4.0) I 0.001 3.9(4.3) <0.004 4.2(3.7) 0.002 
CPAp·first 7.0(4.9) 4.8(5.1) 0.0006 3.5(3.8) <0.000 3.7(3.7) <0.0001 3.7(5.0) 0.006 
i p NS NS NS I NS NS 
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Legend to table 6.3. 
The absolute scores with their standard deviation between brackets on the SOMAT, ABS and 
the POMS. The nonnative scores ± standard deviation of the POMS obtained from Wald and 
Mellenbergh (17), are displayed between brackets behind the title of every subscale. The 
level of significance (Wilcoxon signed-rank) of the improvement of every subscore is 
displayed in the columll following every follow-up visit (vertically). The level of 
significance of the difference in improvement between the two strategies (Mann-Whitney U) 
is displayed in the last row of the corresponding sub score (horizontally). NS means not 
significant and no trend (p > 0.10). 
When comparing the scores on the NHP part I to the recalculated norm scores 
of Erdman (15), all scores at base-line exceed the scores of this norm group of 
98 patients by 2 to 3 times (see table 6.2.). Despite the statistically significant 
improvement of almost every score in the ITT, most scores remained well above 
the mean of this nOlm group. Patients in the UPPP-first and CPAP -first 
strategies showed a 50% improvement in energy score but still exceeded the 
norm value for diseased men by factor 2. At 24 months sleep score was in the 
healthy range in the CPAP-first strategy only. The pain score in the UPPP-first 
strategy remained relatively high during the entire follow-up (20.0 at 24 
months). The AT results support the ITT findings. The NHP part I was also 
used by Fomas et al to evaluate QoL in untreated OSAS-patients (21). They did 
not use weighed scores, so our data can not be compared directly to theirs. They 
found that the worst perceived dimensions were energy, sleep, emotional 
response, which is in concordance with our findings. Meslier et al used the 
NHP part I to evaluate the QoL in 3.225 respondents of 5.339 invited OSAS-
patients on CP AP treatment for at least 6 months (4). All their weighed scores 
were higher than our scores in the CPAP-first strategy and the CPAP therapy 
group, with the exception of emotional response. Their population was older 
(median 60 versus 49) and they found in the same study that older patients have 
significantly higher scores for energy, pain, sleep,social isolation ,and physical 
mobility and significantly lower scores for emotional respons (4). Engleman et 
al nsed the NHP part 2 in a placebo controlled trial to evaluate the effect of 
CPAP in 32 patients with OSAS (22). They found improved ratings for social 
life, sex life, and ability to carry out domestic chores. 
The mean score on the SOMA T in "normals" with a mean age of 24.5 years 
(range 13-72) was fonnd to be 2.1 (SO = 2.3) (16). This means that the scores 
on the SOMAT in our population are high and remain high after treatment, 
between the 80th and 95th percentile of the norm group of Luteijn et al. (ITT and 
AT). Although our population can not be compared directly to these controls, 
this indicates that OSAS patients are likely to experience more physical 
complaints than controls, even after treatment with UPPP or CPAP. As far as 
we know the SOMA T has never been used before to assess QoL in OSAS. The 
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Hopkins Symptom Checklist, of wich the SOMAT is a subscale has been 
complemented with psychiatric items to form the Symptom Checklist -90 
revised (SCL-90) (16). This SCL-90 has been used in a study in 1993, in which 
Gall at all found no differences between patients with mild OSAS 
(ApnealHypopnea-index < 20) and controls (23). 
The ABS has been translated and used in the Dutch situation. We were 
however not able to find useful nOlIDal values to compare with our results. The 
results show however the same tendency as the other questionnaires: a increase 
in positive experiences and a decrease in negative experiences in UPPP and 
CP AP treated patients (ITT and AT). Despite the small but statistically 
significant difference in the increase in positive experiences between the UPPP-
first and CPAP-first strategies at 24 months, the ABS showed no consistently 
statistical differences between UPPP and CPAP either. 
The shortened version of the validated and translated POMS was first described 
in 1990 by Wald and Mellenbergh (17) (see table 6.3.). In our data evelY 
domain of the POMS was considerably affected, and although the standard 
deviations are large, the only two domains approaching normal values after 
treatment were Vigor and Tension (ITT and AT). Mosko et al used the POMS 
to evaluate self-reported mood ratings in patients with sleep disorders in 1989 
(24). Their patients showed more depression, vigor and tension than our 
subjects. This could well be coincidental, because the scores on anger and 
fatigue are similar. The effect of UPPP on the POMS scores was reported in the 
same study in 22 patients (24). The improvement in depression, anger and 
fatigue were statistically significant, the other scores showed the same 
improvement as in our study. Our data confirm the findings by Mosko et al. 
(24). 
That QoL is so severely affected in untreated OSAS may be caused not only by 
OSAS related symptoms, but also by OSAS related sequelaea, some of which 
could be considered as comorbid conditions on their own. OSAS has been 
documented to be associated with cardiac alThythmias, ischemic heart disease, 
cardiac failure, systemic or pulmonary hypertension, and stroke (25). The 
effects of treatment of OSAS on the associated morbidity has been shown to be 
variable and sometimes limited (7). This may partly be responsible for the 
incomplete recovery of QoL parameters. On the other hand the low 
improvement of desaturation parameters and surgery related complaints in 
UPPP treated patients and constant confrontation with the nose-mask in CPAP 
treated patients may have a negative effect of experienced well-being. Meslier 
et al demonstrated that patients with intermediate compliance to CP AP had a 
better perception of their health than poorly compliant patients(4). We did not 
objectively measure compliance to CPAP, allowing no conclusion for this 
aspect. 
Despite the difference in the improvement of desaturation parameters between 
UPPP and CP AP treated patients in our study (chapter 5), we found no 
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difference in improvement of EDS and QoL between the two treatments. The 
discrepancy between objective and subjective improvement after treatment for 
OSAS has been reported earlier, especially in UPPP treated subjects (8-10). 
Several studies showed no correlation between respiratOlY parameters and EDS 
or QoL (23,26,27). Our data and the earlier studies support the hypothesis that 
other factors than sleep related respiratory disturbances or disruption of 
nocturnal sleep, are likely to contribute to the development of EDS and daytime 
dysfunction in patients with sleep apnea. 
This is the first prospective, although uncontrolled study in a relatively large 
population demonstrating that QoL is severely affected in patients with OSAS, 
and that treatment with either UPPP or CPAP may result in an considerable 
improvement of QoL, but without restoring it to normal values. CPAP-treated 
patients showed a better respons and incidentally a subscale approached the 
normal values, but CPAP in general was not found to be superior to UPPP in 
perspective of improving QoL parameters. 
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General Discussion and Conclusions 
Chapter 7 
7.1 Introduction 
In the perspective of its relative high prevalence and the severity of its 
symptoms, OSAS must indeed be considered a major public health problem (I), 
that deserves expetl medical attention and treatment. However, without a 
complete understanding of the pathogenesis and long-tetm effects on health 
outcome of sleep related breathing disorders (2), the development of effective 
treatment modalities, that are relatively non-invasive and well tolerated will 
remain difficult, and further research is therefore of paramount importance. 
In this thesis we focussed on the treatment of OSAS with 
Uvulopalatophatyngoplasty (UPPP) and Continuous Positive Airway Pressure 
(CPAP), and pathogenetic aspects were studied to illustrate the limitations of 
surgical therapy (chapter 2). The main goal of our studies was to assess the 
treatment outcome after UPPP (chapter 3 alld 4) and to evaluate whether the 
treatment of patients with OSAS caused by predominant collaps at the velo-
pharyngeal level should be started with UPPP or CPAP (chapters 5 alld 6). 
7.2 Definition of Obstructive Sleep Apnea Syndrome 
As described in the introduction, different respiratory parameters and thresholds 
are used in the literature to define OSAS. Most definitions were based on the 
recording techniques that were used. The definition of OSAS in this thesis is 
again somewhat different from the intemational literature and is a direct 
consequence of the two recording techniques we used for the diagnosis and 
evaluation of OSAS. Polysomnography is considered the gold standard for a 
definite diagnosis of OSAS (3,4), and for this reason we performed PSG in all 
our patients before including them in any of the described studies. PSG is 
however a very time-consuming procedure and is therefore impracticable for 
regular use during follow-up procedures. For this reason we considered several 
ambulatory devices, and selected the MESAM-4, which was the most 
practicable device available at that time. Pulse oximetry was included in both 
the PSG and MESAM 4 recording and the detailed data on arterial oxygen 
desaturation allowed calculation of the OD! from both recording modalities. 
OD! was obtained by including desaturations exceeding 3% from base-line 
caused by obsttuctive respiratory events only (apneas and hypopneas) when 
interpreting PSG and by excluding all artefacts from the oxygen saturation trace 
provided by the MESAM 4. All ME SAM 4 recordings were scored by hand. 
Esnaola et al. showed that hand-scoring of MESAM 4 as a confirmation test 
compared to simultaneous PSG showed a specificity for the diagnosis of OSAS 
of 0.98 by an AHI threshold of 10, and of 0.97 by a threshold of 5 (5). Koziej et 
al. demonstrated that the correlation between a hand-scored OD! (MESAM 4) 
and a AHI (PSG) was 0.96, with AHI threshold of 10 as criterion for OSAS by 
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PSG. OSAS may therefore be redefined as the presence of daytime sleepiness 
and an ODr 2 5 or an AI 2 5, in the presence of obstructive respiratOlY events of 
at least 10 seconds in case of PSG, or "typical" desaturations combined with 
changes in heart rate and snoring trace in case of MESAM 4. Several studies 
have adressed the use of oximetry in the detection of OSAS (6), but an oxygen 
desaturation index (ODI) as part of the definition of OSAS has been used 
sparsely, and mainly for epidemiologic and screening purposes (7-9). The 
comparability of ODI with data from the literature may be limited, but the 
methodological restrictions of other definitions used must also be considered. 
The apnea-index (AI), apnea-hypopnea index (AHl) or respiratory distress 
index (RDI) are used most frequently (6). The definition of an apnea as a 
complete cessation of airflow though nose and mouth of at least 10 seconds is 
well established, as is the definition of AI as the mean number of apneas per 
hour of recorded sleep. A hypopnea is however poorly defined, but is 
obligatory to the definition of both AHl and RDI. Generally a hypopnea is 
described as a diminished airflow during at least 10 seconds, but due to the 
different recording techniques used it is rather a qualitative than a quantitative 
description of a respiratOlY event and a precise demarcation is impractical (10-
12). 
The use of these indices in defining OSAS and comparing the results of the 
enormous amount of studies published is therefore not as accurate as may be 
suggested. Furthermore the association ofa specific AI or AHI (5,10,15, and so 
forth), with the development of a specific clinical picture and 10ng-tetID health 
effects has never been established (12). 
7.3 Pathogenetic Aspects and Treatment Outcome 
The pathogenesis of OSAS has not been elucidated. The Balallce of Pressures 
Prillciple (13,14), qualitatively describes the sleep related changes in ventilatOlY 
control and muscle tone that result in a disbalance of the dilatOlY and narrowing 
forces acting on the upper airway during sleep, and it is undisputed that 
anatomic narrowing futiher enhances the instability of the upper airway and 
contributes to the OCCUlTence of obstructive respiratOlY events in OSAS. 
Further understanding of the relative contribution of different pathogenetic 
factors is important, because the available treatment modalities may have effect 
on a small part of the causative factors only. In chapter 2 we assessed the 
quantitative contribution of dynamic and static upper airway obstruction 
parameters on the frequency and severity of nocturnal desaturation in heavily 
snoring and OSAS patients. We found that approximately 30% - 40% of the 
variation in ODI and maximal oxygen desaturation were explained by 
obstruction parameters alone. This finding suggests that the effect of surgical 
cOlTection of upper airway anatomy on reducing nocturnal desaturations may be 
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limited. This is in concordance with the effect ofUPPP on OD! in our patients, 
but Riley et al. demonstrated that an invasive stepwise surgical protocol, 
adressing the different obstruction sites of the upper airway may result in a 
treatment outcome comparable to the effect of CPAP in approximately 90% of 
patients (15-17). This observation suggests that reduction of upper airway 
compliance results in further stabilisation of ventilatory control. The stepwise 
protocol of Riley et al. is however very invasive and most patients will be 
treated by more conservative surgical techniques (nasal septum con'ection, 
UPPP etc), with a more limited effect on nocturnal breathing. This may 
especially be true for the idiopathic OSAS, in which anatomical abnonnalities 
of the upper airway causing symptomatic apneas are not present. 
The effect of CP AP is mediated by its influence on several contributive factors. 
The pneumatic splinting of the anatomically narrow upper airway may be most 
important (18,19), but CPAP also increases lung volume, alters central 
chemosensitivity and increases upper airway muscle activity (18-25). From a 
scientific standpoint CPAP should be more effective than surgery in the 
treatment of OSAS, and this hypothesis is supported by the literature and by our 
findings. We must however realise that our understanding of the pathogenesis 
of OSAS is still limited, and that this prevents us from developing more 
rationale treatment strategies that may be less cumbersome than CP AP. 
7.4 The Evaluation of Treatment Strategies 
UPPP and CP AP were introduced simultaneously for the treatment of OSAS 
(26,27). In the early nineties UPPP was still the most performed procedure 
(28), but CPAP is now considered the treatment of first choice, although only 
one prospective randomised placebo controlled trial has been performed to 
evaluate its effect (29-32). Untill recently it remained unresolved, whether 
treatment of OSAS in patients with predominant collaps of the upper airway at 
the velophatyngeallevel should be started with UPPP or CPAP. 
7.4.1 Uvulo-Palato-PhmYllgo-Plasty (UPPP) 
UPPP is perfomled to reduce redundant velophatyngeal tissue to reduce the 
collapsibility of the upper airway. Although the procedure has been widely 
accepted as a treatment modality for OSAS, there is a marked inconsistence 
between subjective and objective improvement of symptoms. Furthermore, 
there is increasing evidence that the initial response decreases over the years 
following treatment. Our studies confirm these general considerations. In 
chapter 3 we described the treatment outcome 6 months after UPPP, and found 
a significant improvement of snoring (73% of patients), and daytime sleepiness 
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(55% of patients), but improvement of am was not significant. In chapter 4 
we described the Iong-tenn outcome in the same study cohort, after a follow-up 
period of II - 74 months. We found that snoring remained significantly 
improved (63% of patients), but that daytime sleepiness relapsed to pre-
operative levels, and that am was not changed. Several explanations for this 
finding can be postulated. As described earlier the process of attribution may 
explain palt of the initial subjective improvement (see chapter 5), and it is likely 
that this attribution will attenuate over the years. Considering the relative small 
improvement of respiratory parameters following UPPP, suggesting a minor 
anatomical correction only, it may well be that this procedure provides a 
temporary set-back or delay in the natural evolution of the syndrome and its 
symptomatology. Although we reperformed the Mueller manoeuver in some of 
our patients, we were not able to show progressive recun·ence of upper airway 
collaps over the years following treatment, but this seems the most plausible 
explanation. A new finding in our long-term study was the significant better 
improvement of ODI after UPPP combined with tonsillectomy, compared to 
UPPP alone (in case tonsillectomy was already performed for other reasons). 
One explanation for this finding may be, that the presence of palatine tonsils 
reduces the upper airway aperture and further enhances collapsibility during 
sleep. Although this mechanism is not suppOited by the finding of the Mueller 
manoeuver, it is reflected by the higher sleep apnea severity as expressed in am 
between UPPP + TE and UPPP only patients at baseline. Removal of this 
causative contributing factor may itself result in better improvement of ODI, but 
the resection of tissue in the tonsillar fossa results in a more lateral expansion of 
the incision and consequently of the suture line. A more generous resection of the 
soft palate may therefore be complementmy to the effect of tonsillectomy alone 
and may contribute to better treatment outcome (33). FurthelIDore several studies 
and our own results showed that improvement of am was related to relatively 
high pre-operative am, and since UPPP + TE patients had more severe OSAS, 
this mechanism may also be paltly responsible (chapter 3 alld 4). 
Another serious limitation ofUPPP is the almost complete absence of clinically 
useful pre-operative selection criteria. It is generally accepted that UPPP should 
not be performed in patients with high body weight, high sleep apnea severity, 
and significant collapse of the upper airway at any other level than the 
velopharynx, but a high number of treatment failures should still be accounted 
for. The presence of tonsillar tissue may be a useful selection criterion, but this 
needs further evaluation in prospective trials. 
Although the effect of UPPP is seriously limited and a relapse of symptoms is 
likely to occur within 3 years following surgery, it can not be disputed that a 
small group of patients (20% - 25%) must still be considered responders on the 
long-term. This finding was confirmed in the analysis of the Dutch Sleep 
Apnea Study (see further). Twenty-three percent of patients initially treated 
with UPPP, did not switch to CPAP after 24 months of follow-up, and no 
125 
Chapter 7 
statistically significant differences in daytime sleepiness, quality of life and 
nocturnal desaturations were found between these patients and patients using 
CPAP. 
7.4.2 Evaluation of UPPP alld CPAP ill two Alte1'llative Treatment 
Strategies 
CPAP is considered treatment of first choice in OSAS, irrespective of the level 
of upper airway obstruction (32). UPPP should by preference be reserved for 
patients with predominant collaps at the velophatyngeal level (34). UPPP and 
CP AP may, therefore, both be indicated for the treatment of OSAS in these 
patients. A single randomised prospective study comparing both treatments has 
never been performed. 
The Dutch Sleep Apnea Study was the first prospective randomised study 
comparing UPPP and CPAP for the treatment of OSAS caused by predominant 
obsttuction at the velophatyngeallevel. The study was performed for the Dutch 
Health Insurance Council. The main goal of this study was to evaluate whether 
treatment in these patients should be started with UPPP or CP AP. The design of 
the study was based on evety day clinical practice with regard to clinical work-
up, diagnosis, treatment indication, and clinical follow-up. Follow-up visits 
were at regular intervals of six months during two years. In case of treatment 
failure patients could switch to the other treatment modality, and this guaranteed 
optimal treatment of any individual patient within the regulations of the study 
protocol. We performed two different statistical analyses. In the Intention-To-
Treat (ITT) analysis patients starting with UPPP were compared to patients 
starting with CPAP, and eventual switchers from therapy remained in the 
original strategy. In the As Treated (AT) analysis four different treatment 
groups were compared: patients after UPPP only, patients on CPA only, patients 
on CPAP secondaty to UPPP, and patients after UPPP secondary to CPAP. The 
results of the AT analysis are described only in the Quality of Life analysis in 
chapter 6. We defined the following end-points: 
1. The number of patients improving at least one point on the 4-point 
daytime sleepiness scale after 6 months of follow-up following the ITT 
principle. 
2. The number of patients improving at least one point on the 4-point 
daytime sleepiness scale after 12 months of follow-up following the ITT 
principle. 
Due to the large number of switches from UPPP to CP AP and the predominant 
switching from CPAP to UPPP at the beginning of the follow-up period (figure 
7.1), we had to consider the amount ofswitchers as a major end-point as well. 
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We therefore defined a complementary end-point: 
3. The percentage of patients switching from treatment after 12 months of 
follow-up. 
The percentage of patients switching from treatment at 6 months was not 
analysed, because in the UPPP-strategy switching was not allowed within 6 
months after surgery. The numbers of patients at 18 and 24 months were too 
small for statistical analysis (chapter 5). Secondary end-points were differences 
in quality of life measures and noctumal OD! between the two strategies. 
Figure 7.1. The cumulative percentage of patients switching between treatments (see text) 
Randomisation 6 months II 12 months 18 months 24 months 
UPPP-strategy UPPP UPPP UPPP UPPP 
16 17 21 23 
6 45 62 77 
CPAP-slratcgy CPAP CPAP CPAP CPAP 
Daytime sleepiness was significantly improved in both strategies, and we found 
no difference between the strategies considering this primary endpoint on 6 and 
12 months of follow-up. Quality of life measures improved significantly in 
both strategies in the ITT analysis, and no consistent differences were found 
between UPPP-first treated and CPAP-first treated patients. The AT analysis 
showed the same result, but patients in the CPAP after UPPP group tended to 
score worse than the other three groups. We found a significant difference in 
the improvement of 001 in advantage of the CPAP-first treated patients at six 
months. At 12, 18, and 24 months the improvement of 001 was significant in 
both strategies, and the differences between the two strategies decreased 
progressively and were not statistically significant. This can be explained by 
the high percentage of patients treated with CPAP in the UPPP-first strategy at 
the later stages of follow-up. We also performed a cost-minimalisation analysis, 
and found that both the direct and consequential costs were significantly lower 
if treatment was started with CPAP. This is due to the fact that, at the end of the 
study 77% of patients were switched from UPPP to CPAP, compared to 23% of 
patients that switched from CP AP to UPPP. In both strategies an equal 
percentage of patients was eventually treated with CP AP, but the short -term 
costs of operation and hospitalisation attached to UPPP in the UPPP-first 
strategy, account for the difference. 
When we reconsider the fact that we designed the study to allow switching from 
treatment in case of treatment failure, as judged by the patient or his physician, 
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we initiated a "self-selection" proces. This proces resulted eventually in an 
equal distribution of treatments in both strategies (75% of CP AP and 25% of 
UPPP), and as a consequence no differences should be found between these two 
similar groups. The analysis of the om provides objective evidence of the 
effectivity of this "self-selection"proces. 
An important consideration is that minor differences in the primaty end-point 
could be present between the two strategies, but that the power of this study 
may not be enough to detect it. The aspects possibly responsible for this lack of 
power are discussed in detail in chapter 5. Although we did not find any 
statistically significant difference with regard to the primary end-points between 
UPPP-first and CPAP first treated patients, this study provides enough 
arguments for CPAP to be considered treatment of first choice for patients with 
OSAS caused by collaps at the velopharyngeal level. Starting treatment with 
CPAP will lead to less treatment failures and to less switching of therapy. 
Starting treatment with CPAP results in better improvement of nocturnal 
oxygen saturation. Starting treatment with CPAP is cheaper, not only because it 
spares the initial costs of UPPP in appoximately 75% of patients, but the direct 
and consequential costs in CP AP treated patients, even if they decide to switch 
to UPPP are significantly lower. Although we found that a maximum of 23% of 
UPPP treated patients were good responders at the end of follow-up, we found 
no clinically useful pre-operative selection criteria for the identification of 
possible responders or possible treatment failures. This means that any 
individual patient has a 23% chance of long ternl effective treatment when 
offered UPPP, versus a 77% chance when offered CP AP. 
7.5 Conclusions and Considerations for the Future 
OSAS may have severe consequences for evety individual patient with regard to 
nocturnal sleep and daytime functioning, and there is enough scientific evidence 
for the relation between OSAS and cardiovascular morbidity (I). Long-term 
population based prospective studies to examine the precise association between 
OSAS and related morbidity and mortality have still not been published, and it 
remains therefore unresolved whether OSAS indeed causes a decrease in public 
health (2). It remains therefore also unresolved whether treatment of OSAS, 
either surgical or by CPAP will result in a decrease in OSAS related 
cardiovascular morbidity and mortality, although numerous studies, and our 
data clearly show a decrease in daytime symptoms and stabilisation of nocturnal 
breathing in a substantial number of patients. It remains therefore undisputed 
that treatment of OSAS will result in improvement of daytime symptoms, but 
further research is needed to establish the association between OSAS and its 
treatment on sleep apnea related morbidity and mortality. This research 
preferably demands prospective randomised controlled trials, but it can hardly 
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be considered ethical to include a control group of untreated OSAS patients. 
Furthermore, these studies should not only consider OSAS as a public health 
problem and as such address public health related cost and outcome measures 
only, but also the long-term outcome from a more individual perspective. For 
the future we need to accurately detect patients with OSAS, and to treat them in 
specialised centres. If possible they should be included in prospective trials 
comparing different treatment options (conservative or surgical). Comparative 
evaluation of the efficacy of the different treatment modalities in perspective of 
symptoms and cardio-vascular sequalae, may allow us to understand long-term 
outcome with respect to these symptoms and long-ternl cardio-vascular 
complications. 
Despite the fact that CPAP was considered treatment of first choice for OSAS 
by many leading investigators, it was not that commonly prescribed by 
physicians in the Netherlands, as it was in other countries (USA, France and 
Get1uany for example). Until recently UPPP was performed frequently, 
especially in patients with predominant collaps of the upper airway at the 
velopharyngeal level. The indication for CPAP was made with reservation, 
because the regulations of the Dutch Health Insurance Counsel allowed 
treatment with CPAP under strict preconditions only, while UPPP was refunded 
by the Health Insurance Companies. The Dutch Sleep Apnea Study and the 
recently proposed Dutch Sleep Apnea Consensus, provided sufficient scientific 
data and opinions of Dutch experts to warrant revision of the indications for 
CPAP as defined by the Dutch Health Insurance Council, and to match these to 
the internationally accepted standards. From now on, CPAP can be considered 
treatment of first choice for sleep apnea patients in the Netherlands as well. 
CPAP has been shown to be vely effective in reducing daytime complaints and 
in stabilising nocturnal breathing, but it must still be considered a cumbersome 
treatment for a considerable number of patients. Several studies showed indeed, 
that compliance to CPAP may be disappointingly low (35,36), and the 
American Thoracic Society stated in 1994, that the compliance may at best 
approach 50% (37), while acceptance may be close to 70% (38-40). This 
observation has several consequences. The long-term results of CPAP on 
daytime complaints, may not be better than that of surgelY (UPPP), which 
seems in concordance with the results of the Dutch Sleep Apnea Study, 
although actual compliance to CPAP was not monitored. More research is 
needed to understand the mechanisms contributing to better compliance, and to 
evaluate new CPAP techniques and masks. Although new technologies develop 
rapidly, it will remain impossible to treat all OSAS patients with CPAP. Until 
now surgelY is the only well evaluated alternative, and further research must be 
initiated to identify useful selection criteria for specific surgical protocols or to 
evaluate new surgical techniques. Our data and that of many others show that 
UPPP, or even more extensive surgical protocols may be effective treatment 
modalities. We should not deny surgery to patients who can't get used to 
129 
Chapter 7 
CPAP, simply because we do not know enough about its possibilities. Although 
no useful clinical criteria have been established, UPPP should merely be 
reserved for patients with relatively mild sleep apnea severity, predominant 
collaps of the upper airway at the velopharyngeal level, and who are not 
seriously overweighed. UPPP in combination with tonsillectomy seems to be 
more effective in improving subjective symptoms and nocturnal desaturation. 
We estimate that 20% to 25% of patients will be treated effectively with regard 
to snoring, daytime sleepiness, and nocturnal desaturation untill three years after 
surgely. 
Some earlier reports emphasize the possible effect of previous surgical (UPPP) 
procedures on the tolerance and treatment outcome of CP AP therapy if 
secondarily indicated (41,42). We found however no support fot this theory, 
because daytime sleepiness, QoL and ODI were consistently improved in the 
CPAP after UPPP-therapy, and these changes were not different compared to 
the other treatment groups. All patients in the CPAP after UPPP-therapy group 
continued treatment and inspiratory pressure levels and CPAP-related 
complaints were not different from the CPAP-therapy group. 
The data presented in this thesis can be summarised by a few short general 
conclusions. In any situation where UPPP and CPAP are simultaneously 
available for the treatment of OSAS in patients with predominant collaps of the 
upper airway at the velopharyngeal level, CP AP should be the treatment of first 
choice. The acceptance of CP AP is significantly better, and it results in less 
treatment failures than UPPP. The improvement of nocturnal desaturations is 
significantly better in CPAP treated patients, but there is no evidence for a 
difference in improvement of daytime sleepiness and quality of life parameters 
between UPPP and CPAP. Treatment with CP AP-first is less expensive than 
treatment with UPPP-first. 
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Summary 
The Obstructive Sleep Apnea Syndrome (OSAS) is characterised by repetitive 
obstruction of the upper airway during sleep, causing obstructive apneas, 
nocturnal oxygen desaturation and fragmentation of sleep (chapter 1). Snoring, 
apneas and daytime sleepiness are the cardinal symptoms of the syndrome. 
OSAS is related to cardiovascular morbidity and mortality. Approximately 4% 
of middle-aged men and 2% of middle aged women meet the criteria of OSAS, 
as defined by the presence of daytime sleepiness and at least 5 desaturations or 
apneas per hour sleep. In perspective of its prevalence, symptoms and long-
term sequelae, the OSAS should be considered a major public health problem. 
Diagnosis and treatment of OSAS and other sleep related breathing disorders 
requiers a multi-disciplinary approach in sleep centers or sleep apnea centers. 
The pathogenesis of OSAS has not been fully elucidated, but sleep related 
changes in ventilatOlY control, sleep related changes in upper airway muscle 
control, and ce11ain aspects of the upper airway anatomy are all important 
contributive factors. To evaluate the relative contribution of static upper airway 
obstruction (purely anatomic), and dynamic upper airway obstruction 
(ventilatOlY and muscular control), we studied 53 men and 7 women with 
excessive snoring or OSAS (chapter 2). Static upper airway obsttuction was 
assessed by cephalometry, while dynamic upper ainvay obstruction was 
assessed by Mueller manoeuvre and pulmonaty function testing. Nocturnal 
sattlration and breathing pattern were documented by polysomnography (PSG). 
The oxygen desaturation index (001) and maximal desaturation were used in 
the analysis. We found that only 8-13% of the variation in nocturnal 
desaturation parameters could be explained by static upper ainvay obstruction, 
and only 30-40% by the combination of static and dynamic obstruction 
parameters. As a consequence 60-70% of the variation in nocturnal 
desaturation must be explained by other mechanisms, indicating that sleep phase 
related changes in ventilatory and upper ainvay muscle control are more 
important in the pathogenesis of sleep related breathing disorders and OSAS 
than pure anatomic nalTowing of the upper ainvay. 
Since their simultaneous introduction for the treatment of OSAS in 1981, 
Uvulo-Palato-Pharyngo-Plasty (UPPP) and Continuous Positive Airway 
Pressure applied by a nose mask (CPAP) were the principal treatment 
modalities for OSAS. Studies on the short-term effect of UPPP on snoring, 
daytime sleepiness and nocturnal breathing parameters showed a high 
variability, while the long term effects of this treatment were sparsely reported. 
To evaluate the short-term and long-term efficacy of UPPP on improving 
snoring, daytime sleepiness and noctumal desaturation, we studied 60 
consecutive patients with OSAS documented by PSG (chapters 3 alld 4). We 
found that more than 70% of patients reported improvement of snoring and 
more than 50% improvement of daytime sleepiness, six months after surgery. A 
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more than 50% reduction in om was found in 35% of patients, and 13% 
showed a decrease of ODI below 5 after the same period of six months. After 
II to 74 months of follow-up in 58 of the original 60 patients, we found that 
snoring remained improved in 63%, daytime sleepiness in 38%, but no 
improvement ofOD!. After comparing the daytime sleepiness scores to the pre-
operative scores, we found that these scores showed a relapse to base-line 
scores. An additional finding in the long-term study (chapter 4) was that the 
outcome was significantly better after UPPP in combination with tonsillectomy, 
compared to UPPP alone. No other pre-operative criteria with respect to 
treatment outcome were found. We concluded that the effect of UPPP is 
limited, but that approximately 20% of patients was treated effectively in the 
long-term. These patients can however not be identified pre-operatively. 
An increasing number of studies reported the effect of CP AP on daytime 
symptoms and nocturnal breathing pattern, and although no prospective 
randomised trial was ever performed, CP AP became the treatment of first 
choice. UPPP was however still considered a treatment option for patients with 
OSAS caused by predominant collaps of the upper airway at the velopharyngeal 
level. UPPP was performed frequently in the Netherlands, while the use of 
CP AP was severely restricted to the guidelines of the Dutch Health Insurance 
Council. We performed a randomised prospective trial using the Intention To 
Treat (ITT) principle to compare two strategies for the treatment of OSAS in 
patients with predominant collaps at the velopharyngeal level (chapter 5). In 
the first strategy the treatment was started with CP AP, and in the second 
strategy with UPPP, with the possibility to switch to the other treatment 
modality in case of treatment failure. We evaluated which strategy resulted in 
better improvement of daytime sleepiness, quality of life, and nocturnal 
desaturations. We also perfOlmed a cost-minimal is at ion analysis. 125 Patients 
were included between November 1992 and May 1995. Follow-up ranged from 
6 to 24 months. At the end of follow-up 77% of UPPP-first patients were 
switched to CPAP and 23% CPAP-first patients were switched to UPPP. At the 
end of follow-up, 77% of the patients in both strategies were treated with CPAP. 
We found no statistical significant differences in improvement of daytime 
sleepiness or quality of life. CPAP-first strategy resulted in better improvement 
of nocturnal desaturation at six months, but due to the switching to the other 
treatment modality, the improvement of ODI was eventually equal in both 
strategies. Although some reports suggested that the effect of CP AP was 
influenced negatively by prior UPPP, we found no significant differences 
between patients in the CP AP after UPPP treatment group and the other 
patients. The mean direct costs and the cumulative consequential costs were 
significantly higher in the UPPP-first strategy. This was the first prospective 
randomised trial comparing UPPP and CP AP for the treatment of OSAS, and 
the results support the international consensus that CP AP is the treatment of 
first choice for OSAS in patients with predominant velopharyngeal obstmction. 
136 
SUll/malY 
We perfonned a separate analysis of Quality of Life parameters (QoL) in the 
same patient group (chapter 6). The aims of this shldy were to evaluate Quality 
of Life (QoL) before and after treatment of OSAS and to assess the differences 
in changes in QoL between UPPP and CPAP treated patients. The QoL 
measures were compared to norm values, both before and after treatment to 
describe the impact of OSAS on QoL and the clinical relevance of changes in 
QoL. QoL was assessed in a generic way with the Dutch translated and 
evaluated versions of the Nottingham Health Profile part I (NHP patt I), and in 
a domain specific way, focussing on somatic and psychological well-being with 
the Somatic subscale of the Hopkins Symptom Checklist (SOMA T), the 
Bradburn Affect Balance Scale (ABS) and the shortened Profile of Mood Scale 
(POMS) in a reliable and validated Dutch versions. We found that the base-line 
scores on all subscales of the NHP part 1, SOMAT, ABS, and POMS were in 
the range of diseased to severely diseased norm groups. In the ITT analysis a 
statistically significant improvement was found on almost all subscales, but 
mean scores were still in the diseased range. The overall comparison of the 
UPPP first and CPAP first treated patients showed no statistically significant 
differences in improvement of QoL. CPAP first treated patients however, 
tended to show a better respons. In the AT analysis the differences between 
UPPP, CPAP, CPAP after UPPP, and UPPP after CPAP were not significant. 
These results show that QoL is severely affected in patients with OSAS, and 
that treatment with UPPP or CPAP results in a considerable improvement, but 
without restoring QoL to normal values. 
The studies described in this thesis allow the following conclusions. In any 
situation where UPPP and CP AP are simultaneously avai lable for the treatment 
of OSAS in patients with predominant collaps of the upper airway at the 
velopharyngeal level, CPAP should be the treatment of first choice. The 
acceptance of CPAP is significantly better, and it results in less treatment 
failures than UPPP. The improvement of nocturnal desaturations is 
significantly better in CPAP treated patients, but there is no evidence for a 
difference in improvement of daytime sleepiness and quality of life parameters 
between UPPP and CPAP. Statting treatment with CPAP is less expensive than 
starting treatment with UPPP. 
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Samenvatting 
Het Obstlllctief Slaapapneusyndroom (OSAS) wordt gekenmerkt door 
herhaaldelijke obstlllctie van de bovenste lllchtweg tijdens de slaap, waardoor 
onderbreking van de ademhaling (apneus), zuurstofdesaturaties en fragmentatie 
van de slaap ontstaan (I/OoJds/uk 1). De belangrijkste symptomen van het 
OSAS zijn snurken, apnells en slaperigheid overdag. Er is een verband tussen 
OSAS en het ontstaan van cardio-vasculaire ziekten. Ais we het OSAS 
definieren als de aanwezigheid van slaperigheid overdag, gecombineerd met de 
aanwezigheid van 5 desaturaties of obstructieve apneus per uur slaap, dan 
voldoet ongeveer 4% van de mannen en 2% van de vrouwen op middelbare 
leeftijd aan deze diagnose. Vanwege deze hoge prevalent ie, de symptomen en 
de lange tetmijn complicaties, moet het OSAS als een probleem voor de 
volksgezondheid beschouwd worden. Het stellen van de diagnose en de 
behandeling van het OSAS, alsmede dat van andere slaap gerelateerde 
fllnctiestoornissen, verdient een multi-disciplinaire benadering in ziekenhuizen 
met ervaring op dit gebied. 
De pathogenese van het OSAS is nog niet opgehelderd, maar slaap gerelateerde 
veranderingen in de controle van de ademhaling, slaap gerelateerde 
veranderingen in de controle van de spieren van de bovenste luchtweg en 
bepaalde anatomische factoren spelen aIle een roI. Om de relatieve bijdrage van 
deze statische (anatomische) en dynamische (controle ademhaling en spieren) 
obstlllctie te evailleren, hebben we 53 mann en en 7 vrollwen bestudeerd 
(hooJds/uk 2). De statische obstlllctie van de bovenste luchtweg werd 
vastgesteld middels X-cephalometrie en de dynamische obstlllctie middels de 
Miillerse maneuvre en longfllnctie onderzoek. De zuurstofsaturatie en het 
ademhalingspatroon werden geevailleerd met polysomnografie (PSG). De 
zuurstofdesaturatie-index (001) en de maxima Ie desaturatie werden in de 
analyse geblllikt. We vonden dat slechts 8-13% van de variatie in nachtelijke 
desaturatie verklaard kon worden door statische luchtweg obstlllctie, en slechts 
30-40% door de combinatie van statische en dynamische luchtweg obstructie. 
Dit betekent dat ongeveer 60-70% van de variatie in nachtelijke desaturatie door 
andere mechanismen verklaard moet worden en dat slaap gerelateerde 
veranderingen in de regulatie van de ademhaling en controle van de spieren van 
de bovenste luchtweg meer bijdragen aan het ontstaan van slaap gerelateerde 
ademhalingsstoomissen en OSAS, dan zlliver anatomische factoren. 
Sinds de gelijktijdige introductie van de UVlllopalatophmyngoplastiek (UPPP) 
en de Continue Positieve Luchtdlllkbehandeling (CP AP) voor de behandeling 
van OSAS in 1981, werden beide methoden veelvllidig toegepast. Onderzoeken 
naar de korte termijn resultaten van UPPP op snurken, slaperigheid overdag en 
nachtelijke ademhaling, lieten veel variatie zien, terwijl er nog nauwelijks 
onderzoek was gedaan naar de resultaten op langere termijn. Om zowel het 
effect van UPPP op de korte als langere tennijn te evalueren, hebben we 60 
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patienten met middels polysomnografie vastgesteld OSAS bestudeerd 
(//OoJdstlikken 3 en 4). We vonden dat 6 maanden na de operatie meer dan 70% 
van de patienten een verbetering van snurken en slaperigheid overdag 
rappOtteerde. Meer dan 50% reductie in om was bereikt in 35% van de 
patienten, en 13% liet een afname van om zien tot onder de 5 per uur. Na II 
tot 74 maanden follow-up van 58 van deze 60 patienten, vonden we in de groep, 
dat snurken verbeterd bleef in 63%, slaperigheid in 38%, maar dat de 
verbetering in ODI was verdwenen. Na vergelijking van de slaperigheidsscores 
met de pre-operatieve scores, bleek de slaperigheid overdag weer even ernstig 
als voor de operatie. Een opvallende bevinding bij de lange-termijn studie 
(//OoJds/lik 4), was dat het resultaat van UPPP gecombineerd met een 
tonsillectomie (TE), significant beter was dan het resultaat van UPPP zonder 
TE. Andere mogelijke pre-operatieve selectiecriteria hebben we niet gevonden. 
We concludeerden dat het effect van UPPP gering was, maar dat ongeveer 20% 
van de patienten ook op de langere termijn effectief behandeld was. Deze 
patienten konden pre-operatief niet geselecteerd worden. 
Een toenemend aantal onderzoekers rapporteerde het effect van CP AP op de 
symptom en en het nachtelijke ademhalingspatroon van het OSAS, en ondanks 
het feit dat er geen prospectieve gerandomiseerde onderzoeken hadden plaats 
gevonden, werd CPAP de behandeling van eerste keus. UPPP werd echter nog 
steeds als een optie voor behandeling beschouwd van patienten met een OSAS 
veroorzaakt door collaps tel' hoogte van het zachte verhemelte. In Nederland 
werd UPPP vaak uitgevoerd, terwijl het voorschrijven van CPAP sterk aan 
banden werd gelegd door de richtlijnen van de Ziekenfondsraad. Om na te gaan 
welke plaats CPAP kon innemen naast UPPP voor de behandeling van OSAS 
bij patienten met collaps op het nivo van het zachte verhemelte, hebben we in 
samenwerking met de Nederlandse Ziekenfondsraad, een gerandomiseerd 
prospectief onderzoek uitgevoerd, waarbij twee strategieen vergeleken werden 
(hooJdstlik 5). In de eerste strategie werd de behandeling gestalt met UPPP 
(UPPP-eerst strategie), en in de tweede met CPAP (CPAP-eerst strategie), 
waarbij de mogelijkheid bestond om in het geval van onvoldoende resultaat van 
behandeling te wisselen. We hebben geevalueerd welke strategie resulteerde in 
grotere verbetering van slapergheid overdag, kwaliteit van leven en nachtelijke 
desaturaties, waarbij we ook een kosten-minimalisatie analyse uitgevoerd 
hebben. Tussen november 1992 en mei 1995 werden 125 patienten in het 
onderzoek opgenomen. Follow-up yond plaats op 6, 12, 18 en 24 maanden na 
start van de behandeling. Aan het eind van het onderzoek waren 77% van de 
patienten uit de UPPP-eerst strategie op CPAP overgegaan, in vergelijking met 
23% uit de CPAP-eerst strategie die op UPPP overgingen. Uiteindelijk werd in 
beide strategieen dus 77% van de patienten met CP AP behandeld. We vonden 
geen verschil in verbetering van slaperigheid overdag of kwaliteit van leven. 
De CPAP-eerst strategie resulteerde in een significant grotere verbetering van 
de ODI na 6 maanden follow-up, maar door het toenemend aantal patienten dat 
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van UPPP naar CPAP wisselde (maar voor de analyse dus in de UPPP-eerst 
strategie bleef) verdween dit verschil in de loop van het onderzoek. We vonden 
geen verschillen tussen patienten die met CPAP na UPPP behandeld werden en 
de andere patienten, dit in tegenstelling tot de suggestie van andere 
onderzoekers, dat het gebruik van CPAP nadelig beYnvloed werd door eerdere 
UPPP. Zowel de directe als de indirecte kosten hoger waren in de UPPP-eerst 
strategie. 
In een aparte analyse hebben we aspecten met betrekking tot de kwaliteit van 
leven in deze patientengroep geevalueerd ("ooIds/uk 6). Het doel van deze 
studie was de kwaliteit van leven voor en na behandeling van het OSAS en de 
verschillen tussen UPPP en CPAP te evalueren. De kwaliteit van leven scores 
voor en na behandeling werden vergeleken met genolllleerde scores, om de 
invloed van OSAS op kwaliteit van leven en de klinische relevantie van 
eventuele verbetering te beschrijven. De kwaliteit van leven werd op een 
gellerieke wijze geevalueerd middels de in het Nederlands vertaalde en 
gevalideerde versie van de Nottingham Health Profile part 1 (NHP patt 1), en 
op een domein specifieke wijze middels de Somatische subscale van de Hopkins 
Symptom Checklist (SOMA T), de Bradburn Affect Balance Scale (ABS) en de 
verkorte versie van de Profile of Mood States (POMS). We vonden na 
vergelijking met de genormeerde scores, dat de uitgangsscores (voor 
behandeling) op aile schalen van de NHP part 1, SOMAT, ABS en de POMS in 
het bereik van ziek tot ernstig ziek lagen. Na behandeling waren bijna aile 
subscores significant verbeterd, maar nog steeds in het bereik van ziek. We 
vonden geen statistisch significante verschillen tussen de UPPP-eerst en de 
CPAP-eerst strategie, maar er was een tendens tot grotere verbetering in de 
CPAP-eerst strategie. In een subgroep analyse, waarbij CPAP, UPPP, CPAP na 
UPPP en UPPP na CPAP behandelde patienten vergeleken werden, von den we 
ook geen verschillen. Deze gegevens laten zien dat de kwaliteit van leven 
el11stig aangedaan is bij OSAS-patienten en dat behandeling wei leidt tot een 
aanzienlijke verbetering, maar niet tot een "normalisering" hiervan. 
In hoofdstuk 5 en 6 beschreven we de resultaten van het eerste prospectief 
gerandomiseerde onderzoek, waarbij UPPP en CP AP direkt vergeleken werden. 
De resultaten bevestigen de al langer internationaal heersende consensus, dat 
CPAP de behandeling van eerste keuze dient te zijn voor patienten met het 
OSAS veroorzaakt door collaps van de luchtweg op het nivo van het zachte 
verhemelte. De beschreven onderzoeken leiden tot de volgende conclusies. In 
elke situatie waar zowel UPPP als CPAP beschikbaar zijn voor de behandeling 
van patienten met het OSAS en collaps van het zachte verhemelte, verdient 
CPAP de absolute voorkeur. CPAP wordt beter verdragen, resulteelt in minder 
wisselingen van therapie en resulteert in grotere verbetering van nachtelijke 
saturatie. Er zijn geen aanwijzingen dat CPAP ook resulteert in grotere 
verbetering van slaperigheid overdag of kwaliteit van leven. Het is goedkoper 
om de behandeling te staltenmet CPAP, dan met UPPP. 
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List of Abbreviations 
List of Abbreviations 
ABS 
AHI 
AI 
AT 
BIPAP 
BMI 
COPD 
CPAP 
D! 
EDS 
EEG 
EMG 
EOG 
ITT 
LAUP 
MESAM-4 
MPH 
MSLT 
MSP 
MTB 
NHP 
NREM 
NS 
OD! 
OSAS 
PAS 
PEF 
PIF 
POMS 
PSG 
QoL 
RD! 
REM 
SD 
SOMAT 
SPD 
SPL 
SRBD 
TE 
UARS 
UPPP 
: Bradburn Affect Balance Scale 
: Apnea-Hypopnea Index 
: Apnea Index 
: As Treated (in statistical analysis) 
: Bi-level Positive Airway Pressure 
: Body Mass Index (kgfn}) 
: Chronic Obstructive Pulmonary Disease 
: Continuous Positive Airway Pressure 
: Desaturation Index 
: Excessive Daytime Sleepiness 
: Electro-Encephalo-Graphy 
: Electro-Myo-Graphy 
: Electro-Oculo-Graphy 
: Intention To Treat (in statistical analysis) 
: Laser Assisted Uvulo-(Palato-Pharyngo) Plasty 
: Madaus Electronic Sleep Analysing machine type 4 
: distance between Mandibular Plane and Hyoid 
: Multiple Sleep Latency Test 
: collapse by Mueller manoeuver at the Soft Palate 
: collapse by Mueller manoeuver at the Tongue Base 
: Nottingham Health Profile 
: Non-Rapid Eye Movement sleep 
: Not statistically Significant 
: Oxygen Desaturation Index 
: Obstructive Sleep Apnea Syndrome 
: Posterior Airway Space 
: Peak Expiratory Flow 
: Peak Inspiratory Flow 
: Profile of Mood States 
: Polysomnography 
: Quality of Life 
: Respiratory Distress Index 
: Rapid Eye Movement sleep 
: Standard Deviation 
: Somatic subscale of the Hopkins Symptom Checklist 
: Soft Palate Diameter 
: Soft Palate Length 
: Sleep Related Breathing Disorder 
: Tonsillectomy 
: Upper Airway Resistance Syndrome 
: Uvulo-Palato-Pharyngo-Plasty 
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Dankwoord 
Bij de uitvoering van de in dit proefschrift beschreven onderzoeken zijn veel 
mensen betrokken geweest en ook de totstandkoming van dit boekje is niet de 
verdienste van een persoon. Het is onmogelijk om iedereen bij naam te noemen 
zonder een aantal personen die een onmisbare bijdrage geleverd hebben te 
vergeten. Zonder uitzondering ben ik iedereen zeer dankbaar die een bijdrage, 
in welke vorm dan ook geleverd heeft. Enkele personen wiI ik hier met name 
noemen. 
Mijn promotor en opleider Prof. Dr. F.G.A. van der Meche. Frans, ik ben je 
zeer erkentelijk voor het in mij gestelde vertrouwen en voor de mimte die ik 
gekregen heb om grote delen van het onderzoek op mijn wijze en in mijn tempo 
uit te voeren. Je probleem gerichte benadering is op vele momenten van 
doorslaggevend belang geweest. Ik denk hierbij vooral terug aan de 
vergaderingen tijdens de afronding van het ontwikkelingsgeneeskundig project. 
Zowel de samenwerking in onderzoeksverband, als op de afdeling neurologie, 
ervaar ik nog steeds als zeer prettig. 
Mijn copromotor Dr. R.M.L. Poublon. Rene, ik denk regelmatig temg aan onze 
samenwerking binnen de werkgroep functiestoornissen in de slaap. Deze 
periode is voor mij zeer leerzaam geweest. Met name wiI ik je ook bedanken 
voor je altijd even enthousiaste ondersteuning en voor je kritische conmlentaren 
op alles wat de UPPP betrof. Je betrokkenheid heb ik steeds als zeer 
motiverend ervaren. 
Mijn copromotor Dr. Ir. P.I.M. Schmitz. Paul, met geen van de betrokken 
onderzoekers is de samenwerking zo hecht geweest. Vele avonden en vrije 
dagen hebben we samen doorgebracht met het voorbewerken van de data files en 
het uitvoeren van de statistische analyses. Je systematische aanpak is voor mij 
nog steeds een voorbeeld. Ik ben je niet aIleen erkentelijk voor je professionele 
betrokkenheid, maar ook voor de ruimte die er altijd geweest is voor niet 
wetenschappelijke onderwerpen. Ik zal de bezoeken aan de Daniel missen. 
Hans van del' Sluijs is altijd het aanspreekpunt geweest bij problemen met 
CP AP-apparatuur, zowel voor patienten als voor behandelaars. Hans, ik heb 
altijd erg prettig met je samengewerkt en ik heb veel van je geleerd. Ik ben blij 
dat we elkaar nog regelmatig buiten het ziekenhuis zien. 
Alie Plug was als de datamanager betrokken bij het slaapapneuonderzoek. Alie, 
ondanks de kleine meningsverschillen die we gehad hebben, denk ik nog 
regelmatig met veel plezier terug aan de jaren die we samen op de 22e hebben 
doorgebracht. Ik ben je zeer dankbaar voor je enornle inzet en gezelligheid. 
Na het vertrek van Alie werden haar werkzaamheden overgenomen door 
Monica van der Hoven. Monica, bedankt dat je dit project er ook nog bij hebt 
willen nemen. . 
Robert van Wegen wiI ik bedanken voor zijn enthousiaste medewerking tijdens 
het uitwerken en opschrijven van de twee UPPP onderzoeken. Robert, ik heb 
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het erg gezellig gevanden dat je er was. 
Onze systeembeheerders ap zawel de 22e als ap de afdeling nenrolagie, Kris 
Sieradzan an Laurens van Briemen. Kris, ik dank je vaar al je antwaarden ap 
mijn vragen aver databanken en camputers. Zelfs als je erg druk was, maakte je 
altijd even tijd. Ik dank je aak vaal' aIle mamenten buiten het ziekenhuis. We 
maeten de draad snel weer eens appakken. Laurens, ik heb meer dan eens 
gebruik gemaakt van je bereidheid am problemen met betrekking tat saft- en 
hardware ap te lassen. Ik dank je vaar je samenwerking ap de afdeling en aan 
de klimwand. 
Tan Mus is werkzaam ap de afdeling Klinische Neurafysialagie. Tan, vaar het 
eerst werkten we samen in 1991, taen ik als student een keuzeanderzaek deed 
naar de geleiding van de nervus peroneus bij enkelzwikkers. Zawel taen als nu, 
was je altijd bereid een helpende hand tae te steken. Ik wiI je hier hartelijk vaal' 
bedanken. 
Het landelijk slaapapneuanderzaek was naait magelijk geweest zander de 
medewerking van aIle betrokkenen in de verschillende centra. Ik wiI aIle artsen 
en labaranten zeer hartelijk bedanken vaar hun enthausiasme bij het uitvaeren 
van al het extra werk dat het anderzaek met zich meebracht. Met name wiI ik 
de labarantes van anze eigen afdeling bedanken vaal' de prettige samenwerking 
en vaal' hun enarme inzet bij het aansluiten en uitwerken van de 
slaapregistraties. 
Oak aIle callega's - artsen, daktersassistenten, administratieve krachten en 
verpleegkundigen --<lie ik niet specifiek genaemd heb, wiI ik bedanken vaal' de 
samenwerking. Jullie callegialiteit heeft mij de ruimte en mativatie gegeven am 
aak tijdens de eerste jaren van mijn apleiding aan dit anderzaek te blijven 
werken. 
Mijn paranymfen. Wibe, ik weet dat je ap het punt staat apnieuw een grote stap 
in je leven te gaan zetten. Bedankt dat je desandanks tijd wiIt vrijmaken am mij 
in deze laatste fase te andersteunen. Fap, dit is niet anze eerste promatie samen. 
Hae groat is de tegenstelling!!. Bedankt vaar je tijd in deze periade. Ik wens 
jullie aIle vaarspaed. Wibe en Fap, ik waardeer jullie enthallsiasme en 
vriendschap die callegialiteit ver avertreffen. 
Gerhard Visser, apleider neurafysialagie. Gerhard, zander jauw adviezen, zau 
dit baekje er zeker slechter hebben uitgezien. Bedankt. 
Karin, lange tijd heef! dit project ans leven belnvlaed en vaak was ik 
anvaldaende bereikbaar vaar jau en de kinderen. Het grate werk is nu gedaan. 
Karin, Tim en Lara, ik ben erg dankbaar vaar jullie lief de en vriendschap, die 
vaar mij zaveel belangrijker zijn dan de afronding van deze promatie. 
Henk 
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De schrijver van dit proefschrift werd op 26 december 1964 geboren in 
Enschede. Hij volgde zijn middelbare schoolopleiding aan het "Revius 
Lyceum" te Doorn, alwaar hij in 1983 het VWO (Gymnasium) diploma haalde. 
In 1984 begon hij met de studie geneeskunde aan de Erasmus Universiteit te 
Rotterdam. In oktober 1991 haalde hij zijn arts-examen. Tot medio december 
1991 is hij werkzaam geweest in de functie van arts bij de Rotterdam Medical 
Research Foundation. Van december 1991 tot eind juni 1992 was hij AGNIO-
neurologie (Assistant Geneeskundige Niet In Opleiding) in het Onze Lieve 
Vrouwe Gasthuis te Amsterdam. Sinds I juli 1992 is hij werkzaam aan de 
afdeling neurologie van het Academisch Ziekenhuis Rotterdam. Na een korte 
periode van 3 maanden als AGNIO, is hij tot februari 1996 bezig geweest met 
de in dit proefschrift beschreven onderzoeken. In deze periode is hij nauw 
betrokken geweest bij de diagnostiek en behandeling van patienten met slaap 
gerelateerde functiestoornissen. Sinds I februari 1996 is hij in het Academisch 
Ziekenhuis te Rotterdam in opleiding tot neuroloog (opleider Prof. Dr. F.G.A. 
van der Meche). 
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